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ABSTRACT 
Profound advances in cardiovascular disease (CVD) treatments have been made over the last two 
decades.  However, poor adherence to preventative therapies remains a critical problem in the 
health of Canadians.  Despite decades of research, contemporary knowledge about adherence is 
often based on theory that has not been confirmed with quantitative research findings.  For 
example, adherence to preventative medications is widely considered to reduce risks for major 
health outcomes.  However, major differences in the estimation of medication adherence benefits 
exist. Thus, a study was conducted to determine if the association between poor adherence and 
the risk of death was influenced by the method used to identify optimal adherence. The impact of 
adherence to statin medications on mortality was assessed among a cohort of 9,051 individuals 
who received a statin medication following discharge from a hospitalization for acute coronary 
syndrome (ACS). Using a fixed-summary measure, optimal adherence to statins was not 
associated with mortality benefits (adjusted HR 0.97, 95%CI 0.86 to 1.09, p=0.60).  In contrast, 
the repeated measures approach resulted in a significant 25% reduction in the risk of death 
among adherent individuals (adjusted HR 0.75, 95%CI 0.67 to 0.85, p<0.01). However, neither 
estimate could be regarded as the most robust. Thus, until a gold standard method is established, 
researchers should report the estimates resulting from both methods.   
Among all adherence predictors, socioeconomic status (SES) is widely considered to be 
prominent because of its associations with many factors theoretically affecting adherence such as 
economic, social, and education-related features. However, published studies have reported 
inconsistent results about the impact of SES on adherence.  A systematic review of published 
studies examining predictors of antihypertensive medications adherence was performed.  Almost 
half of studies reviewed neglected to measure SES; and in studies where SES was measured, 
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income assessment was typically the only measure.  Overall, only a minor association between 
SES and adherence was observed after pooling all available data (pooled adjusted risk estimate 
for non-adherence according to SES (high versus low) 0.89, 95% CI 0.87 to 0.92; p<0.001). 
It was hypothesized that the performance of adherence prediction models would improve if SES 
was represented using more comprehensive measures.  A retrospective cohort of individuals who 
received a statin medication following discharge from a hospitalization for coronary heart 
disease was identified and followed for one year.  Multi-domain measures did not improve the 
prediction performance of the population adherence model compared to single-domain measures.  
Overall, all SES measures examined had a very limited impact on prediction adherence.  
Supporting patients to adhere to their medications is a vital goal health care providers strive to 
achieve. Non-adherence to preventative medications is highly prevalent among patients 
surviving acute coronary syndrome (ACS). However, only few patients receive appropriate care 
after their ACS through support programs such as cardiac rehabilitation (CR). Because 
pharmacist’s interventions were shown to have beneficial impact on medication adherence in 
various settings, a streamlined pharmacist’s intervention in CR setting was investigated through 
a randomized clinical trial. The impact of this intervention was assessed through the proportion 
of patients who achieved optimal adherence. Although this proportion did not improve among 
the intervention group in comparison to the control group, an unexpected high prevalence of 
optimal adherence was obtained. A selection bias of highly motivated individuals in this study 
may explain this extraordinary adherence level.  
iv 
 
Results of the four independent research studies included in this dissertation provide novel 
insight relating to the factors, outcomes, and possible modalities to mitigate non-adherence in 
Canada.  Further research is essential to help in relieving this major population health problem.   
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CHAPTER -1- INTRODUCTION 
“Patient compliance has become the best documented, but least understood, health behaviour” 
Becker and Maiman
1
  
1.1 Rational 
Cardiovascular disease (CVD) is the second leading cause of death in Canada, causing 
approximately 27 % of all Canadian deaths.
2
  In addition, CVD is responsible for a high burden 
of morbidity across the country.  Every year over 55,000 Canadians are treated for a myocardial 
infarction requiring approximately 500,000 days of hospitalization.
3
 As a result, the total cost of 
CVD exceeds $20 billion dollars annually.
4
 Considering that many CVD events recur at a high 
rate, prevention strategies aimed to patients with established disease is a high priority for the 
entire nation.
5
    
Several pharmacological therapies reduce the risk for recurrent events in patients who survive a 
heart attack. For example beta-blockers (BB), antiplatelet agents, angiotensin converting enzyme 
inhibitors (ACEI), and lipid lowering agents such as statins can independently decrease the 
incidence of new vascular event by almost 25% in addition to improving quality of life.
6,7
  
Despite these highly successful results in clinical trials, cohort studies have shown that evidence-
based pharmacotherapy may be underused in the post-myocardial infarction (post-MI) period.  
Much of this underutilization can be attributed to poor medication adherence.    
1.2 Medication Adherence 
Medication adherence is often defined as the act of taking medications according to a 
prescription given by a health care professional, both in terms of the right dose and the right 
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interval.
8-10
  Various alternative terms for adherence have been proposed to recognize the role of 
patients in the decision-making process about their medications.
11,12
  The term compliance is no 
longer favoured because it infers a passive obedience to the prescriber’s instructions.10,13  In 
contrast, the term concordance was proposed to recognize patients as active participants in their 
own care.
14
 Regardless of the term used to describe this phenomenon, it is agreed that 
medications should be taken in a manner that replicates clinical trials in order to achieve the 
expected therapeutic benefits.  Decades of research have repeatedly shown that adherence to 
medications is extremely poor among patients with chronic diseases.  On average, only half of all 
patients who are prescribed a long-term (i.e., chronic) medication continue to take it regularly as 
prescribed.
8
  The cost of medication non-adherence has been estimated over $100 billion 
annually in the United States making it a priority for health care providers and policy makers 
alike
8
  
1.3 Types of non-adherence 
By definition, medication non-adherence can be exhibited by individuals who over-use, under-
use, or do not take their medications at all.  However, the main focus of adherence research 
relates to the problem of medication under-use, especially among individuals with chronic 
diseases.
15
  Medication non-adherence relating to under-use is commonly stratified into three 
distinct categories: a) primary non-adherence, b) secondary non-adherence (or poor execution), 
and C) non-persistence.
9,16
 These three types of non-adherence are defined by unique refill 
patterns and probably differ in terms of their prevalence, causes and potential solutions.
17,18
 
Accordingly, it is important to identify the specific type of non-adherence reported in published 
studies to prevent inaccurate interpretations of available data.
19
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Between 5 to 30% of prescriptions ordered for patients are never picked up from a pharmacy.  
This pattern of non-adherence is defined as “primary non-adherence”.20-25 In many prescription 
databases, it is impossible to distinguish primary non-adherence from cases where prescribers 
have not issued a prescription at all.  In fact, under-prescribing has been the focus of numerous 
health care system studies looking at the management of patients with chronic diseases.
26-28
 
However, the emergence of electronic prescriptions and electronic health records has enabled 
researchers to recognize primary non-adherence that may have been previously misclassified as 
underprescribing.
29,30
  Similarly, the provision of prescriber-issued samples of new medication 
may also be misclassified as primary non-adherence or underutilization in databases with limited 
access to prescribing information.
31-33
 
Poor execution (or secondary non-adherence) is exhibited when patients skip doses, fail to obtain 
refills on time, or interrupt therapy for periods of time.
11,34
 This pattern of non-adherence is 
unique because individuals continue to take their medication, albeit in lower-than recommended 
quantities.  As discussed earlier, other terms such as “non-compliance” have been used to 
describe this pattern of medication behaviour, but its use is declining because it implies a 
paternalistic relationship between patients and prescribers.   
Finally, patients often discontinue their medications altogether.  This pattern of non-adherence is 
termed non-persistence.
35
 Persistence is often measured by the length of time between filling the 
first prescription to discontinuation of the medication altogether.
10,11
    
1.4 Assessment of adherence using electronic refill claims databases  
Electronic prescription refill databases are the most frequently used information sources for 
adherence studies, and are especially useful for studying large populations.
36
 These databases 
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enable researchers to quantify non-adherence in large cohorts using objective methods and are 
not subject to the bias associated with self-reporting.  
Electronic refill databases can also be linked to other health-administrative databases allowing 
researchers to examine the association between medication adherence and health outcomes.  For 
example, administrative databases have been used to quantify the level of morbidity and 
mortality associated with non-adherence by linking prescription records with other health 
administrative databases.
37-45
 For instance, Pladevall et al linked prescription records with 
laboratory data and reported that an increase of 10% in non-adherence to metformin and statins 
was associated with an increase of 0.14% in HbA1c and an increase of 4.9 mg/dl in LDL 
cholesterol levels.
46
  Similarly, Ho et al linked prescription records with vital statistics database 
and found that adherence to cardio-protective medications including ACE inhibitors or 
angiotensin receptor blockers, beta-blockers, and statin was associated with a 48% relative 
reduction in all-cause mortality.
47
 However, investigating major health outcomes among 
adherent and non-adherent patients is difficult due the potential for bias between these non-
randomized comparator groups.  Little information is available to understand the most robust 
approach to examine the influence of adherence on major health outcomes. 
Adherence estimates generated from electronic dispensation records have been compared with 
other methods of measurements. Generally, administrative data adherence measures were found 
to have moderate association with serum or urine medication levels and with physiological 
effects of the medication.
48
 However, some studies showed a strong association with serum drug 
level and physiological effects. For example, refill measures of adherence to the anticonvulsant 
medication phenytoin were found to be significantly associated with mean plasma concentration 
of the medication.
49
 Similarly, measures of adherence to blood pressure medications was found 
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to be strongly associated with controlled blood pressure.
49
 In addition, adherence measured 
through refill databases are highly correlated to pill counts or home inventories.
48,50-52
 
Grymonpre et al examined prescription refill data amongst community-dwelling subjects who 
were taking 2 or more medications (including ACEIs) during 3 home visits.  Compared to pill 
counts, consistently high concordance was observed for non-ACE inhibitors and ACE inhibitors 
alike (85% and 95% respectively).
50
   
This method, however, has several theoretical limitations. First, filling a prescription constitute a 
mandatory but not adequate condition for drug consumption. Patients may not consume the 
medications after they have filled the prescription, or may consume them in erratic times. 
53
 
Accordingly, administrative database measure of adherence may in fact overestimate adherence 
levels. Second, patients my use free medication samples obtained from their physician, and not 
fill a prescription through a pharmacy. Third, these databases do not usually include information 
about medication that can be obtained without a prescription (over the counter medications or 
OTCs). Lastly, some databases may not include prescriptions filled in pharmacies outside a 
specific managed care system. Most importantly, administrative databases usually lack important 
clinical variables required for adherence prediction models. Regardless of its limitations, this 
method is the most validated practical and low cost method to be used in large population-based 
studies.      
1.5 Specific burden of non-adherence in cardiovascular medications 
Adherence to cardiovascular medications is suboptimal. In terms of primary non-adherence, it 
seems that almost one in five patients do not obtain even a single fill of their prescription for 
cardiovascular medications. In Massachusetts, for example, a study reported that 20% of new e-
prescriptions for anti-hypertensives (AHT) and lipids prescriptions were not filled at all.
29
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Similarly, in Ontario, 26% of patients who survived myocardial infarction (MI) did not fill all 
cardiovascular medications prescriptions within 120 days after discharge from hospital.
54
 Similar 
findings were reported in other jurisdiction.
55,56
 
Poor- execution and non-persistence are also very common with CVD medications.  For 
example, in Saskatchewan, only about 60% of patients surviving an acute MI remained adherent 
(adherence> 80%) to statins, B-blockers, or ACEI after one year.
57
 The remaining 40% either 
continued their medication with lower frequency, or stopped their medication altogether.  
Discontinuation rates for statins medications range from 19% at 30 days to 40% after one year of 
treatment initiation.
58
 Likewise, the discontinuation rates of anti-hypertension medications are 
comparable.
59-61
 The highest risk for non-adherence occurs early in the treatment regardless of 
the type of CVD medication studied.  For example, out of all patients classified as non-adherent 
in their first year of statin therapy, 40% had completely discontinued the medication within 3 
months of the first dispensation.
62
 In another study, 22% of patients who received a new 
prescription for statin medication did not have a second fill of their prescription.
63
 Among new 
users of antihypertensive medications, 39% of all non-adherent patients had only received a 
single refill before quitting.
64
 This phenomenon has been shown frequently in the literature 
among multiple populations.
57,65,66
   
Despite the wealth of studies showing very poor adherence to virtually all types of chronic 
medications.  There are signs that rates of adherence have slowly improved in recent years.
67-69
 
For example, overall adherence to BBs among heart failure patients increased by almost 50% 
between 1994 and 2003.
70
 Similar trends have been observed with statins,
71
  and other anti-
hypertensive medications
72
 but the specific reasons for these positive trends remain unclear.  
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Nonetheless, a substantial burden of non-adherence remains to virtually all chronic disease 
medications. 
1.6 Importance of medication adherence 
Optimal adherence to chronic medications has been associated with positive therapeutic 
outcomes for many chronic health-conditions.
73-76
 For example, individuals exhibiting good 
adherence to antihypertensives have lower blood pressure than those who do not.
77
 Similarly, 
optimal adherence to cholesterol-lowering medications has been associated with a significant 
reduction in low density lipoprotein-cholesterol (LDL-cholesterol).
78
  More notably, adherence 
to medications has been associated with significant reductions in morbidity and mortality. For 
instance, chronic medication adherence was associated with a 44% reduction (95% CI 26% to 
57%) in all-cause mortality in a systematic review pooling results from 8 randomized clinical 
trials and 13 observational cohort studies containing 46,847 subjects with different disease 
states.
79
   
Among these studies, non-adherence to statin medications was found to be associated with 
increased mortality risk (HR=1.25),
80
 and a significant increase in major coronary events 
following discharge from a myocardial infarction.
81,82
  Similarly, stopping statin medications 
after discharge from a myocardial infarction was found to be associated with an increased risk of 
a re-infarction (HR= 1.66).
83
  However, the estimated effect of optimal adherence to statin 
medications and mortality has varied significantly between studies. The reduction in mortality 
associated with optimal statin adherence ranges from 20% in some studies,
80
 and up to 80% in 
others.
84
 One of the most important reasons for these variable estimates is the presence of bias 
between patients who exhibit optimal adherence versus those exhibiting poor adherence.  In 
general, high adherence to a chronic medication may be a marker of other healthy behaviours 
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that can influence patient outcomes.  This ‘healthy adherer’ effect becomes difficult to identify 
and account for in analyses of health outcomes associated with various adherence levels.
79
  
Although many published studies have reported substantial benefits of optimal statin adherence 
with respect to lower morbidity and mortality, few studies have investigated how different study 
designs may influence the estimates themselves.  More research is needed to understand the most 
robust approach to obtain valid estimates of the benefits of optimal adherence on health 
outcomes.  These estimates are important for health services planning and policy development as 
well as understanding the areas where health care services can be improved.  
1.7 Determinants of non-adherence 
A vast number of potential adherence determinants have been examined previously in the 
literature.
85-88
 The World Health Organization (WHO) divides possible determinants into four 
broad categories: patient variables, disease variables, treatment variables, and health-system 
variables.
18,89
 Sometimes, social/economic variables are distinguished from patient variables 
(Figure 1-1).
12
  Patient variables include age, gender, race, and patient’s beliefs, knowledge and 
attitudes.
90
  Treatment variables include treatment regimen complexity,
91,92
 number of doses per 
day,
93
 cost of medications,
8,94,95
 the overall burden of prescribed medications,
96
 administration 
route,
97
 appearance of the medication,
98,99
 side effects
8,16,100
 and the duration of the treatment.
101
  
Disease-related variables include disease severity, symptom severity, and disease duration.
102
 
Health-system variables include the level of personalized or individual care, the availability of 
on-site interactions with patients (such as home care), and the quality of the communication 
between HCP and patients. 
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Figure ‎1-1: Categories of the determinants of adherence.
*
 
 
* Sabate´ E. Adherence to Long-Term Therapies: Evidence for Action. Vol 2011. 
http://www.who.int/chp/knowledge/publications/adherence_report/en/ ed. Geneva, Switzerland: 
World Health Orgnization; 2003. 
1.7.1 Social-Economic Status (SES) 
Socioeconomic status (SES) is an intriguing determinant of non-adherence because of its 
associations with economic, social, and education-related factors.  It is a multifactorial 
characteristic that represents an individual’s position relative to a social hierarchy and is 
determined by economic, social, and employment-related factors.
103
 
104
 SES cannot be 
understood without a comparison to others in a given population; individuals with high SES 
possess more material resources, have greater access to educational opportunities, and receive 
more social support compared to those in low SES strata.
105
    
SES is an important predictor of health status, health care system utilization, as well as health 
outcomes. Individuals characterized in low SES strata consistently experience poorer health in 
terms of higher infant mortality as well as higher incidence of both infectious and non-infectious 
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diseases.
104,106
 For example, low SES was found to be associated with a 44% increase in the  risk 
of coronary heart disease after adjusting for all other risk factors.
107
  
SES is a complex integration of multiple factors that include both material and social domains.
104
 
However, the impact of SES on health outcomes cannot be attributed to one factor in isolation of 
other factors.
106,108
 Individuals with low SES may face important barriers to accessing health care 
services,
109
 they may have poor health literacy,
110
 they may be unable to prioritize health due to 
other daily struggles, and/or they may be unable to afford health treatments or lifestyle 
modification strategies.  Although research on SES has primarily focused on the negative impact 
of these factors on health outcomes, a strong theoretical link can be made for their impact on 
medication adherence also.  Thus, using comprehensive measures of SES could potentially 
improve the ability of multivariate models to explain the determinants of medication non-
adherence.   However, objective evidence for the role of SES as a determinant of medication 
adherence is lacking. 
1.8 Interventions to improve adherence 
Several randomized controlled trials (RCTs) have been performed to examine interventions 
focused on improving adherence to chronic medications.
111-115
 Interventions may be targeted by 
the provider at patient-level, or may be applied universally at health-system or policy-levels.
116
 
Within patient-level interventions, three main categories can be identified: informational, 
behavioural, and combined strategies.
115
 Most adherence interventions provide patient-education 
or individualized patient-care from allied health care professionals (i.e., pharmacists or 
nurses).
117
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1.8.1 Pharmacist’s interventions 
Several studies have examined community pharmacist interventions to increase medication 
adherence. In a systematic review of studies examining pharmacist interventions to improve care 
for patients with diabetes, Evans et al identified 40 studies overall; 9 of these interventions were 
targeting medication adherence.
118
 In general, interventions involve lengthy multi-steps 
interactions with patients.
118
  For example, in one randomized controlled trial to improve 
adherence to statin medications, participants were required to return to the pharmacy for five 
appointments lasting 10-15 minutes each. Visits contained extensive counseling about statin 
indications, benefits, adverse effects, dosing; importance of adherence, and intended duration of 
treatment.
119
 In addition, a letter were sent to patients to request information about statin 
medications, any drug-related problems, and barriers to adherence. At the end of the study, 
adherence did not differ significantly between intervention group and control group (99.5%, and 
99.2% respectively).  
Altogether, published interventions are expensive and time consuming, making implementing 
them in real life practice difficult to implement.
117
 At the same time, it is recommended that 
adherence interventions must be multifaceted and persistent in order to impact adherence in a 
meaningful way.  Thus, more work is required to investigate efficient interventions able to 
support adherence without placing unreasonable demands on health care providers.     
1.9 Summary 
Poor adherence to medications is a major problem in health care that remains poorly understood.  
Although estimates about the prevalence of poor adherence have been consistently derived from 
population based studies, disagreement persists regarding many other facets of this problem.  
First, despite strong theoretical frameworks for the root causes of poor adherence, the importance 
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of certain factors such as socioeconomic status remains unproven.  Second, widely published 
estimates of the benefits of optimal adherence on health outcomes have not been scrutinized for 
the possible role of bias such as the healthy adherer phenomenon.  Finally, successful 
interventions have not been identified; previous attempts have had minimal effects or have been 
highly demanding on health provider time.  Therefore, a PhD. research program was carried out 
to examine various aspects of medication adherence to cardiovascular medications using various 
research methodologies. 
1.10 Research questions:  
1) Does the association between adherence to statin medications and mortality depend on 
the study design? 
2) To what extent can socio-economic status (SES) influence non-adherence to anti-
hypertensive (AHT) medications; and what are the approaches used in the literature to 
account for it?  
3) Does the use of multiple-domain measure of SES have a stronger association with non-
adherence to statin medications compared to single domain measures?  
Can a streamlined, easy to implement pharmacist intervention improve adherence among cardiac 
rehabilitation patients?  
 
1.11 Research Objectives  
The objectives of this program of research were:  
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1) To perform an observational study examining the association between statin adherence and 
mortality using a fixed baseline measure (i.e., a summary measure) and a repeated-measures 
approach to contrast the estimates for benefit and investigate signs of bias in each. 
2) To perform a systematic review and meta-analysis of the literature pertaining to SES and non-
adherence to AHT medications using population-based electronic prescription data to estimate the 
proportion of studies that identified SES as a potential risk indicator of non-adherence; to describe 
the type of SES measurements that were used in each study; and to quantify the association between 
SES and non-adherence to AHT medications.   
3) To perform an observational study examining if the use of the multiple domain measure of SES, 
the deprivation index, would be a stronger predictor of non-adherence to statin medications 
compared to single domain measures among a cohort of patients with established CHD in 
Saskatchewan, Canada.        
4) To perform a randomized controlled trial examining if an expanded pharmacist role in a cardiac 
rehabilitation program can improve the accessibility to patients AND improve health indicators such 
as adherence and risk factor control. 
1.12 Program of Research 
This thesis is composed of four separate, but related, studies.  Each individual study addresses a 
specific research question serving the overall research objective related to medication adherence 
to cardiovascular medications. The first study (chapter 2) is an observational study that compared 
the association between statin medication adherence and all-cause mortality when adherence was 
assessed by fixed summary measure and by repeated-measures methods. The second study 
(chapter 3) is a systematic review and meta-analysis that examined the use of SES as a potential 
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risk indicator of non-adherence to AHT medications.  The third study (chapter 4) is an 
observational study that compared the association between adherence to statin medications and 
SES when it was measured by multiple-domain and by single-domain measures. The fourth 
study (chapter 5) is a randomized clinical trial examining the intervention of clinical pharmacist 
to improve medications adherence. 
  
 15 
 
1.13 References 
 1. Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and 
medical care recommendations. Med Care. 1975;13(1):10-24. 
2. Statistics Canada. Table102-0561 - leading causes of death, total population, by age group and 
sex, canada, annual, CANSIM (database). 
http://www5.statcan.gc.ca/cansim/a05?lang=eng&id=1020561. Updated 2012. Accessed 01/06, 
2014. 
3. Johansen H, Thillaiampalam S, Nguyen D, Sambell C. Diseases of the circulatory system--
hospitalization and mortality. Health Rep. 2005;17(1):49-53. 
4. Thériault L, Stonebridge C, Browarski S. The canadian heart health strategy: Risk factors and 
future cost implications report. . 2010. 
5. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular S. Canadian 
cardiovascular society position statement--recommendations for the diagnosis and treatment of 
dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22(11):913-927. 
6. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360(9326):2-
3. 
7. Arca M, Gaspardone A. Atorvastatin efficacy in the primary and secondary prevention of 
cardiovascular events. Drugs. 2007;67 Suppl 1:29-42. 
8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. 
 16 
 
9. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular 
outcomes. Circulation. 2009;119(23):3028-3035. 
10. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology 
and definitions. Value Health. 2008;11(1):44-47. 
11. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining 
adherence to medications. Br J Clin Pharmacol. 2012;73(5):691-705. 
12. Sabate´ E. Adherence to long-term therapies: Evidence for action. Vol 2011. 
http://www.who.int/chp/knowledge/publications/adherence_report/en/ ed. Geneva, Switzerland: 
World Health Orgnization; 2003. 
13. Cohen SM. Concept analysis of adherence in the context of cardiovascular risk reduction. 
Nurs Forum. 2009;44(1):25-36. 
14. Treharne GJ, Lyons AC, Hale ED, Douglas KM, Kitas GD. 'Compliance' is futile but is 
'concordance' between rheumatology patients and health professionals attainable? Rheumatology 
(Oxford). 2006;45(1):1-5. 
15. Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology 
and definitions of medication adherence and persistence in research employing electronic 
databases. Med Care. 2013;51(8 Suppl 3):S11-21. 
16. Vermeire E, Hearnshaw H, Royen PV, Denekens J. Patient adherence to treatment: Three 
decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331-42. 
 17 
 
17. Becker MH. Patient adherence to prescribed therapies. Med Care. 1985;23(5, Proceedings of 
Conference "HSR 84: Planning for the Third Decade of Health Services Research"):539-555. 
18. Unni E, Farris KB. Determinants of different types of medication non-adherence in 
cholesterol lowering and asthma maintenance medications: A theoretical approach. Patient Educ 
Couns. 2011;83(3):382-390. 
19. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. 
Ther Clin Risk Manag. 2005;1(3):189-199. 
20. Beardon PHG, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary 
non-compliance with prescribed medication in primary care. BMJ: British Medical Journal. 
1993;307(6908):846-848. 
21. Waters WHR, Gould NV, Lunn JE. Undispensed prescriptions in A mining general practice. 
The British Medical Journal. 1976;1(6017):1062-1063. 
22. Rashid A. Do patients cash prescriptions? Br Med J (Clin Res Ed). 1982;284(6308):24-26. 
23. Watts RW, McLennan G, Bassham I, el-Saadi O. Do patients with asthma fill their 
prescriptions? A primary compliance study. Aust Fam Physician. 1997;26 Suppl 1:S4-6. 
24. Raebel MA, Ellis JL, Carroll NM, et al. Characteristics of patients with primary non-
adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med. 
2012;27(1):57-64. 
 18 
 
25. Raebel MA, Ellis JL, Carroll NM, et al. Characteristics of patients with primary non-
adherence to medications for hypertension, diabetes, and lipid disorders. Journal of General 
Internal Medicine. 2011;27(1):57-64. 
26. Ekedahl A, Mansson N. Unclaimed prescriptions after automated prescription transmittals to 
pharmacies. Pharmacy World & Science. 2004;26(1):26-31. 
27. Solomon MD, Majumdar SR. Primary non-adherence of medications: Lifting the veil on 
prescription-filling behaviors. J Gen Intern Med. 2010;25(4):280-1. 
28. Liberman J, Hutchins D, Popiel R, Patel M, Jan S. <br />Determinants of primary 
nonadherence in asthma-controller and dyslipidemia pharmacotherapy  Am J Pharm Benefits. 
2010;2(2):111-118. 
29. Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: Analysis of 
195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284-290. 
30. Fischer MA, Choudhry NK, Brill G, et al. Trouble getting started: Predictors of primary 
medication nonadherence. Am J Med. 2011;124(11):1081.e9-1081.e22. 
31. Cutrona SL, Woolhandler S, Lasser KE, Bor DH, McCormick D, Himmelstein DU. 
Characteristics of recipients of free prescription drug samples: A nationally representative 
analysis. Am J Public Health. 2008;98(2):284-289. 
32. Cutrona SL, Woolhandler S, Lasser KE, et al. Free drug samples in the united states: 
Characteristics of pediatric recipients and safety concerns. Pediatrics. 2008;122(4):736-742. 
 19 
 
33. Tjia J, Briesacher BA, Soumerai SB, et al. Medicare beneficiaries and free prescription drug 
samples: A national survey. J Gen Intern Med. 2008;23(6):709-714. 
34. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed 
antihypertensive drug treatments: Longitudinal study of electronically compiled dosing histories. 
BMJ. 2008;336(7653):1114-1117. 
35. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: Three 
decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331-342. 
36. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication 
adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 
2006;15(8):565-74; discussion 575-7. 
37. Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication 
adherence on coronary artery disease costs and outcomes: A systematic review. Am J Med. 
2013;126(4):357.e7-357.e27. 
38. Bouchard M-, Dragomir A, Blais L, Bérard A, Pilon D, Perreault S. Impact of adherence to 
statins on coronary artery disease in primary prevention. Br J Clin Pharmacol. 2007;63(6):698-
708. 
39. Breekveldt-Postma NS, Penning-Van Beest FJA, Siiskonen SJ, et al. The effect of 
discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr 
Med Res Opin. 2008;24(1):121-127. 
 20 
 
40. Corrao G, Conti V, Merlino L, Catapano AL, Mancia G. Results of a retrospective database 
analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily 
clinical practice in italy. Clin Ther. 2010;32(2):300-310. 
41. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin 
treatment and readmission of patients after myocardial infarction: A six year follow up study. 
Heart. 2002;88(3):229-233. 
42. Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the 
primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10):1013-1024. 
43. Amin AP, Mukhopadhyay E, Nathan S, Napan S, Kelly RF. Association of medical 
noncompliance and long-term adverse outcomes, after myocardial infarction in a minority and 
uninsured population. Translational Research. 2009;154(2):78-89. 
44. Chapman R, Jones DN. Duck diversity in greater brisbane: Native species, domestic races 
and the influence of feeding. The Sunbird. 2010;40(2):29-38. 
45. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after 
myocardial infarction. N Engl J Med. 2011;365(22):2088-2097. 
46. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and 
adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 
2004;27(12):2800-2805. 
 21 
 
47. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective 
medications and mortality among patients with diabetes and ischemic heart disease. BMC 
Cardiovasc Disord. 2006;6:48. 
48. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy 
administrative databases: A proposal for standard definitions and preferred measures. Ann 
Pharmacother. 2006;40(7-8):1280-1288. 
49. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: 
Methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-116. 
50. Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS. Validity of a prescription claims 
database to estimate medication adherence in older persons. Med Care. 2006;44(5):471-477. 
51. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug 
exposure assessment. J Clin Epidemiol. 1997;50(5):619-625. 
52. Johnson RE, Vollmer WM. Comparing sources of drug data about the elderly. J Am Geriatr 
Soc. 1991;39(11):1079-1084. 
53. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy 
records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. 
Med Care. 1999;37(9):846-857. 
54. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence 
after acute myocardial infarction. Circulation. 2008;117(8):1028-1036. 
 22 
 
55. Pedan A, Varasteh L, Schneeweiss S. Analysis of factors associated with statin adherence in 
a hierarchical model considering physician, pharmacy, patient, and prescription characteristics. J 
Manag Care Pharm. 2007;13(6):487-496. 
56. Shah NR, Hirsch AG, Zacker C, Taylor S, Wood GC, Stewart WF. Factors associated with 
first-fill adherence rates for diabetic medications: A cohort study. J Gen Intern Med. 
2009;24(2):233-237. 
57. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. 
Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a 
first cardiovascular event: A retrospective cohort study. Can J Cardiol. 2005;21(6):485-488. 
58. Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of 
nonadherence to statin therapy: A meta-analysis. Can J Cardiol. 2012;28(5):574-80. 
59. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin 
Ther. 1998;20(4):671-681. 
60. Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based 
analysis of persistence with antihypertensive drug therapy in primary care practice in italy. Clin 
Ther. 2002;24(8):1347-57; discussion 1346. 
61. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of 
discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J 
Am Board Fam Med. 2007;20(1):72-80. 
 23 
 
62. Lemstra M, Blackburn D. Nonadherence to statin therapy: Discontinuation after a single fill. 
Can J Cardiol. 2012;28(5):567-573. 
63. Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription 
medication gaps: A comprehensive measure of adherence to new prescriptions. Health Serv Res. 
2009;44(5 Pt 1):1640-1661. 
64. Evans CD, Eurich DT, Remillard AJ, Shevchuk YM, Blackburn D. First-fill medication 
discontinuations and nonadherence to antihypertensive therapy: An observational study. Am J 
Hypertens. 2012;25(2):195-203. 
65. Akincigil A, Bowblis JR, Levin C, Jan S, Patel M, Crystal S. Long-term adherence to 
evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern 
Med. 2008;23(2):115-121. 
66. Robertson T, Cooke C, Lee H. Use of secondary prevention drug therapy in patients with 
acute coronary syndrome after hospital discharge. Journal of managed care pharmacy. 
2008;14(3):271. 
67. Esposti LD, Saragoni S, Batacchi P, Geppetti P, Buda S, Esposti ED. Antihypertensive 
therapy among newly treated patients: An analysis of adherence and cost of treatment over years. 
Clinicoecon Outcomes Res. 2010;2:113-120. 
68. Setoguchi S, Choudhry NK, Levin R, Shrank WH, Winkelmayer WC. Temporal trends in 
adherence to cardiovascular medications in elderly patients after hospitalization for heart failure. 
Clin Pharmacol Ther. 2010;88(4):548-554. 
 24 
 
69. Setoguchi S, Glynn RJ, Avorn J, Levin R, Winkelmayer WC. Ten-year trends of 
cardiovascular drug use after myocardial infarction among community-dwelling persons > or 
=65 years of age. Am J Cardiol. 2007;100(7):1061-1067. 
70. Lamb D, Eurich D, McAlister F, et al. Changes in adherence to evidence-based medications 
in the first year after initial hospitalization for heart failure: Observational cohort study from 
1994 to 2003. Circulation: Cardiovascular Quality and Outcomes. 2009;2(3):228. 
71. Choudhry NK, Setoguchi S, Levin R, Winkelmayer WC, Shrank WH. Trends in adherence to 
secondary prevention medications in elderly post-myocardial infarction patients. 
Pharmacoepidemiol Drug Saf. 2008;17(12):1189-1196. 
72. Esposti LD, Saragoni S, Batacchi P, Geppetti P, Buda S, Esposti ED. Antihypertensive 
therapy among newly treated patients: An analysis of adherence and cost of treatment over years. 
Clinicoecon Outcomes Res. 2010;2:113-120. 
73. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical 
treatment outcomes: A meta-analysis. Med Care. 2002;40(9):794-811. 
74. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: An unrecognized 
cardiovascular risk factor. MedGenMed. 2007;9(3):58. 
75. Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM. Adherence in 
chronic disease. Annu Rev Nurs Res. 2000;18:48-90. 
76. Frishman WH. Importance of medication adherence in cardiovascular disease and the value 
of once-daily treatment regimens. Cardiol Rev. 2007;15(5):257-263. 
 25 
 
77. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure 
control to adherence with antihypertensive monotherapy in 13 managed care organizations. J 
Manag Care Pharm. 2006;12(3):239-245. 
78. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on 
hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 
2006;166(17):1836-1841. 
79. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between 
adherence to drug therapy and mortality. BMJ. 2006;333(7557):15. 
80. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based 
pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 
2007;297(2):177-186. 
81. Ruokoniemi P, Korhonen MJ, Helin-Salmivaara A, et al. Statin adherence and the risk of 
major coronary events in patients with diabetes: A nested case-control study. Br J Clin 
Pharmacol. 2011;71(5):766-776. 
82. Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel 
blocker and statin medications and likelihood of cardiovascular events among US managed care 
enrollees. BMC Cardiovasc Disord. 2010;10:29-2261-10-29. 
83. Shaya FT, Gu A, Yan X. Effect of persistence with drug therapy on the risk of myocardial re-
infarction. P T. 2008;33(5):288-295. 
 26 
 
84. Wei L, Wang J, Thompson P, Wong S, et al. Adherence to strain treatment and readmission 
of patients after myocardial infarction: A six year follow up study. Heart. 2002;88(3):229-33. 
85. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20(4):764-
771. 
86. Meichenbaum D. Facilitating treatment adherence :A practitioner's guidebook. New York: 
Plenum Press; c1987. 
87. Kusserow RP. Medication regimens: Causes of noncompliance. Washington, DC: Office of 
the Inspector General.; 1990. 
88. Haynes RB, Sackett DL. Compliance with therapeutic regimens. Baltimore: Johns Hopkins 
University Press; 1976:293. 
89. Unni EJ, Farris KB. Unintentional non-adherence and belief in medicines in older adults. 
Patient Educ Couns. 2011;83(2):265-8. 
90. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient 
adherence: A meta-analysis. Med Care. 2007;45(6):521-528. 
91. Stange D, Kriston L, von-Wolff A, Baehr M, Dartsch DC. Reducing cardiovascular 
medication complexity in a german university hospital: Effects of a structured pharmaceutical 
management intervention on adherence. J Manag Care Pharm. 2013;19(5):396-407. 
92. Libby AM, Fish DN, Hosokawa PW, et al. Patient-level medication regimen complexity 
across populations with chronic disease. Clin Ther. 2013;35(4):385-398.e1. 
 27 
 
93. Chappuy H, Treluyer JM, Faesch S, Giraud C, Cheron G. Length of the treatment and 
number of doses per day as major determinants of child adherence to acute treatment. Acta 
Paediatr. 2010;99(3):433-437. 
94. Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: Findings 
from a 2003 national survey. Health Aff (Millwood). 2005;Suppl Web Exclusives:W5-152-W5-
166. 
95. Hutchison LC, Jones SK, West DS, Wei JY. Assessment of medication management by 
community-living elderly persons with two standardized assessment tools: A cross-sectional 
study. Am J Geriatr Pharmacother. 2006;4(2):144-153. 
96. O'Connor JL, Gardner EM, Mannheimer SB, et al. Factors associated with adherence 
amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis. 
2013;208(1):40-49. 
97. Peidro-Garces L, Otero-Fernandez R, Lozano-Lizarraga L. Adherence to and satisfaction 
with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study. Rev 
Esp Cir Ortop Traumatol. 2013;57(1):53-60. 
98. Sapra M, Weiden PJ, Schooler NR, Sunakawa-McMillan A, Uzenoff S, Burkholder P. 
Reasons for adherence and non-adherence. Clin Schizophr Relat Psychoses. 2013:1-19. 
99. Kesselheim AS, Misono AS, Shrank WH, et al. Variations in pill appearance of antiepileptic 
drugs and the risk of nonadherence. JAMA Intern Med. 2013;173(3):202-208. 
 28 
 
100. Morrison A, Wertheimer AI. Compilation of quantitative overviews of studies of adherence. 
Drug Inf J. 2004;38(2):197-210. 
101. Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: A 
systematic review. Horm Res Paediatr. 2013;79(4):189-196. 
102. Billups SJ, Malone DC, Carter BL. The relationship between drug therapy noncompliance 
and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy. 
2000;20(8):941-949. 
103. Adler NE, Boyce T, Chesney MA, et al. Socioeconomic status and health. the challenge of 
the gradient. Am Psychol. 1994;49(1):15-24. 
104. Williams D, Moss N, Krieger N. Measuring social class in US public health research: 
Concepts, methodologies, and guidelines. Annu Rev Public Health. 1997;18:341-378. 
105. Townsend P. The rich man in his castle: In britain inequality is spiralling out of control. 
(social inequality) (editorial). Br Med J. 1994;309(6970):1674. 
106. Williams DR. Socioeconomic differentials in health: A review and redirection. Soc Psychol 
Q. 1990;53(2):81. 
107. Franks P, Winters PC, Tancredi DJ, Fiscella KA. Do changes in traditional coronary heart 
disease risk factors over time explain the association between socio-economic status and 
coronary heart disease? BMC cardiovascular disorders. ;11:28. 
 29 
 
108. Macintyre S. The patterning of health by social position in contemporary britain: Directions 
for sociological research. Soc Sci Med. 1986;23(4):393-415. 
109. Olah ME, Gaisano G, Hwang SW. The effect of socioeconomic status on access to primary 
care: An audit study. CMAJ. 2013;185(6):E263-9. 
110. Bennett CL, Ferreira MR, Davis TC, et al. Relation between literacy, race, and stage of 
presentation among low-income patients with prostate cancer. J Clin Oncol. 1998;16(9):3101-
3104. 
111. Laba TL, Bleasel J, Brien JA, et al. Strategies to improve adherence to medications for 
cardiovascular diseases in socioeconomically disadvantaged populations: A systematic review. 
Int J Cardiol. 2013. 
112. Suhrcke M, Boluarte TA, Niessen L. A systematic review of economic evaluations of 
interventions to tackle cardiovascular disease in low- and middle-income countries. BMC Public 
Health. 2012;12:2-2458-12-2. 
113. Williams A, Manias E, Walker R. Interventions to improve medication adherence in people 
with multiple chronic conditions: A systematic review. J Adv Nurs. 2008;63(2):132-143. 
114. Haynes RB, Wang E, Da MG. A critical review of interventions to improve compliance 
with prescribed medications. Patient Educ Couns. 1987;10(2):155-166. 
115. Touchette DR, Shapiro NL. Medication compliance, adherence, and persistence: Current 
status of behavioral and educational interventions to improve outcomes. J Manag Care Pharm. 
2008;14(6 (suppl S-d)):S2-S10. 
 30 
 
116. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-
administered medications for chronic diseases in the united states: A systematic review. Ann 
Intern Med. 2012;157(11):785-795. 
117. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing 
medication adherence. Cochrane Database Syst Rev. 2008;(2)(2):CD000011. 
118. Evans CD, Watson E, Eurich DT, et al. Diabetes and cardiovascular disease interventions 
by community pharmacists: A systematic review. Ann Pharmacother. 2011;45(5):615-628. 
119. Eussen SR, van der Elst ME, Klungel OH, et al. A pharmaceutical care program to improve 
adherence to statin therapy: A randomized controlled trial. Annals of Pharmacotherapy. 
2010;44(12):1905-1913. 
120. Simpson RJ,Jr, Mendys P. The effects of adherence and persistence on clinical outcomes in 
patients treated with statins: A systematic review. J Clin Lipidol. 2010;4(6):462-471. 
121. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based 
secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203-212. 
122. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad 
range of adverse outcomes in patients with coronary artery disease. Am Heart J. 
2008;155(4):772-779. 
123. Esposti LD, Saragoni S, Benemei S, et al. Adherence to antihypertensive medications and 
health outcomes among newly treated hypertensive patients. Clinicoecon Outcomes Res. 
2011;3:47-54. 
 31 
 
124. Wei L, Fahey T, MacDonald TM. Adherence to statin or aspirin or both in patients with 
established cardiovascular disease: Exploring healthy behaviour vs. drug effects and 10-year 
follow-up of outcome. Br J Clin Pharmacol. 2008;66(1):110-116. 
125. Kettani F, Dragomir A, Côté R, et al. Impact of a better adherence to antihypertensive 
agents on cerebrovascular disease for primary prevention. Stroke. 2009;40(1):213-220. 
126. Hong J, Novick D, Treuer T, et al. Predictors and consequences of adherence to the 
treatment of pediatric patients with attention-deficit/hyperactivity disorder in central europe and 
east asia. Patient Prefer Adherence. 2013;7:987-995. 
127. Fitzgerald AA, Powers JD, Ho PM, et al. Impact of medication nonadherence on 
hospitalizations and mortality in heart failure. J Card Fail. 2011;17(8):664-669. 
128. Yu AP, Nichol MB. A time-varying survival model for the association of adherence with 
HMG-COA inhibitors to the risk of adverse events. Value Health. 2003;6(3):191-192. 
129. Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal 
patient outcomes: Insights from the veterans health administration. Am Heart J. 
2014;167(6):810-817. 
130. Tulloch J, Evans B. Evaluation of the accuracy of the saskatchewan health pharmaceutical 
information program for determining a patient's medication use immediately before admission. 
Can J Hosp Pharm. 2009;62(1):21-27. 
 32 
 
131. Liu L, Reeder B, Shuaib A, Mazagri R. Validity of stroke diagnosis on hospital discharge 
records in saskatchewan, canada: Implications for stroke surveillance. Cerebrovasc Dis. 
1999;9(4):224-230. 
132. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity 
associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25(8):1035-1043. 
133. Austin PC, Tu JV, Ko DT, Alter DA. Factors associated with the use of evidence-based 
therapies after discharge among elderly patients with myocardial infarction. CMAJ. 
2008;179(9):901-908. 
134. Varas-Lorenzo C, Castellsague J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. 
Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute 
coronary syndromes in the saskatchewan hospital automated database. Pharmacoepidemiol Drug 
Saf. 2008;17(8):842-852. 
135. Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and 
procedure codes for cardiovascular and gastrointestinal serious adverse events in a 
commercially-insured population. Pharmacoepidemiol Drug Saf. 2010;19(6):596-603. 
136. Petersen LA, Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of 
acute myocardial infarction in an administrative database. J Gen Intern Med. 1999;14(9):555-
558. 
137. Lee DS, Stitt A, Wang X, et al. Administrative hospitalization database validation of 
cardiac procedure codes. Med Care. 2013;51(4):e22-6. 
 33 
 
138. Gurevich Y, McFarlane A, Morris K, Jokovic A, Peterson GM, Webster GK. Estimating the 
number of coronary artery bypass graft and percutaneous coronary intervention procedures in 
canada: A comparison of cardiac registry and canadian institute for health information data 
sources. Can J Cardiol. 2010;26(7):e249-53. 
139. Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic 
obstructive pulmonary disease in the saskatchewan health care datafiles. Stat Med. 
1995;14(24):2627-2643. 
140. Martin, Wiley-Exley, Richards, Domino, Carey, Sleath,. Contrasting measures of adherence 
with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 
2009;43(1):36-44. 
141. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for 
medication compliance and persistence studies using retrospective databases. Value Health. 
2007;10(1):3-12. 
142. Leslie SR, Gwadry-Sridhar F, Thiebaud P, Patel BV. Calculating medication compliance, 
adherence and persistence in administrative pharmacy claims databases. Pharmaceutical 
Programming. 2008;1(1):13-19. 
143. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med. 
1997;241(4):317-325. 
144. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: A 
cross-national study. JAMA. 1998;279(18):1458-1462. 
 34 
 
145. Strom BL. Pharmacoepidemiology. 4th ed. Chichester; Hoboken, NJ: J. Wiley; 2005:889. 
146. Collett 1952- D, Collett D, 1952-. Modelling survival data in medical research. Boca 
Raton, Fla.: Boca Raton, Fla. : Chapman & Hall/CRC; 2003. 
147. Belsley DA, Belsley DA. Regression diagnostics : Identifying influential data and sources 
of collinearity. New York: New York : Wiley; 1980. 
148. Tu JV, Nardi L, Fang J, et al. National trends in rates of death and hospital admissions 
related to acute myocardial infarction, heart failure and stroke, 1994-2004. CMAJ. 
2009;180(13):E118-25. 
149. Pedan A, Varasteh L, Schneeweiss S. Analysis of factors associated with statin adherence in 
a hierarchical model considering physician, pharmacy, patient, and prescription characteristics. J 
Manag Care Pharm. 2007;13(6):487-496. 
150. Sharma, M., Ansari. M., Abou-Setta,A. Systematic review: Comparative effectiveness and 
harms of combination therapy and monotherapy for dyslipidemia. Annals of Internal Medicine. 
2009;151:622-630. 
151. Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, 
Jukema JW. The efficacy of statin monotherapy uptitration versus switching to 
ezetimibe/simvastatin: Results of the EASEGO study. Curr Med Res Opin. 2008;24(3):685-694. 
152. Virani SS, Woodard L, Ramsey D, Ballantyne C, Petersen LA. Is high-dose statin therapy 
associated with lower statin adherence compared with low-dose therapy? an analysis from a 
national cohort. J Am Coll Cardiol. 2014;63(12_S). 
 35 
 
153. Government of Saskatchewan. Drug plan and extended benefits branch annual report 2010-
2011. ; 2011. 
154. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging 
improve adherence? A systematic review. Bull World Health Organ. 2004;82(12):935-939. 
155. Lee JK, Grace KA,Taylor AJ. Effect of a pharmacy care program on medication adherence 
and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized 
controlled trial. JAMA. 2006;296(21):2563-2571. 
156. Huser MA, Evans TS, Berger V. Medication adherence trends with statins. Adv Ther. 
2005;22(2):163-171. 
157. Pampalon R, Hamel D, Gamache P, Raymond G. A deprivation index for health planning in 
canada. Chronic Dis Can. 2009;29(4):178-191. 
158. Krieger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R. Geocoding 
and monitoring of US socioeconomic inequalities in mortality and cancer incidence: Does the 
choice of area-based measure and geographic level matter?: The public health disparities 
geocoding project. Am J Epidemiol. 2002;156(5):471-482. 
159. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 
1987;40(5):373-383. 
160. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-
9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619. 
 36 
 
161. Quail JM, Lix LM, Osman BA, Teare GF. Comparing comorbidity measures for predicting 
mortality and hospitalization in three population-based cohorts. BMC Health Serv Res. 
2011;11:146. 
162. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in 
ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. 
163. Lemstra M, Alsabbagh MW. Proportion and risk indicators of nonadherence to 
antihypertensive therapy: A meta-analysis. Patient Prefer Adherence. 2014;8:211-218. 
164. Wong MC, Su X, Jiang JY, Tang JL, Griffiths SM. Profiles of discontinuation and 
switching of thiazide diuretics: A cohort study among 9398 chinese hypertensive patients. 
Hypertens Res. 2011;34(7):888-893. 
165. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug 
choice and comorbidity on antihypertensive therapy compliance: Results from a population-
based study in the elderly. Am J Hypertens. 1997;10(7 Pt 1):697-704. 
166. Yang Y, Thumula V, Pace PF, Banahan BF,3rd, Wilkin NE, Lobb WB. Predictors of 
medication nonadherence among patients with diabetes in medicare part D programs: A 
retrospective cohort study. Clin Ther. 2009;31(10):2178-88; discussion 2150-1. 
167. Shaya FT, Du D, Gbarayor CM, Frech-Tamas F, Lau H, Weir MR. Predictors of 
compliance with antihypertensive therapy in a high-risk medicaid population. J Natl Med Assoc. 
2009;101(1):34-39. 
 37 
 
168. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-
aged patients with essential hypertension. Ann Pharmacother. 2005;39(9):1401-1408. 
169. Signorovitch JE, Samuelson TM, Ramakrishnan K, et al. Persistence with nebivolol in the 
treatment of hypertension: A retrospective claims analysis. Curr Med Res Opin. 2012;28(4):591-
599. 
170. Taira DA, Gelber RP, Davis J, Gronley K, Chung RS, Seto TB. Antihypertensive adherence 
and drug class among asian pacific americans. Ethn Health. 2007;12(3):265-281. 
171. van Wijk BL, Shrank WH, Klungel OH, Schneeweiss S, Brookhart MA, Avorn J. A cross-
national study of the persistence of antihypertensive medication use in the elderly. J Hypertens. 
2008;26(1):145-153. 
172. Wong MC, Jiang JY, Griffiths SM. Antihypertensive drug adherence among 6408 chinese 
patients on angiotensin-converting enzyme inhibitors in hong kong: A cohort study. J Clin 
Pharmacol. 2010;50(5):598-605. 
173. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence 
across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728-740. 
174. Gogovor A, Dragomir A, Savoie M, Perreault S. Comparison of persistence rates with 
angiotensin-converting enzyme inhibitors used in secondary and primary prevention of 
cardiovascular disease. Value Health. 2007;10(5):431-441. 
 38 
 
175. Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C. 
Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag 
Care. 2011;17(9):609-616. 
176. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the department of 
veterans affairs. Am J Med. 2007;120(1):26-32. 
177. Friedman O, McAlister FA, Yun L, Campbell NR, Tu K, Canadian Hypertension Education 
Program Outcomes Research Taskforce. Antihypertensive drug persistence and compliance 
among newly treated elderly hypertensives in ontario. Am J Med. 2010;123(2):173-181. 
178. Wong MC, Lau RK, Jiang JY, Griffiths SM. Discontinuation of angiotensin-converting 
enzyme inhibitors: A cohort study. J Clin Pharm Ther. 2012;37(3):335-341. 
179. Corrao G, Zambon A, Parodi A, et al. Do socioeconomic disparities affect accessing and 
keeping antihypertensive drug therapy? evidence from an italian population-based study. J Hum 
Hypertens. 2009;23(4):238-244. 
180. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies 
after discharge for acute coronary syndromes: An ongoing prospective, observational study. Am 
J Med. 2004;117(2):73-81. 
181. Wong MC, Jiang JY, Griffiths SM. Adherence to combination therapy among ethnic 
chinese patients: A cohort study. Hypertens Res. 2010;33(5):416-421. 
 39 
 
182. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with 
amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 
2003;9(5):424-429. 
183. Yang Y, Thumula V, Pace PF, Banahan BF,3rd, Wilkin NE, Lobb WB. Nonadherence to 
angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-
risk patients with diabetes in medicare part D programs. J Am Pharm Assoc (2003). 
2010;50(4):527-531. 
184. Kramer JM, Hammill B, Anstrom KJ, et al. National evaluation of adherence to beta-
blocker therapy for 1 year after acute myocardial infarction in patients with commercial health 
insurance. Am Heart J. 2006;152(3):454.e1-454.e8. 
185. Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with 
antihypertensive drugs in new patients. J Hum Hypertens. 2002;16(6):439-444. 
186. Shah ND, Dunlay SM, Ting HH, et al. Long-term medication adherence after myocardial 
infarction: Experience of a community. Am J Med. 2009;122(10):961.e7-961.13. 
187. Wong MC, Jiang JY, Su X, Wang H, Tang JL, Griffiths SM. Individuals at risk of beta-
blocker discontinuation: A cohort study in 19,177 chinese patients. Clin Res Cardiol. 
2010;99(5):277-284. 
188. Ude M, Schuessel K, Quinzler R, Leuner K, Muller WE, Schulz M. Generic switch after 
ramipril patent expiry is not associated with decreased pharmacy refill compliance: A 
retrospective study using the DAPI database. J Hypertens. 2011;29(9):1837-1845. 
 40 
 
189. Sung SK, Lee SG, Lee KS, Kim DS, Kim KH, Kim KY. First-year treatment adherence 
among outpatients initiating antihypertensive medication in korea: Results of a retrospective 
claims review. Clin Ther. 2009;31(6):1309-1320. 
190. Wong MC, Jiang JY, Griffiths SM. Factors associated with compliance, discontinuation and 
switching of calcium channel blockers in 20,156 chinese patients. Am J Hypertens. 
2009;22(8):904-910. 
191. Wong MC, Jiang JY, Griffiths SM. Factors associated with compliance to thiazide diuretics 
among 8551 chinese patients. J Clin Pharm Ther. 2011;36(2):179-186. 
192. Wong MC, Jiang JY, Gibbs T, Griffiths SM. Factors associated with antihypertensive drug 
discontinuation among chinese patients: A cohort study. Am J Hypertens. 2009;22(7):802-810. 
193. Wong MC, Jiang JY, Griffiths SM. Factors associated with antihypertensive drug 
compliance in 83,884 chinese patients: A cohort study. J Epidemiol Community Health. 
2010;64(10):895-901. 
194. Wong MC, Jiang JY, Griffiths SM. Short-term adherence to beta-blocker therapy among 
ethnic chinese patients with hypertension: A cohort study. Clin Ther. 2009;31(10):2170-7; 
discussion 2150-1. 
195. Frech-Tamas FH. Impact of medication burden on adherence with antihypertensive drugs. 
[Ph.D.]. Rutgers The State University of New Jersey - New Brunswick; 2010. 
 41 
 
196. Pataky RE. Persistence and adherence with cardiovascular and lipid-lowering drugs 
following acute myocardial infarction in british columbia. [MSc.]. University of British 
Columbia - Vancouver; 2009. 
197. Rasmussen JN, Gislason GH, Rasmussen S, et al. Use of statins and beta-blockers after 
acute myocardial infarction according to income and education. J Epidemiol Community Health. 
2007;61(12):1091-1097. 
198. Roe CM, Motheral BR, Teitelbaum F, Rich MW. Compliance with and dosing of 
angiotensin-converting-enzyme inhibitors before and after hospitalization. Am J Health Syst 
Pharm. 2000;57(2):139-145. 
199. Khan NA, Yun L, Humphries K, Kapral M. Antihypertensive drug use and adherence after 
stroke: Are there sex differences? Stroke. 2010;41(7):1445-1449. 
200. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive 
treatment by two-drug combination as first step. evidence from daily life practice. J Hypertens. 
2010;28(7):1584-1590. 
201. van Dijk L, Heerdink ER, Somai D, et al. Patient risk profiles and practice variation in 
nonadherence to antidepressants, antihypertensives and oral hypoglycemics. BMC Health Serv 
Res. 2007;7:51. 
202. van Wijk BL, Avorn J, Solomon DH, et al. Rates and determinants of reinitiating 
antihypertensive therapy after prolonged stoppage: A population-based study. J Hypertens. 
2007;25(3):689-697. 
 42 
 
203. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year 
persistence with antihypertensive drugs. J Hypertens. 2005;23(11):2101-2107. 
204. Lai EJ, Grubisic M, Palepu A, Quan H, King KM, Khan NA. Cardiac medication 
prescribing and adherence after acute myocardial infarction in chinese and south asian canadian 
patients. BMC Cardiovasc Disord. 2011;11:56. 
205. Charles H, Good CB, Hanusa BH, Chang CC, Whittle J. Racial differences in adherence to 
cardiac medications. J Natl Med Assoc. 2003;95(1):17-27. 
206. Bailey JE, Lee MD, Somes GW, Graham RL. Risk factors for antihypertensive medication 
refill failure by patients under medicaid managed care. Clin Ther. 1996;18(6):1252-1262. 
207. Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive 
drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41(2):397-401. 
208. Zeng F, Patel BV, Andrews L, Frech-Tamas F, Rudolph AE. Adherence and persistence of 
single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr 
Med Res Opin. 2010;26(12):2877-2887. 
209. Brixner DI, Jackson KC,2nd, Sheng X, Nelson RE, Keskinaslan A. Assessment of 
adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts 
in free-and fixed-dose combinations. Curr Med Res Opin. 2008;24(9):2597-2607. 
210. Patel BV, Remigio-Baker RA, Thiebaud P, Preblick R, Plauschinat C. Improved persistence 
and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. 
BMC Fam Pract. 2008;9:61. 
 43 
 
211. Roe CM, Motheral BR, Teitelbaum F, Rich MW. Angiotensin-converting enzyme inhibitor 
compliance and dosing among patients with heart failure. Am Heart J. 1999;138(5 Pt 1):818-825. 
212. Karp I, Chen SF, Pilote L. Sex differences in the effectiveness of statins after myocardial 
infarction. CMAJ. 2007;176(3):333-338. 
213. Alsabbagh MHDW, Lemstra M, Eurich D, et al. Socioeconomic status and nonadherence to 
antihypertensive drugs: A systematic review and meta-analysis. Value Health. 2014;17(2):288-
296. 
214. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount 
and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin 
Oncol. 2011;29(18):2534-2542. 
215. Batal HA, Krantz MJ, Dale RA, Mehler PS, Steiner JF. Impact of prescription size on statin 
adherence and cholesterol levels. BMC Health Serv Res. 2007;7:175. 
216. Vinker S, Shani M, Baevsky T, Elhayany A. Adherence with statins over 8 years in a usual 
care setting. Am J Manag Care. 2008;14(6):388-392. 
217. Wong MC, Jiang JY, Griffiths SM. Factors associated with compliance to thiazide diuretics 
among 8551 chinese patients. J Clin Pharm Ther. 2011;36(2):179-186. 
218. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-
for-profit health maintenance organization: A population-based retrospective cohort study in 
israel. Clin Ther. 2008;30(11):2167-2179. 
 44 
 
219. Nahon S, Lahmek P, Saas C, et al. Socioeconomic and psychological factors associated 
with nonadherence to treatment in inflammatory bowel disease patients: Results of the ISSEO 
survey. Inflamm Bowel Dis. 2011;17(6):1270-1276. 
220. Ross NA, Oliver LN, Villeneuve PJ. The contribution of neighbourhood material and social 
deprivation to survival: A 22-year follow-up of more than 500,000 canadians. Int J Environ Res 
Public Health. 2013;10(4):1378-1391. 
221. Burrows S, Auger N, Gamache P, St-Laurent D, Hamel D. Influence of social and material 
individual and area deprivation on suicide mortality among 2.7 million canadians: A prospective 
study. BMC Public Health. 2011;11:577-2458-11-577. 
222. Pampalon R, Hamel D, Gamache P. A comparison of individual and area-based socio-
economic data for monitoring social inequalities in health. Health Rep. 2009;20(4):85-94. 
223. Statistics Canada. 2006 population census. .  
224. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a danish 
population: Compliance study 1993-1998. Br J Clin Pharmacol. 2002;53(4):375-378. 
225. Statistics Canada. 2001 census of canada: Community profiles. . 2001. 
226. Harrell FE,Jr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing 
models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 
1996;15(4):361-387. 
 45 
 
227. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more 
correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 
1988;44(3):837-845. 
228. Hosmer DW, Lemeshow S. Applied logistic regression. Second Edition ed. USA: Wiley-
Interscience; 2000. 
229. Rubin DB. Multiple imputation after 18+ years. Journal of the American Statistical 
Association. 1996;91(434):pp. 473-489. 
230. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed ed. USA: Wiley-
Interscience; 2002. 
231. Graham JW, Hofer SM, Donaldson SI, MacKinnon DP, Schafer JL. Analysis with missing 
data in prevention research. In: Bryant K, Windle M,  West S, eds. The science of prevention: 
Methodological advances from alcohol and substance abuse research. 1st edition ed. 
Washington, D.C. USA: American Psychological Association; 1997:325-366. 
232. Pampel FC, Krueger PM, Denney JT. Socioeconomic disparities in health behaviors. Annu 
Rev Sociol. 2010;36:349-370. 
233. Weiss BD, Blanchard JS, McGee DL, et al. Illiteracy among medicaid recipients and its 
relationship to health care costs. J Health Care Poor Underserved. 1994;5(2):99-111. 
234. Parker R. Health literacy: A challenge for american patients and their health care providers. 
Health Promotion International. 2000;15(4):277-283. 
 46 
 
235. Wong ES, Piette JD, Liu CF, et al. Measures of adherence to oral hypoglycemic agents at 
the primary care clinic level: The role of risk adjustment. Med Care. 2012;50(7):591-598. 
236. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy 
data. J Clin Epidemiol. 1992;45(2):197-203. 
  
 
CHAPTER -2- DOES THE ASSOCIATION BETWEEN ADHERENCE TO 
STATIN MEDICATIONS AND MORTALITY DEPEND ON 
MEASUREMENT APPROACH? A RETROSPECTIVE COHORT STUDY 
2.1 Abstract 
Background: Optimal adherence to statin medications has been associated with low mortality 
rates.  However, it is not clear if the estimated benefits of statin adherence are influenced by the 
measurement strategy.  Objectives: The aim of this study was to examine the relationship 
between mortality and statin adherence using two different approaches to adherence 
measurement (summary versus repeated-measures).   Methods: A retrospective cohort study was 
conducted using administrative data from Saskatchewan, Canada between 1994 and 2008.  
Eligible individuals received statins following discharge from a hospitalization for acute 
coronary syndrome (ACS).  Adherence was measured using proportion of days covered (PDC) 
expressed either as: 1) a fixed summary measure, or 2) as a repeatedly measured covariate.  Cox-
proportional hazards models were used to estimate the association between each adherence 
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measure and mortality after multivariable adjustment.  Results: Among 9,051 eligible 
individuals, optimal adherence (≥80%) modeled with a fixed summary measure was not 
associated with mortality benefits (adjusted HR 0.97, 95%CI 0.86 to 1.09, p=0.60).  In contrast, 
optimal adherence defined by the repeated-measures approach was associated with a significant 
25% reduction in the risk of death (adjusted HR 0.75, 95%CI 0.67 to 0.85, p<0.01). Conclusions: 
The relationship between statin adherence and mortality is largely influenced by the 
measurement approach used. Although surveillance of adherence and health outcomes should 
continue, estimates must be generated using different measures until the most valid approach can 
be identified.           
2.2 Background 
Observational studies using health-administrative databases have reported low mortality rates 
among individuals exhibiting high adherence to statin medications (HMG Co-A reductase 
inhibitors).
120
  However, these studies have produced highly variable estimates of benefit.  
Depending on the study, individuals exhibiting high adherence have been associated with 20%,
80
 
50%,
121,122
 or even 81%
84
 lower risks of death.  An important source of variability may be due to 
the different approaches used to measure adherence.   
In studies using electronic refill databases, adherence is often measured by the ‘medication 
possession ratio’ (MPR) or the ‘proportion of days covered’ (PDC).  This approach estimates the 
percentage of days during a defined observation period where medication was available for 
consumption based on the total quantity obtained from pharmacy refills.
25
  In descriptive studies, 
adherence is typically expressed as a single measure summarizing the entire observation period 
often lasting one year or more.
123-125
  Although the summary measure of adherence offers a 
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simple and straightforward result to represent the entire period of follow-up, it does not account 
for the possibility that patients may exhibit different levels of adherence over time.      
Medication adherence can also be measured repeatedly during a period of follow-up and 
regarded as a time-dependent variable.
126,127
  This measurement method may have advantages 
over the summary measure because it is more sensitive to changes in adherence over time.  For 
example, a summary adherence measure of 58% calculated over a one-year period could actually 
reflect an individual with 16% adherence during the first six months and 100% adherence in the 
last six months of observation.  In fact, it has been suggested that a repeated-measures approach 
is advantageous in revealing a robust association with mortality.
127-129
 However, no empiric data 
can be found to support this claim.  Indeed, no previous study has investigated if the association 
between mortality and medication adherence is influenced by measurement approach. Thus, we 
contrasted the estimated impact of statin adherence on mortality using two measurement 
approaches, a fixed summary measure versus repeated-measures, on the same cohort of patients 
with acute coronary syndrome.     
2.3 Methods 
2.3.1 Data source 
Administrative data maintained by the Saskatchewan Ministry of Health (MOH) were used for 
this study. Saskatchewan MOH databases contain valid data and have been used to produce high 
quality pharmacoepidemiological studies.
57,70,130-132
 Specifically, we used information from the 
population registry, prescription drug file (pharmacy dispensations), physician services and 
hospital services databases. The Saskatchewan MOH covers almost 99% of the province’s 
residents for both physician and hospital services. The only exceptions are federal prisons 
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inmates and members of the armed forces and the Royal Canadian Mounted Police (RCMP) 
because they are recipients of the federal government’s health benefits.  On the other hand, the 
prescription drug database captures medication dispensations for 90% of the provincial 
population; it excludes patients who receive federal prescription coverage such as the First 
Nations population.  Information on medications available “over-the-counter” (i.e., OTC) or 
excluded from the provincial drug formulary were not available in this study.   
2.3.2 Cohort 
The cohort included individuals at least 30 years of age who received at least one dispensation 
for a statin medication (i.e., HMG-CoA reductase inhibitor) within 90 days
80,133
 of discharge 
from a hospitalization with a most responsible/primary diagnosis of myocardial infarction (MI) 
or unstable angina (UA) between January 1
st
, 1994 and December 31
st
, 2008.  Individuals were 
required to have continuous beneficiary status for 1825 days (i.e., 5 years) before the index 
hospitalization and survive for and maintain provincial beneficiary status for at least 102 days 
after their first statin dispensation.  Individuals were excluded if they could not be followed for at 
least 102 days or received any statin medication within 365 days prior to the index 
hospitalization. The codes used to identify MI and UA conditions [Appendix 2-1] were shown to 
have positive predictive, sensitivity, and specificity estimates of 85 to 98%.
134-139
  For individuals 
with several eligible hospitalizations the earliest hospital discharge date for ACS was deemed the 
index date.   
2.3.3 Adherence  
Adherence was measured from the first statin dispensation date until death, provincial health 
coverage termination, or end of the study period (December 31, 2008).  The PDC method was 
used to calculate adherence
48,140,141
 with an adjustment to prevent overestimation.  Specifically, 
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each statin dispensation was assigned a ‘completion date’ corresponding to the number of 
medication doses supplied.
142
  If a subsequent dispensation was obtained early, the new supply 
was not applied until the previous ‘completion date’ plus one day.  Also, any excess supply of 
medication extending beyond the last follow-up day was removed from the calculation [Figure 2-
1].
142
  Similar to other studies, 80% level of adherence or higher was considered optimal 
adherence
143,144
 and switching between statins was allowed. Additionally, we removed any days 
of hospitalization during the observation period from the denominator because medications 
dispensed to inpatients are not included in the prescription drug database.
145
   
The assessment of adherence was applied in two ways.  In method “A”, a single summary 
measure of adherence was calculated between the date of the first dispensation and the date of 
death, provincial health coverage termination, or end of the study period (December 31, 2008).  
In method “B”, the same period of follow-up was divided into three-month intervals (i.e., 102 
days) where adherence was measured in each.  Unused supplies from a previous interval were 
applied to the subsequent interval to prevent underestimation.  
2.3.4 Analysis Procedure 
The association between statin adherence and mortality was graphed using Kaplan-Meier 
survival probability graph and was assessed using a time-to-event analysis with multivariable 
Cox proportional-hazard regression models.  Each model considered survival starting 102 days 
post discharge from index hospitalization and contained all available demographic, condition-
related, therapy-related, patient-related, and health-system-related variables, as categorical 
variables [Appendix 2-2], in addition to the adherence category as a dichotomous variable (i.e., 
high versus low). In method (A), the summary measure of adherence was entered in the model as 
a fixed baseline covariate, whereas method (B) contained adherence as a time-dependent 
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repeated-measures covariate assessed every 102 days.  We obtained the adjusted hazard ratios 
(HR) with 95% confidence intervals for adherent patients compared with non-adherent patients. 
The proportional hazards assumption was assessed visually using the log cumulative hazard (the 
“log-log") plot and Schoenfeld residuals versus observed event time’s plot.146 Multicollinearity 
between all non-adherence variables was examined by calculating the variance inflation factor 
(VIF) where values greater than 10 were interpreted as representing substantial 
multicollinearity.
147
 Baseline variables, except adherence, that had evidence of multicollinearity 
were removed from the model.  
In a sensitivity analysis, adherence was further stratified into three groups (≤20%, 21% - 79%, 
and ≥80%) versus the binary variable (≥80% vs < 80%) to determine if estimates of benefit were 
substantially affected. We used SAS 9.3 software (SAS Institute Inc., Cary, NC, USA) to 
perform the analysis.  
2.4 Results 
From 43,118 individuals who had a hospitalization with ACS and/or a coronary revascularization 
procedure in Saskatchewan between January 1
st
, 1994 and December 31
st
, 2008, 9,051 
individuals (21.0%) met all inclusion criteria [Figure 2-2]. Among all individuals in the cohort, 
69.2% (n=6,260) were male and the mean age was 64.8 years (median=66.0, SD=12.3). More 
than half of patients (58.5%; n=5,292) received a revascularization procedure during their ACS 
hospitalization. Additionally, roughly one third (36.7%, n=3,325) had a diagnosis of 
hypertension in the pre-index year, and 13.6% (n=1,232) had a diabetes diagnosis [Table 2-1].  
The mean follow-up time was 1,721 days (SD 1,138.4, median 1,525.0) or 4.7 years. The mean 
PDC calculated over the entire follow-up period was 70.6% (median=84.0%, SD=31.9%), and 
the percentage of individuals achieving optimal adherence (i.e. ≥80%) was 54.6% (n=4,939). 
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The percentage of adherent individuals increased substantially over the study period from 40.7% 
in 1994 to 77.8% in 2008.  
Adherence categorization by the fixed baseline summary measure was generally concordant with 
the repeated measures approach.  The adherence category matched on both measures in 76.7% of 
individuals (median 80.2%, SD=15.4%)  However, the concordance between the two measures 
declined over time [Figure 2-3]. Non-concordance was typically a result of the fixed summary 
measure classifying non-adherence versus optimal adherence using the repeated-measures 
approach.  In contrast, the percentage of cases of optimal adherence by the fixed summary 
measure but poor adherence by the repeated-measures was relatively infrequent and remained 
stable over time [Figure 2-3].      
Among the 4,939 individuals exhibiting optimal adherence by the summary measure, 12.3% 
(n=606) died compared to 14.6% (n=600) of non-adherent individuals. However, optimal 
adherence (i.e. ≥80%) defined by the fixed summary measure was not associated with a lower 
risk of death in the time-to-event analysis [Figure 2-4] (crude HR 1.07, 95%CI 0.96 to 1.20, 
p=0.25; adjusted HR 0.97, 95%CI 0.86 to 1.09, p=0.60).  Similar results were obtained when 
non-adherence was categorized as < 20% (i.e., rather than < 80%) in a sensitivity analysis (crude 
HR 0.91, 95%CI 0.77 to 1.08; p=0.28; adjusted HR 0.96, 95%CI 0.80 to 1.14).  In contrast, 
optimal adherence measured as a time-dependent variable was clearly associated with a lower 
risk for death [Figure 2-5] (crude HR 0.80, 95%CI 0.71 to 0.89, p<0.01; adjusted HR 0.75, 
95%CI 0.67 to 0.85, p<0.01).  Similar results were obtained when non-adherence was 
categorized as < 20% (i.e., rather than < 80%) in a sensitivity analysis (data not shown).  In all 
cases, the proportionality assumption of the Cox model was met, and no collinearity was 
observed in included covariates.  
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2.5 Discussion 
We examined the association between statin adherence and the risk of death using two distinct 
adherence measures that have been used in previous studies.
80
  The association was substantially 
impacted by the measurement approach despite an identical adherence metric (i.e., PDC) and 
threshold (i.e., ≥80%) for defining optimal adherence.  Optimal statin adherence defined by the 
fixed summary measure was not associated with a beneficial effect on mortality (adjusted HR 
0.97, 95%CI 0.86 to 1.09, p=0.60).  In contrast, optimal adherence to statins defined by a time-
dependent variable was associated with a significantly lower risk of death (adjusted HR 0.75, 
95% CI 0.67 to 0.85).   
The reasons for such conflicting estimates on the association between statin adherence 
measurements are not entirely clear.  The study was carried out on the same cohort, over the 
same observation period, and accounted for identical confounders with the exception of 
adherence measurement.  The repeated-measures approach appeared to be more sensitive to 
situations where patients improved their adherence behavior over time.  However, it is 
impossible to determine if this increased sensitivity to optimal adherence behavior facilitated the 
detection of a valid relationship with mortality, or if it permitted the influence of survival 
bias.
128,129
  In the latter case, healthy patients with long-standing non-adherence may have had 
greater opportunity to exhibit optimal adherence in the latter part of the observation period using 
a repeated-measures approach.  To our knowledge, this observation has not been reported 
previously.      
Our study identified a dramatic improvement in statin adherence over the past decade.  This 
trend has been reported previously in other jurisdictions with statins and other medications 
also.
68,71
  Considering these trends, along with steady population decreases in coronary heart 
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diseases event rates over time,
148
 it is possible that the consequences of poor statin adherence 
may in fact be less dramatic in recent years.  Although conflicting results from observational 
studies could be ideally resolved if randomized trial results were available, the nature of this 
phenomenon prevents rigorous examination using experimental design.          
Some limitations can be noted in this study. First, although PDC is a validated adherence 
measurement method, our adjustment to prevent overestimation is not validated, and may have 
affected our estimates. It is possible that this adjustment disadvantaged one of the methods only 
(i.e., the summary approach or the repeated-measures approach). Second, requiring patients to 
fill a statin prescription within 90 days of their ACS hospitalization may have excluded patients 
exhibiting non-adherence at the beginning of follow-up (primary non-adherence). If true, this 
could have weakened the association through a biased selection of patients.   Lastly, the choice 
of 102 days (3 months) to assess adherence in the repeated-measures method may have 
influenced the associations observed.  However, shorter intervals would result in lower 
granularity of the measure and longer periods would result in lower sensitivity to periodic 
changes in adherence.     
Estimates for the benefits of statin adherence on mortality are significantly influenced by the 
measurement methods used and a gold-standard approach cannot be established using 
conventional techniques.  Based on the results of this study, adherence has improved 
dramatically since the 1990s and is nearing 80% in recent years.  Although surveillance of 
adherence and health outcomes should continue, estimates must be generated using different 
measures until the most valid approach can be identified.         
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 B. Data with adjusted date(s) 
and quantities 
A. Original data 
Measurement period 
Index date 
First dispensation  
Second dispensation 
Over supply 
Third dispensation Fourth dispensation  
Over 
supply 
Measurement period 
Index date 
First dispensation  
Second dispensation Third dispensation Fourth 
Adjusted date of second prescription 
Covered days Covered days Covered 
Adjusted quantity of fourth prescription 
Figure ‎2-1: Adjustment of the adherence measure (proportion of days covered) to prevent 
overestimation from early refills 
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43,118 individuals experienced a hospitalization for acute 
coronary syndrome (ACS) and/or revascularization procedure 
between January 1
st
, 1994 and December 31
st
, 2008   
Excluded 163 individuals whose age< 30 on index date 
42,955 individuals 
Excluded 1,686 individuals WITHOUT continuous beneficiary status 
over 5 years pre-index  
41,269 individuals 
32,154 individuals 
Excluded 9,115 individuals who had a revascularization index ONLY 
with no documented MI or UA during index hospitalization 
30,524 individuals 
Excluded 1,630 individuals with at least one ACS hospitalization or 
revascularization procedure within 5 years pre-index date 
Excluded 4,329 individuals WITH at least one prescription of statin 
within 1 year pre-index date 
26,195 individuals 
Excluded 5,299 individuals who filled their first statin prescription 
beyond 90 days post-index date 
20,896 individuals 
Excluded 3,791 with less than 102 days of follow-up post 
17,177 individuals 
9,051 individuals 
Excluded 8,126 individuals who did not have any statin prescription 
post-index 
Figure ‎2-2: Flow chart of individuals in study 
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Figure ‎2-3: Concordance between two measures of statin adherence (summary measure 
and repeated-measures) among patients with coronary heart disease.
2
 
  
                                                 
2
 Categories: concordance: 1*1: adherent in interval by repeated-measures and by adherent by summary measure or 
0*0: non-adherent in interval by repeated-measures and by non-adherent by summary measure; discordance: 1*0: 
adherent in interval by repeated-measures, but non-adherent by summary measure; and 0*1: non-adherent in interval 
by repeated-measures, but adherent by summary measure. 
€
 Percentages were calculated among all individuals who survived to this, but not the next, adherence assessment 
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Figure ‎2-4: Kaplan-Meier estimates of survival among individuals classified using 
adherence summary measure (ADH_CONT) as adherent (1) or non-adherent (0).   
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Figure ‎2-5: Kaplan-Meier estimates of survival among individuals classified using 
adherence repeated-measures (adh) as adherent (1) or non-adherent (0).   
  
 
  
 
Time from 102 days post index till exit 
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Figure ‎2-6: Kaplan-Meier estimates of survival among individuals classified using the first 
and last adherence periods (adh) as (1) continuously adherent,  (2) declined adherence, (3) 
improved adherence, and 4) continuously non-adherent  
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Figure ‎2-7: Kaplan-Meier estimates of survival among individuals classified using only the 
last adherence period (adh) as (1) adherent,  and (0) non-adherent 
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Table ‎2-1: Characteristic of individuals included in cohort 
Characteristics Adherence <80% as 
defined by a summary 
measure (n=4,112; 45.4%) 
Adherence ≥ 80% as 
defined by a summary 
measure (n=4,939; 54,6%) 
Overall N=9,051 P-value 
from 
Chi-
Square 
or t-test 
n % n % N %  
PDC, mean (SD) 0.41 (0.25) 0.95 (0.07) 0.71 (0.32) <0.01 
Death 600 14.6 606 12.3 1206 13.3 <0.01 
Age (years) mean (SD) 64.16 (12.57) 65.35 (12.04) 64.81 (12.30) <0.01 
<55 1036 25.2 1311 26.5 2347 25.9 <0.01 
55-65 849 20.6 1062 21.5 1911 21.1 
66-73 1177 28.6 1495 30.3 2672 29.5 
Male, (n, %) 2854 69.4 3406 69.0 6260 69.2 0.65 
Index year 1994-1997 329 8.0 218 4.4 547 6.0 <0.01 
1998-2001 1141 27.7 922 18.7 2063 22.8 
2002-2005 1777 43.2 2018 40.9 3795 41.9 
2006-2008 865 21.0 1781 36.1 2646 29.2 
Follow-up (in days) from first prescription, 
mean (SD) 
1931.43 (1134.79) 1546.42 (1111.51) 1721.34 (1138.35) 0.16 
Time from index to 
statin prescription,  
mean (SD) 8.46 (19.43) 6.22 (16.82) 7.24 (18.09) <0.01 
>1 day 1011 24.6 894 18.1 1905 21.0 <0.01 
Type of index 
diagnosis 
 
ACS+ 
revascularization 
procedure 
2098 51.0 3194 64.7 5292 58.5 <0.01 
ACS only 2014 49.0 1745 35.3 3759 41.5 
Any hospitalization in pre-index year, (n, %) 1011 24.6 1109 22.5 2120 23.4 0.02 
Charlson comorbidity score (Deyo 
adaptation) >1, (n, %) 
325 7.9 404 8.2 729 8.1 0.63 
Diagnosis in 
hospital or 
physician records 
in pre-index year 
Diabetes 532 12.9 700 14.2 1232 13.6 0.09 
Hypertension 1406 34.2 1919 38.9 3325 36.7 <0.01 
High statin dose* on first prescription post 
index, (n, %) 
2141 52.1 3166 64.1 5307 58.6 <0.01 
Duration (in days) 
of index 
hospitalization,  
mean (SD) 8.40 (7.73) 9.24 (8.12) 8.86 (7.95) <0.01 
≤10 days, (n, %) 935 22.7 1378 27.9 2313 25.6 <0.01 
Atorvastatin on first prescription post index, 
(n, %) 
2388 58.1 2933 59.4 5321 58.8 0.21 
≥5 physician’s visits in the first 3 months 
following the first statin prescription 
3030 73.7 3849 77.9 6879 76.0 <0.01 
Deprivation index 
quintile 
Missing 168 4.1 161 3.3 329 3.6 0.06 
1 (most deprived) 871 21.2 947 19.2 1818 20.1 
2 680 16.5 789 16.0 1469 16.2 
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3 881 21.4 1109 22.5 1990 22.0 
4 779 18.9 1006 20.4 1785 19.7 
5 (least deprived) 733 17.8 927 18.8 1660 18.3 
At least one 
prescription in post-
index year 
ACEI/ARB 3199 77.8 4282 86.7 7481 82.7 <0.01 
anticoagulants 586 14.3 870 17.6 1456 16.1 <0.01 
Antiplatelet 2228 54.2 3180 64.4 5408 59.8 <0.01 
BB 3449 83.9 4262 86.3 7711 85.2 <0.01 
CCB 890 21.6 1078 21.8 1968 21.7 0.83 
Diuretics 1389 33.8 1865 37.8 3254 36.0 <0.01 
HF BB 46 1.1 92 1.9 138 1.5 <0.01 
Nitrates 2916 70.9 3529 71.5 6445 71.2 0.57 
Other lipid drugs 213 5.2 187 3.8 400 4.4 <0.01 
>4 distinct (non-statin) medications received 
in post-index year 
2397 58.3 3302 66.9 5699 63.0 <0.01 
Specialty of 
prescribing 
physician of the first 
statin prescription 
GP 633 15.4 579 11.7 1212 13.4 <0.01 
cardiologist 1937 47.1 2673 54.1 4610 50.9 
internist 984 23.9 998 20.2 1982 21.9 
cardiac surgeon 239 5.8 384 7.8 623 6.9 
other 319 7.8 305 6.2 624 6.9 
Abbreviations:  ACS: Acute Coronary Syndrome; ACEI/ARB: Angiotensin Converting Enzyme-Inhibitor /Angiotensin Receptor-Blockers; BB: 
Beta-blockers; CCBs: Calcium Channel Blockers; DM: Diabetes Mellitus; GP: General Practitioner; HTN: Hypertension; PROC: Procedure of 
revascularization. 
*High dose statin was defined149-152 as having rosuvastatin >5mg, atorvastatin ≥20mg, or simvastatin ≥40mg 
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Appendix ‎2-1: Subjects’ selection of eligible individuals depending on the existence of 
coronary heart diseases 
Subject Selection Diagnoses from Hospital Services Database 
ICD-9* ICD-10-CA Description 
410 I21 - I22.xxx myocardial infarction (MI) 
411 I20.0xx and I24.xxx unstable angina (UA) 
*ICD-9 was used until March 31, 2001, when ICD-10-CA reporting started 
ICD-9: Manual of the international statistical classification of diseases, injuries, and causes 
of death, 9th revision. Geneva: The Organization; 1977.  
ICD-10-CA: International statistical classification of diseases and related health problems, 
tenth revision, Canada. Canadian Institute for Health Information; 2003. 
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Appendix ‎2-2: Variables considered for the baseline adjustment 
Variable category Included variables 
Demographic variables  age at index date 
 gender 
 year of discharge 
Condition-related variables  type of index diagnosis (ACS only, ACS plus 
revascularization) 
 duration of index hospitalization 
 number of days between index date and first 
dispensation of statin 
Therapy-related factors  filling at least one prescription for specific 
cardiovascular medication(s) during the first year post-
index including (beta-blockers; angiotensin converting 
enzyme-inhibitor (ACEI) or angiotensin receptor-
blockers (ARB); calcium channel blockers (CCBs); 
diuretics; anticoagulants; antiplatelet; nitrates; or other 
lipid drugs - yes/no for each) [Appendix 2-3] 
 filling at least one prescription with a quantity of 28  
tablets
153
 as an evidence of unit-of-use packaging
154,155
 
 receiving a high (versus low) statin dose on first 
prescription post index
149-152
  
 the individual statin used on first prescription post index 
(atorvastatin versus others)
156
 
 burden of medications defined as the total number of 
distinct medications’ therapeutic groups dispensed to 
subject 
Patient-related factors  socio-economic status (SES) assessed by the deprivation 
index (DI) developed by Pampalon et al.
157
 This was 
identified by mapping individuals’ residential postal 
codes to geographic-level statistics for the Statistics 
Canada census.
158
  
 comorbidities calculated by Deyo-adapted Charlson 
score method using hospitalizations data
159-162
 
 specific comorbid conditions of diabetes,163 and 
hypertension
58
 reported in any physician or 
hospitalization visit in the year prior to the index date 
[Appendix 2-4] 
Health system-related 
factors 
 specialty of prescribing physician for the first statin 
dispensation (general practitioner (GP), cardiologist, 
general internist, cardiac surgeon, other) 
 number of physicians visits in the first 3 months 
following the first statin dispensation 
 any prior hospitalization in the pre-index year. 
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Appendix ‎2-3: Medications assessed in the multivariable model 
Medication category Medications included 
Statin mediation (i.e., HMG-CoA 
reductase inhibitors) 
Atorvastatin, atorvastatin / amlodipine combination, 
cerivastatin, fluvastatin, lovastatin, pravastatin, 
rosuvastatin, and simvastatin 
Angiotensin Converting Enzyme-
Inhibitors (ACE-Inhibitors) 
Benazepril, captopril, cilazapril, cilazapril / HCTZ 
combination, enalapril, enalapril/HCTZ combination, 
fosinopril, lisinopril lisinopril/HCTZ combination, 
perindopril ,perindopril/indapamide  combination, 
quinapril quinapril/HCTZ combination, ramipril, and 
trandolapril 
Angiotensin Receptor-Blockers 
(ARBs) 
Candesartan, candesartan/HCTZ combination, 
eprosartan, eprosartan / HCTZ combination, 
irbesartan,  irbesartan/HCTZ combination, losartan,  
losartan/HCTZ combination, olmesartan, 
Olemsartan/HCTZ combination, telmisartan,  
telmisartan/HCTZ combination, valsartan, and  
valsartan/HCTZ combination 
Beta Blockers Acebutolol, atenolol, atenolol / chlorthalidone 
combination, labetolol, metoprolol, metoprolol / 
HCTZ combination, nadolol, oxprenolol, pindolol, 
pindolol/HCTZ combination, propranolol, 
propranolol / HCTZ combination, timolol, and 
timolol / HCTZ combination 
Calcium Channel Blockers 
(CCBs) 
Dihydropyridine (DH-
CCB) 
Amlodipine, felodipine, 
nicardipine, and 
nifedipine long acting,  
Non-dihydropyridine 
(NDH-CCB) 
diltiazem, and verapamil 
Diuretics Amiloride, amiloride/HCTZ, bumetanide, 
chlorthalidone, ethacrynic acid, furosemide, 
hydrochlorothiazide (HCTZ), indapamide, 
metolazone, spironolactone, spironolactone/HCTZ, 
triamterene, triamterene/HCTZ 
Anticoagulants Acenocoumarol,  dalteparin,  enoxaparin,  heparin,  
nadroparin,  tinzaparin,  warfarin 
Antiplatelet ASA,  clopidogrel,  dipyridamole /ASA,  
pentoxifylline,  sulfinpyrazone,  ticlopidine 
Nitrates Erythrityl tetranitrate,  isosorbide dinitrate,  
isosorbide-5-mononitrate,  nitroglycerin 
Other lipid drugs Bezafibrate, cholestyramine, clofibrate, colestipol, 
ezetimibe, fenofibrate, gemfibrozil, niacin, probucol 
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Appendix ‎2-4: Comorbid conditions 
Comorbid conditions used in the multivariable model from hospital and physician 
administrative health databases 
ICD-9* ICD-10-CA Description 
250.x E10 - E14.xxx Diabetes & diabetes with complications 
401 - 404.x 
I10 to I15.xxx 
except when I11 is 
reported with I50 
where’s case is 
considered heart 
failure 
hypertension 
*ICD-9 was used until March 31, 2001, when ICD-10-CA reporting started 
ICD-9: Manual of the International Statistical Classification of Diseases, Injuries, and Causes 
Of Death, 9th revision. Geneva: The Organization; 1977.  
ICD-10-CA: International Statistical Classification of Diseases and Related Health Problems, 
tenth revision, Canada. Canadian Institute for Health Information; 2003. 
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CHAPTER -3- SOCIO-ECONOMIC STATUS AND NON-ADHERENCE TO 
ANTI-HYPERTENSIVE DRUGS. A SYSTEMATIC REVIEW AND META-
ANALYSIS 
 
3.1 Abstract 
Background: Although conventional wisdom suggests that low socio-economic status (SES) is a 
robust predictor of medication non-adherence, the strength of this association remains unclear. 
Objectives: i) to estimate the proportion of studies that identified SES as a potential risk indicator 
of non-adherence; ii) to describe the type of SES measurements; iii) to quantify the association 
between SES and non-adherence. Research Design: Systematic review and meta-analysis. Data 
Sources: We searched multiple electronic databases for studies examining non-adherence to anti-
hypertensives measured by electronic prescription databases where explanatory factors were 
considered. A random-effects model meta-analysis was performed and heterogeneity was 
examined using the I
2
 statistic. Results: Fifty-six studies with 4,780,293 subjects were included. 
Twenty-four (43%) did not report any SES measures.  When it was reported (n=32), only 7 
(13%) examined more than one component but none performed a multi-dimensional assessment.  
The majority of studies relied upon income or income-related measures (such as prescription-
drug benefits or co-payments) (27/32, 84%).  Meta-analysis could be quantified in 40 cohorts 
reported in 30 studies.  Overall, the pooled adjusted risk estimate for non-adherence according to 
SES (high versus low) was 0.89, 95% CI 0.87 to 0.92; I
2
=95%, p<0.001. Similar patterns were 
observed in all subgroups examined. Conclusion: published studies have not found a strong 
                                                 

 This work is published in Value in health (2014 Mar;17(2):288-96.), and available online at 
http://www.valueinhealthjournal.com/article/S1098-3015%2813%2904396-9/abstract. License to reuse this article in 
a dissertation/thesis was obtained from Elsevier publisher on July 3, 2014 (license number 3421501215399). 
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association between low SES and non-adherence to anti-hypertensive medications.  However, 
important limitations in the assessment of SES can be identified in virtually all studies.  Future 
studies are required to ascertain if a stronger association is observed when SES if determined by 
comprehensive measures.  
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3.2 Introduction 
 Socio-Economic Status (SES) is a multi-dimensional construct that represents an individual’s 
position relative to other people in the community.   It is commonly considered a product of the 
interaction between material and social factors. Material factors include income, education and 
employment, whereas social factors are usually represented by living arrangements and family 
structure.
1
 In health-care research, low SES has proven to be a strong predictor of health-care 
utilization, morbidity, and premature death.
2-5
 Low SES may also be an important determinant of 
non-adherence to chronic medications such as antihypertensives (AHTs).
6,7
  
SES is an intriguing factor in the search for determinants of population-level non-adherence to 
AHTs because of its associations with economic, social, and education-related factors.  Indeed, 
all of these factors may influence regular medication use.
8
 Although the relationship between 
SES and non-adherence has been inconsistent,
9
 we hypothesized that methodological approaches 
may have attenuated an important relationship.  Electronic prescription databases are the most 
frequently used methods for non-adherence assessment,
10,11
 however, they often lack important 
patient-level information required to describe SES in detail.  As a result, indirect measures of 
income such as receipt of prescription-drug benefits through government co-payments are often 
used as the sole indicators of SES in many studies,
12-15
 while direct measures of income from 
taxation records are rarely utilized.
6
  In addition, studies generally do not account for non-income 
related SES factors and even fewer incorporate multiple SES measurements representing 
different dimensions.
16,17
  Finally, several population-based studies can be identified where SES 
factors are absent altogether.
18-20
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In order to understand the extent to which SES may influence non-adherence to AHT 
medications, as well as the approaches used to account for it, we conducted a systematic review 
and meta-analysis of the literature pertaining to SES and non-adherence to AHT medications 
using population-based electronic prescription data.  Our study had three objectives: i) to 
estimate the proportion of studies that identified SES as a potential risk indicator of non-
adherence; ii) to describe the type of SES measurements that were used in each study; iii) to 
quantify the association between SES and non-adherence to AHT medications.   
3.3 Methods 
3.3.1 Search Strategy 
We used a comprehensive search strategy of electronic databases including: Medline 
(OVID,1964 to February 24, 2012), Embase (OVID,1947 to February 24, 2012), International 
Pharmaceutical Abstracts (OVID, 1970 to January 31, 2012), the Cochrane Library (Wiley, 1800 
to February 28, 2012), Scopus (Elsevier, from 1823 to February 28, 2012), CINAHL (EBSCO, 
1937 to February 28, 2012), PsycINFO (OVID, 1806 to February Week 3 2012), Sociological 
Abstracts (ProQuest, 1952 to February 28, 2012), ProQuest Dissertations & Theses (PQDT) 
(1639 to February 28, 2012), Web of Science (Thomson Reuters, 1899 to February 28, 2012), 
and OAIster  (1975 to Dec 31, 2011). Reference lists of identified articles were manually 
searched for additional studies not captured in the electronic database reviews. 
3.3.2 Study Selection 
Studies were included if they satisfied the following criteria: a) examined non-adherence to AHT 
medications, b)  used electronic prescription databases as the source of non-adherence 
information, and c) conducted  multivariable modelling to determine the independent effect of 
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explanatory covariates on the outcome of non-adherence; and d) were published in English or 
French. Eligible AHT medications included angiotensin converting enzyme inhibitors or 
angiotensin receptor blockers (ACEIs/ARBs), beta-blockers (BBs), calcium channel blockers 
(CCBs) or thiazide diuretics for any indication. Studies were not restricted by design or 
publication date.  In some cases, we contacted authors of studies to clarify or obtain data. 
3.3.3 Review Procedure and Assessment of Methodological Quality 
The identification of studies was carried out in two steps.  First, after removal of duplicates, two 
of the authors (WA and ML) examined the titles and abstracts identified in the initial search.  
Secondly, the same two reviewers (WA and ML) examined full-text articles for each study 
identified in the first step for both eligibility and methodological quality. Disagreement between 
the two reviewers was resolved by additional review and discussion and then, if required, with 
tie-breaking by a third reviewer (DB). Quality of included studies was assessed by the reviewers 
(WA and ML) with a checklist developed by the International Society for Pharmacoeconomics 
and Outcome Research (ISPOR) for retrospective database studies.
21,22
 This checklist has been 
used in systematic reviews previously,
23
 and it consists of 27 quality review questions related to 
data source, research design, study population, variable definitions, statistics and discussion.  
From each study, we determined whether a SES measure was assessed by identifying any 
material factor (e.g., income, education or employment) or social factor (e.g., living alone, or 
family structure) that was included in the non-adherence model.  In cases were these traditional 
SES measures were not used, we identified ethnicity as a possible indirect measure in a 
sensitivity analysis. Ethnicity was defined as any categorization according to race or any cultural 
factor.
24,25
 We also recorded estimates of the ratio effects measures of non-adherence to AHT 
medications along with 95% confidence intervals (95% CI) corresponding to the measure of 
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SES. Additionally, we abstracted information on region of origin, publication year target 
medication(s), adherence measurement (MPR-related versus discontinuation-related
11
) number 
of subjects (total/ low SES/ higher SES), follow-up (observation) days, and the number of SES 
domains captured in each study.  We categorized SES covariates as income-related and non-
income-related and sub-categorized income-related SES covariates as follows: income-level, 
health-plan coverage or medication copayment amount, and receipt of social assistance or 
income security benefits.  Income-level factors were identified as direct (e.g., by linking taxation 
data to dispensation records) or indirect (e.g., from census neighbourhood or coverage type).  
3.3.4 Statistical Analysis  
We assessed the agreement in study inclusion/exclusion between reviewers in each step by 
Cohen’s kappa statistic (κ).26 We adopted the following interpretations for κ: 0.60 < κ was 
considered low agreement,  0.60 ≤ κ ≤ 0.79 was considered good agreement and κ ≥ 0.80 was 
considered very good agreement.
27
 We assessed heterogeneity using the I
2
 statistic and 
corresponding τ2 (Tau-squared) test. This statistic represents the proportion of variability that can 
be attributed to between-studies variability.
28
 We adopted the following interpretations for the I
2
 
statistic: 0% to 40%-low heterogeneity; 41% to 74% - moderate heterogeneity, and 75% to 100% 
- considerable heterogeneity. All estimates were pooled where possible irrespective of the level 
of heterogeneity observed and subgroup analyses completed to explore potential sources of study 
heterogeneity.
29
 We then conducted a random-effects model meta-analysis using the inverse-
variance (IV) method to estimate the effect of SES on medication non-adherence from the pooled 
data.
28-30
 A random-effects model accounts for potential heterogeneity between the populations 
and unmeasured confounding.
28
  For studies reporting more than one non-adherence measure, we 
prioritized Medication Possession Ratio-related (MPR-related) outcomes over other measures. 
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MPR is calculated usually by summing all days’ supply during a certain period of observation of 
the medication and divide it by the total days of that period.
10
 For studies reporting more than 
one SES variable, we used the measure with the largest effect size regardless of the direction of 
the association. When categorical SES measures had more than two levels, we reported the risk 
estimate of the highest SES level relative to the lowest.  
Subgroup analyses were conducted for type of non-adherence measurement, type of medication, 
type of SES measurement, and the region of origin of the data.  We used the Z-test for overall 
effects and χ2 statistic to test for differences in the between-groups effects.31 Finally, because 
ethnicity may be considered an indirect SES measurement,
24,25
 we performed a sensitivity 
analyses by including ethnicity as a measure of SES to assess the proportion of studies that 
identified SES as a potential risk indicator of non-adherence. Additionally, we performed a 
sensitivity analysis by using the estimate with the lowest effect size instead of the highest for 
studies reporting more than one SES variable. We evaluated publication bias visually using the 
funnel plot.
32
 We adopted the protocol developed by The Cochrane Collaboration and used 
Review Manager (Version 5.1.7 Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2011) to perform the meta-analysis.
29
  
3.4 Results 
3.4.1 Included studies 
Our search identified 11,351 titles/abstracts with 56 studies meeting our inclusion criteria. 
(Figure 3-1; eTable 3-1). Overall agreement for inclusion/exclusion of studies between the 
reviewers was found to be good (κ=0.79, and κ=0.69 for first and second steps respectively) 
(Figure 3-1). Of these 56 included studies, eight studies
33-39
 scored less than 50% on the 
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methodological quality review. The median methodological quality score was 68% and inter-
quartile range was 19%. 
Table 3-1 summarizes the characteristics of included studies. The total number of subjects 
included in our review was 4,708,293 (range 236 to 1,075,285 per study). The majority of studies 
were conducted in Europe (11/56, 20%) and North America (34/56, 61%). Studies ranged from 
assessing one AHT medication (6/56, 11%), to assessing combinations of two medications or 
more. Non-adherence was measured by discontinuation/non-persistence (25/56, 45%), 
Medication Possession Ratio (MPR) related measurements (26/56, 47%) or both (5/56, 8%). The 
follow up duration was 180 days or less in 13 studies, 181 days to 365 days in 31 studies, and 
more than 365 days in 8 studies.    
3.4.2 SES Measures 
Overall, 24/56 studies (43%) did not assess SES with any material or social measure. However, 
when ethnicity was considered as an eligible SES measure, the proportion of studies with no SES 
measure decreased to 19/56 studies (34%). An SES measure was lacking in all studies published 
prior to 2004 (9 studies), compared to 15 of 47 studies (32%) published between 2004 and 2012.  
Of the 32 studies which assessed SES, two studies did not report estimates of the effect of SES 
on non-adherence and could not be obtained from authors.
40,41
  
No study organized SES variables into multidimensional scales or indices such as a deprivation 
index.
42,43
  From all studies that assessed SES, 25 studies (78%, 25/32) identified only one SES 
measure among their study subjects.  Of these, prescription-drug coverage or medication 
copayment amount based on income was most commonly used (17/25 studies). 
9,15,38,44-57
 Four 
studies captured income level,
41,58-60
 three studies used social assistance benefits or income 
security benefits,
61-63
 and education level was identified in one study only.
64
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Seven studies (22%, 7/32) identified more than one SES measure in their study population. All 
of the studies contained at least one income-related variable and three identified income-related 
measures only.
36,39,65
  Non-income variables in the remaining studies included education and 
employment,
66
 education,
67
 living alone
40
 or household composition.
6
  
In total, seven studies captured income level either alone or in addition to other SES measures.  
Of these, classification into income groups was obtained directly by linking taxation data to 
dispensation records in three studies,
6,59,67
 indirectly from census neighbourhood income in two 
studies
40,58
 and indirectly from low-income drug coverage in two studies.
60,65
    
3.4.3 Non-adherence with higher SES 
Excluding the two studies where an estimate could not be obtained,
40,41
 we extracted data for 40 
cohorts in 30 studies reporting an SES variable.  Higher SES was associated with lower risk of 
non-adherence in 31/40 cohorts (77.5%), with no difference in one cohort, and with higher risk 
of non-adherence in 8 cohorts (Figure 3-2). Overall, the pooled adjusted risk estimate indicated a 
lower risk of non-adherence among individuals with higher SES: 0.89 (95% CI 0.87-0.92; 
p<0.001); however, high heterogeneity was observed (Tau=0.01; I
2
 = 95%). Inspection of the 
funnel plot did not suggest potential publication bias (Figure 3-3).    
To explore heterogeneity in the results, we performed several sub-group analyses.  However, 
similar results were observed in studies scoring above 50% on the quality checklist (pooled 
adjusted risk estimate 0.90, 95% CI 0.87-0.92, I
2
=95%) and scoring below 50% (pooled adjusted 
risk estimate 0.86, 95% CI 0.66-1.12, I
2
=84%). A sub-group analysis was not performed on non-
income related measures because they were only identified in one study. Studies that used 
discontinuation as the endpoint (pooled adjusted risk estimate 0.91, 95% CI 0.87-0.96, I
2
=92%) 
showed consistent results with those that used MPR-related measures (0.88, 95% CI 0.85-0.92, 
 98 
 
I
2
=93%), and studies from North America and Europe (0.90, 95% CI 0.87-0.94, I
2
=95%) 
produced similar results to those from other countries (0.86, 95% CI 0.81-0.92, I
2
=87%).  
In the sensitivity analysis, using the measure with the lowest effect size (for studies reporting 
more than one SES variable) did not change the pooled adjusted risk estimate (0.90, 95%CI 0.88-
0.92, I
2
=95%).  Smaller heterogeneity was observed in certain cohorts restricted by specific type 
of medication used.  Pooled adjusted risk estimate representing the influence of higher SES were 
different for cohorts receiving ACEIs (0.83, 95%CI 0.79-0.88, I
2
=0%), BBs (0.77, 95%CI 0.66-
0.9, I
2
=95%), CCBs (0.98, 95%CI 0.85-1.14, I
2
=70%), HCTZ (0.81, 95%CI 0.74-0.90, I
2
=0%), 
or for ARBs (1.0 95%CI 1.0-1.0, I
2
=84%), where the test for subgroup difference was significant 
p<0.001) (Figure 3-4).  However, the pooled estimate remained relatively consistent with the 
overall findings.    
3.5 Discussion 
Among published studies of non-adherence to AHT medications using electronic prescription 
databases, 43% did not account for any SES measure despite their theorized importance as a 
determinant of non-adherence.
8
 When SES was assessed, the vast majority of studies identified 
single factors relating to income and none examined SES using a comprehensive measure.  
Pooled analyses indicated that higher SES is associated with an 11% decrease in the adjusted-
risk of non-adherence; however, heterogeneity between included studies was very high.  
Although the quantitative impact of SES on medication non-adherence cannot be confirmed from 
this meta-analysis due to high levels of heterogeneity, incomplete (or absent) SES measures, and 
inconsistent approaches in the literature, these results clearly demonstrate major deficiencies in 
previous attempts to understand this complex issue.  As a result, SES cannot be considered a 
strong predictor of medication non-adherence because the evidence supporting this view remains 
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theoretical at best, at least with respect to antihypertensive medications.  In reality, it must be 
recognized that current knowledge about SES and non-adherence is extremely poor.               
To our knowledge, this is the first systematic review specifically evaluating the effects of SES on 
non-adherence to AHT medications and the results suggest that more research is needed to 
ensure consistent and comprehensive approach to the assessment of SES as a possible risk 
indicator.  We chose hypertension as disease state because of its prevalence, chronicity, lack of 
symptoms and treatability.
68
 It has been clearly shown that the prevalence of non-adherence to 
AHT medications is high and adverse health outcomes are commonly observed compared to 
those demonstrating optimal adherence.
69-71
  As a result, even small improvements in non-
adherence are likely considered clinically meaningful.
72-75
 
The most probable explanation for these findings is that administrative databases including 
electronic prescription databases do not have ready access to SES information.  However, the 
importance of the SES factors as potential risk indicators of non-adherence may also be under-
recognized.  Accordingly, our understanding of the complex relationship between SES and 
medication non-adherence is likely incomplete because it is based on studies using a very limited 
set of SES measures, at least in studies focused on AHT medications.     
SES could be an important determinant of non-adherence not only through its impact on 
affordability and access to medications, but through its effect on health literacy and medication 
knowledge.
76
  Indeed, higher SES reduced the risk estimate of non-adherence in 31/40 of cohorts 
examined; however the opposite effect of SES was observed in 8/40 cohorts examined. Thus, our 
systematic review confirms and characterizes the inconsistent findings relating to SES and non-
adherence reported in previous narrative reviews.
11,77,78
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Our review had several limitations. First, our study examined AHT studies only, so the results 
may not generalize to other chronic disease medications. Second, we only included studies that 
used electronic prescription databases as the source of non-adherence information. However, 
electronic prescription databases are the most frequently used source of non-adherence 
information among large populations.
10
 Third, it is highly likely that the pooled risk estimates 
was influenced by the lack of detailed SES information and the inconsistent approaches to SES 
measurement in the published literature.  Indeed, the vast majority of SES measures were 
restricted to income-related measures.  Even more, all included studies are observational cohort 
studies; thus, their estimates may be highly influenced by residual confounding.  However, 
subgroup analyses did not reveal systematic differences between studies stratified by quality, 
country of origin, SES measure, or adherence measure.  Fourth, we used the checklist developed 
by ISPOR for retrospective database studies to assess publications’ quality. However, a new 
questionnaire developed by AMCP/NPC/ISPOR Comparative Effectiveness Research 
Collaborative Initiative, could have improved our quality assessment.
79
 Lastly, although we did 
not observe any publication bias, it is possible that negative studies assessing SES and non-
adherence could not be published. 
SES is frequently overlooked in studies of non-adherence to AHT medications using electronic 
prescription databases and it has never been examined in a comprehensive way. Based on the 
available literature, higher SES appears to be associated with a small reduction in the occurrence 
of non-adherence to AHT medications.  However, this estimate is based on studies that contained 
many limitations. Thus, more research is clearly needed to help clarify this relationship.  
Considering the public health importance of this outcome and the relative lack of knowledge 
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about its determinants, failure in taking SES into account could prevent targeting of interventions 
for those who need them. 
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Appendix ‎3-1: eTable : Studies identified in the systematic review 
Reference 
(Year)/ 
Country 
Medication(s) 
studied 
Adherenc
e measure 
No of 
subjects 
(total/low 
SES/ high 
SES) 
Follo
w-up 
(days
) 
SES covariates 
studied  
OR/HR of non-
adherence (95%CI) p-
value  
SES 
measure 
used 
Number of 
domain(s) in 
SES 
measure 
(one/Multipl
e) 
Quality 
score 
Wong114 
(2011)/Hong 
Kong 
HCTZ Discontinu
ation  
(9398/ 
2536/6862
) 
180 
 
Pay status 
Fee waivers 
Fee payers 
OR for discontinuation 
1.00 (reference) 
0.85 (0.74–0.98) 0.027 
Payment 
status 
one 13/25 
(>50%) 
Rasmussen80 
(2007)/ON, 
Canada 
BBs, CCBs PDC BBs 
cohort: 
(24319/72
32/17087), 
CCBs 
(9168/321
2/5956) 
365 BBs cohort 
Low income (no/yes) 
 
CCBs cohort 
 
Low income (no/yes) 
OR for PDC <40% 
vs.≥80% 
1.05(0.91-1.11) 
 
OR for PDC<40%  vs. 
≥80% 
 
1.07(0.94-1.23) 
Income one 18/25 
(>50%) 
Setoguchi68(
2010) /New 
Jersey, USA 
ABs, BBs PDC  46,278 365   None NA 15/25 
(>50%) 
Monane115 
(1997) / 
New Jersey, 
USA 
ACEIs, BBs, 
CBs,  HCTZ  
Days 
covered 
8643 365   None NA 14/25 
(>50%) 
Bloom59 
(1998)/ USA 
ACEIs, ARBs, 
BBs, CCBs, 
HCTZ 
Discontinu
ation 
21723 365   None NA 15/25 
(>50%) 
Degli 
Esposti60 
(2002)/Italy 
ACEIs, BBs, 
CCBs, HCTZ 
Discontinu
ation  
16783 365   None NA 17/25 
(>50%) 
Yang116 
(2009)/USA 
ACEIs, ARBs PDC 1075285 180   None NA 14/26 
(>50%) 
Shaya117 
(2009)/Mary
land, USA 
Combination of 
ACEIs, CCBs, 
or HCTZ 
MPR 568 365 
(at 
least) 
  None NA 15/25 
(>50%) 
Elliott61 
(2007)/USA 
amlodipine, 
HCTZ, 
lisinopril,  
valsartan 
Discontinu
ation 
60685 365   None NA 15/24 
(>50%) 
Perreault118 
(2005)/Québ
ec, Canada 
ACEIs, BBs, 
CCBS,  
diuretics alone 
or in 
combination 
Discontinu
ation 
(21011/44
12/16599) 
365  
Social assistance 
(no/yes)   
 
OR for Discontinuation  
 
0.75(0.70-0.79) 
 
Social 
assistance 
status  
one 15/24 
(>50%) 
signorovitch
119 (2012) / 
USA  
BBs Discontinu
ation 
173200 365   None NA 14/25 
(>50%) 
Taira120 
(2007) / 
Hawaii, 
USA120 
ACEIs, ARBs, 
BBs, CCBs, 
HCTZ 
MPR (28395/19
499/8896) 
365-
1095 
Education 
<High school 
High school 
College 
Post-graduate 
OR for MPR<80% 
1(reference) 
0.91(1.00-0.83) 
0.84(0.91-0.77) 
0.87(1.00-0.77) 
Education one 17/25 
(>50%) 
Van Wijk121 
(2008)/ 
Pennsylvani
a USA, BC 
Canada  
and the 
Netherland 
ACEIs, ARBs, 
BBs, CCBs, 
HCTZ 
  
Discontinu
ation 
USA: 
(9664/365
1/6013) 
Canada: 
(25377/ 
7180/1464
7), The 
Netherland
: 
(24603/13
763/10840
) 
365 
(at 
least) 
USA cohort 
Income 
Low 
High 
 
Canada cohort 
Income 
Low 
Medium 
High 
 
The Netherlands 
cohort 
Income 
Low 
High 
HR for Discontinuation 
 
1 (reference)  
1.06 (0.98–1.14) 0.130 
 
HR for Discontinuation 
 
1 (reference) 
0.86(0.79–0.93)<0.001 
0.81(0.77–0.85)<0.001 
 
HR for Discontinuation 
 
 
1 (reference) 
0.95(0.90–0.99)0.016 
Income  one 16/24 
(>50%) 
 114 
 
Wong122 
(2010)/Hong 
Kong 
ACEIs MPR (6408/162
2/4786) 
- Pay status 
Fee waivers 
Fee payers 
OR for MPR<80% 
1.00_(reference) 
0.85(0.72-1.02)0.08 
Payment 
status 
one 19/24 
(>50%) 
Yeaw123 
(2009)/USA  
ARBs Discontinu
ation and 
PDC 
7722 360  
Copay of index 
medication 
 
Copay of index 
medication 
OR for Discontinuation 
 
1.00(1.00-1.00)<0.001 
 
OR for PDC<80% 
1.00(1.00-1.00)<0.001 
Copay one 19/25 
(>50%) 
Lamb70 
(2009)/Saska
tchewan, 
Canada 
ACEIs, ARBs, 
BBs 
Fill 
frequency  
8805 365   None NA 19/25 
(>50%) 
Gogovor124 
(2007)/Queb
ec, Canada 
ACEIs Discontinu
ation  
Secondary 
prevention
: (1620/ 
521/1099 
), primary 
prevention
: 
(4596/933 
/ 3663) 
216 
(mean
) 
Secondary 
prevention 
Social assistance 
(no/yes) 
Primary prevention 
Social assistance 
(no/yes) 
 
OR for discontinuation 
 
0.98(0.79–1.20) 
OR for discontinuation 
 
0.79(0.70–0.90) 
 
Social 
assistance 
status  
one  
Vegter125 
(2011)/The 
Netherland 
ACEIs, ARBs Discontinu
ation 
51181  365   None NA 17/24 
(>50%) 
Siegel126 
(2007)/USA 
ACEIs, ARBs, 
CCBS, HCTZ, 
and alpha 
blockers 
MPR 40492 180 
(At 
least) 
  None NA 17/25 
(>50%) 
Friedman127 
(2010)/Ontar
io, Canada 
ACEIs, ARBs, 
CCBS, HCTZ 
Discontinu
ation and 
MPR 
(207473/4
0778/4025
8) 
total/lowes
t 
quintile/hi
ghest 
quintile 
730  
 
Income (per quintile) 
 
 
 
Income (per quintile) 
 
Income (per quintile) 
OR for discontinuation 
(same medication) 
0.96(0.96-0.97)<.0001 
OR Class 
discontinuation (any 
AHT medication) 
 
0.97(0.98-0.97)<.0001 
OR for MPR<80% 
0.91(0.89-0.93)<.0001 
Income  one 18/25 
(>50%) 
Wong128 
(2011)/Hong 
Kong 
ACEIs Discontinu
ation  
(7153/183
9/5314) 
180 Pay status 
Fee waivers 
Fee payers 
OR for discontinuation 
1(reference) 
0.86(0.73-1.00)0.055 
Payment 
status 
one 19/25 
(>50%) 
Corrao129 
(2009)/Italy 
ACEIs, BBs, 
CCBs, diuretics  
Discontinu
ation 
(71469/14
293/14293
) 
(total/lowe
st 
quintile/hi
ghest 
quintile) 
365  
Income >2333 € 
Income 1500–2333 € 
Income 1083–1500 € 
Income 625–1083 € 
Income ≤625 € 
Living together 
Living alone 
HR for discontinuing  
0.98(0.95-1.02) 
1.01(1.00-1.02) 
1.01(1.00-1.02) 
1.02(1.01-1.04) 
1.00(reference) 
1.00(reference) 
1.00(0.98-1.02) 
Income/Ho
usehold 
compositio
n  
one/one 14/25 
(>50%) 
Eagle130 
(2004)/USA
+ 13 
countries 
ACEIs, BBs Discontinu
ation 
BBs: 
(7738), 
ACEIs: 
(2379) 
180   None NA 17/25 
(>50%) 
Wong131 
(2010)/Hong 
Kong 
Combination 
therapy 
including 
triamterine 
/HCTZ, 
amiloride 
/HCTZ, 
irebesartan 
/HCTZ, and 
losartan/ 
HCTZ 
Discontinu
ation 
(29253/72
99/21954) 
180 Pay status 
Fee waivers 
Fee payers 
 
OR for discontinuation 
1.00(reference) 
0.90(0.81–1.00)0.059 
 
Payment 
status 
one 17/25 
(>50%) 
Wogen132 
(2003)/USA 
Amlodipine, 
valsartan,  
lisinopril 
Discontinu
ation 
(142945) 365   None NA 19/25 
(>50%) 
Yang133 
(2010)/USA 
ACEIs, ARBs PDC  (599141) 270 
(mini
mum) 
  None NA 19/25 
(>50%) 
 115 
 
Kramer134 
(2006)/USA
* 
BBs 
 
PDC  (17035/34
19/13616) 
360 Health plan type 
Commercial v 
Medicare / Males 
age 35-64         
Commercial v 
Medicare / Females 
age 35-64   
Commercial v 
Medicare / Males 
age 65+      
Commercial v 
Medicare / Females 
age 65+ 
OR for PDC<75% 
 
0.33(0.26-0.42) 
 
0.42(0.23-0.77) 
 
0.67(0.57-0.78) 
 
0.57(0.48-0.69) 
Health 
plan type 
one 15/25 
(>50%) 
Degli 
Esposti135 
(2002)/Italy 
ACEIs, ARBs, 
BBs, CCBs, 
diuretics 
Discontinu
ation 
(7312) 1005   None NA 18/25 
(>50%) 
Shah136 
(2009)/Minn
esota, USA 
ACEIs, ARBs, 
BBs 
Discontinu
ation 
BBs: 248, 
ACEI:180 
1530 
(Mea
n) 
  None NA 20/25 
(>50%) 
Wong137 
(2010)/Hong 
Kong 
BBs Discontinu
ation 
(19177/50
88/14089) 
180 Pay status 
Fee waivers 
Fee payers 
OR for discontinuation  
1.00 (reference) 
0.78 (0.71–0.85) <0.001 
Payment 
status 
one 22/25 
(>50%) 
Ude138 
(2008)/Germ
any 
ACEIs MPR 221881 365-
547 
  None NA 19/25 
(>50%) 
Sung139 
(2009)/Kore
a 
ACEIs, ARBs, 
BBs, CCBs, 
HCTZ, 
combination 
CMA  (725220/6
70678/522
65) 
365 
(Mini
mum) 
Health security 
program 
NHIP 
MAP 
OR for CMA<80% 
 
0.99(0.97-1.02) 
1.00(reference) 
Health 
plan type 
one 19/25 
(>50%) 
Evans64 
(2009)/Saska
tchewan, 
Canada 
ACEIs, ARBs, 
BBS, CCBs 
Discontinu
ation 
(52039/10
865/41174
) 
(total/SAP
+Family+S
enior/none
) 
365 Income security 
benefit 
None 
SAP 
Family-based 
Senior-based 
OR for discontinuation 
0.88(0.76-1.00)0.05 
1(reference) 
0.63(0.51-0.76) <0.0001 
0.95(0.89-1.03) 0.23 
Income 
security 
benefit 
one 21/25 
(>50%) 
Wong140  
(2009)/Hong 
Kong 
CCBs MPR and 
discontinu
ation  
(20156/52
80/14876) 
180 Pay status 
Fee waivers 
Fee payers 
Pay status 
Fee waivers 
Fee payers 
OR for MPR<80% 
1.00(reference) 
0.92(0.83-1.00)0.05 
OR for discontinuation 
1.0 (reference) 
0.87 (0.73–1.04) 0.128 
Payment 
status 
one 20/25 
(>50%) 
Wong141  
(2010)/Hong 
Kong 
HCTZ MPR  (8551/227
9/6272) 
180 Pay status 
Fee waivers 
Fee payers 
OR for MPR<80% 
1.00(reference) 
0.78(0.68-0.89) <0.001 
Payment 
status 
one 20/25 
(>50%) 
Wong142 
(2009)/Hong 
Kong 
ACEI, BBs, 
CCBs, HCTZ  
 
Discontinu
ation 
(93286/24
814/68472
) 
180 Pay status 
Fee waivers 
Fee payers 
OR for Discontinuation 
1.00 (ref.) 
0.83 (0.79–0.87) <0.001 
Payment 
status 
one 18/25 
(>50%) 
Wong143  
(2010)/Hong 
Kong 
ACEIs, ARBs, 
BBs, CCBs, 
HCTZ, others 
(including a-
blockers, 
potassium-
sparing and 
other diuretics, 
vasodilators and 
combos) 
MPR (83884/21
860/62024
) 
189 
(max) 
Pay status 
Fee waivers 
Fee payers 
 
OR for MPR<80% 
1.00(reference) 
0.88(0.84-0.92) <0.001 
 
 
Payment 
status 
one 19/25 
(>50%) 
Wong144 
(2009)/Hong 
Kong 
BBs MPR (15918/40
57/11861) 
Two 
conse
cutive 
visits 
Pay status 
Fee waivers 
Fee payers 
OR for MPR<80% 
1.00(reference) 
0.86(0.78-0.94)0.001 
 
Payment 
status 
one 13/25 
(>50%) 
Frech-
Tamas145 
(2010)/USA 
ACEIs, ARBs, 
BBs,   CCBs, 
HCTZ, 
combination 
MPR  (68538) 365  
Average copay 
OR MPR<80% 
 0.977< 0.0001 
Copay one 17/23 
(>50%) 
 116 
 
Pataky146 
(2007)/BC, 
Canada 
ACEIs, BBs PDC  ACEIs: 
(11494/41
17/3220), 
BBs: 
(12949/45
87/3674) 
(Total 
/Top30% 
/low30%) 
365 ACEIs group: 
Private Payer  
Income Group 
Low 30% 
middle 40%   
top 30%  
Social Assistance 
(no/yes) 
BBs group: 
Private Payer  
Income Group 
Low 30% 
middle 40%   
top 30%  
Social Assistance 
(no/yes)  
OR for PDC<80% 
0.81(0.74-0.89)<0.001 
 
1.00(reference) 
1.10(1.00-1.22)0.062 
0.83(0.74-0.93)0.002 
 
1.15( 0.93-1.40)0.191 
 
 
0.88(0.80-0.96)0.007 
1(reference) 
1.03(0.93-1.14)0.612 
0.88(0.79-0.99)0.034 
 
1.08(0.88-1.31)0.460 
Health 
plan 
type/Inco
me 
group/Soci
al 
assistance 
one/one/one 17/25 
(>50%) 
Rasmussen14
7  
(2007)/Den
mark 
BBs First gap Income 
(29160/97
09/9738), 
Education 
(29160/15
078/3430) 
180 Age 30-64 year 
Income 
High 
Medium 
Low 
Education 
High 
Medium 
Low 
Age 65-74 
Income 
High 
Medium 
Low 
Education 
High 
Medium 
Low 
OR for first gap>90days 
 
1.02(0.96–1.10) 0.79 
1.01(0.95–1.08) 0.79 
1(reference) 
 
1.08(0.99–1.17) 0.03 
0.97(0.92–1.03) 0.03 
1(reference) 
 
 
1.11(1.01–1.22)0.05 
1.01(0.93–1.11)0.05 
1(reference) 
 
1.05(0.93–1.18)0.68 
1.03(0.95–1.12)0.68 
1(reference) 
Income 
/Education 
one/one 18/25 
(>50%) 
Roe148 
(2000)/USA 
ACEIs Discontinu
ation 
236 180   None NA 16/25 
(>50%) 
Khan149 
(2010)/Ontar
io, Canada** 
ACEIs, ARBs, 
BBs, CCBs,    
HCTZ,  
ACEIs+ HCTZ  
MPR Income:(3
571/1453/
2118), 
living 
alone(3571
/704/2867) 
365 No OR reported for 
SES covariates 
 Income/Li
ving alone 
one/one 17/26 
(>50%) 
Corrao 150 
(2010)/Italy 
ACEIs, ARBs, 
BBs, CCBs, 
alpha-blockers  
Discontinu
ation  
CDL 
cohort 
(433680), 
CSD 
(12491) 
270   None NA 14/25 
(>50%) 
Van Dijk 
2007 151 /The 
Netherland 
ACEIS, ARBs, 
BBs, and 
diuretics 
 
Early 
drop-out 
and Refill 
adherence 
14219 365 Education 
Precollege  
College/university 
Type of insurance 
Public 
Private 
Employment status 
Not employed/school 
Employed/school 
 
 
Education 
Precollege  
College/university 
Type of insurance 
Public 
Private 
Employment status 
Not employed/school 
Employed/school 
OR for early drop-out 
1(reference) 
1.34(1.06-1.69) 
 
1(reference) 
1.12(0.93-1.35) 
 
1(reference) 
1.08(0.88-1.32) 
 
OR for refill 
adherence<80% 
1(reference) 
1.04(0.85-1.27) 
 
1(reference) 
1.09(0.95-1.25) 
 
1(reference) 
1.07(0.89-1.27) 
Education/
type of 
health 
insurance/
employme
nt status 
one/one/one 16/24 
(>50%) 
Van Wijk 
2007152 /The 
Netherland 
ACEIs, ARBs, 
BBs, CCBs and  
HCTZ 
Reinitiatin
g after 
discontinu
ation 
(18357/11
027/ 7330) 
Max 
2190 
Type of insurance 
 
Public 
Private 
OR for NOT reinitiating 
 
1(reference) 
0.99(0.95–1.04) 
Type of 
insurance 
one 16/24 
(>50%) 
Van Wijk 
2005153 /The 
Netherland 
ACEIs, alpha-
blockers, BBs, 
CCBs and 
HCTZ 
Discontinu
ation 
(2325/840/ 
1485) 
- Type of insurance 
Public 
Private 
OR for discontinuation 
1(reference) 
1.16(0.93-1.47) 
Type of 
insurance 
one 16/24 
(>50%) 
Lai154 
/(2011) / 
Canada** 
ACEIs, 
BBs, CCBs, and 
diuretics 
PDC (9926/237
7/1649) 
365 Income OR for PDC<80% Income one 19/25 
(>50%) 
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Charles 155 
(2003)/ USA 
ACEIs, BBs 
and CCBs 
Adherence 
ratio 
ACEI 
cohort 
(2377), 
BBs cohort 
(1659), 
CCB ( 
2148) 
540   None NA 11/24 
(<50%) 
Baily 156 
(1996)/USA 
ACEIS, 
adrenergic 
agents, alpha-
blockers, 
BBs, CCBs, 
direct 
vasodilators, 
and thiazide 
diuretics 
Refill 
failure 
1366 -   None NA 11/25 
(<50%) 
Glader 157 
(2010) 
/Sweden 
ACEIs/ARBs, 
BBs,   CCBs, 
diuretics  
Persistence 12152 720   None  
(Living 
alone vs 
institutiona
lized and  
the support 
of next of 
kin were 
not 
considered 
as SES) 
NA 11/25 
(<50%) 
Zeng 158 
(2010) /USA 
ARBs and 
CCBs 
PDC 4525 365 Type of insurance 
Medicaid 
Commercial HMOs 
Copay category 
0-5$ 
6-15$ 
16-25$ 
26-50$ 
>50$ 
OR for PDC<80% 
1(reference) 
0.60(0.44-0.81)0.01 
 
1(reference) 
1.08(0.94-1.25) 
0.95(0.82-1.11) 
1.09(0.94-1.23) 
1.49(1.28-1.75) 
Type of 
insurance/
copayment 
category 
1/1 11/24 
(<50%) 
Brixner 159 
(2008) / 
USA 
Valsartan and 
HCTZ 
combination` 
MPR 8711 365   None NA 12/25 
(<50%) 
Patel 160 
(2008) / 
USA 
HCTZ alone or 
with combined 
with either 
ACEI, ARBs or 
BBs  
MPR and 
discontinu
ation 
48212 365 Type of insurance 
Medicaid 
Commercial HMOs 
HR for discontinuation 
1(reference) 
0.75 <0.0001 
 
Type of 
insurance/
average 
copay 
1/1 12/25 
(<50%) 
Roe 161 
(1999) / 
USA 
ACEIs MPR 869 210   None NA 12/24 
(<50%) 
Liberman  
(39) / (2011) 
/ USA 
ACEIs, ARBs MPR ACEIs: 
7400  
ARBs:327
4 
365 ACEIs: 
Income ( by zip 
code) 
Highest quintile 
Lowest quintile 
Copayment 
Highest quintile 
Lowest quintile 
ARBs: 
Income ( by zip 
code) 
Highest quintile 
Lowest quintile 
Copayment 
Highest quintile 
Lowest quintile 
OR for MPR<80% 
 
0.84(0.73-0.98) 
1(reference) 
 
1.09(0.55-2.17) 
1(reference) 
 
 
0.65(0.52-0.81) 
1(reference) 
 
1.53(1.09-2.13) 
1(reference) 
Income / 
Copaymen
t ($ per 
day of 
supply) 
1/1 8/24 
(<50%) 
Abbreviations: ACEIs: Angiotensin Converting Enzyme Inhibitors; AHT: Antihypertensive; ARBs: Angiotensin Receptor Blockers; BBs: Beta Blockers; CCBs: Calcium 
Channel Blockers; CI: Confidence Interval; HCTZ: Hydrochlorothiazide; HMO:  Health Maintenance Organization; HR  Hazards Ratio; M+C:  Medicare + Choice; MAP:   
Medical Aid Program; MPR:  Medication Possession Ratio; NA: Not Applicable; NHIP:  National Health Insurance Program; OR Odds Ratio; PDC:  Proportion of Days 
Covered; POS:  Point Of Service, PPO:  Preferred Provider Organization; SAP Saskatchewan Assistance Plan 
* Risk estimates were obtained through contact with author(s). 
** Risk estimates could not be obtained through contact with author(s). 
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Figure ‎3-1: Flow chart for titles/abstracts and articles included in the review 
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Figure ‎3-2:  Pool risk estimates of non-adherence with high SES  
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Figure ‎3-3: Funnel plot of studies identified in the systematic review 
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Figure ‎3-4: Pool risk estimates of non-adherence with high SES, stratified by medication 
studied 
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Table ‎3-1: Characteristics of included studies 
Characteristic 
Number of 
subjects 
% of total sample 
(n=4708293) 
Number of 
studies (%) 
(N = 56) 
Region of data origin 
North American 
2666720 56.6% 
35 (62.5%) 
Europe 
880224 18.7% 
10 (17.9%) 
Other countries 
1161349 24.7% 
11 (19.6%) 
Date of publication 
Before 2004 
206025 4.4% 
9 (16.1%) 
2004 and after 
4502268 95.6% 
47 (83.9%) 
AHT Medication(s) studied 
ACEIs 27114 
0.6% 
6 (10.7%) 
ARBs 18396 
0.4% 
2 (3.6%) 
BBs 102690 
2.2% 
6 (10.7%) 
CCBs 29324 
0.6% 
2 (3.6%) 
HCTZ 17949 
0.4% 
2 (3.6%) 
Other (if more than one 
medication was studied) 
4512820 
95.8% 
38 (67.8) 
Adherence measure type 
MPR-related 3058762 65% 26 (46.4%) 
Discontinuation 1351749 28% 25 (44.6%) 
Both 
297782 
 
6.3% 5 (9.0%) 
Number of SES 
measurements 
None 
2961112 
62.9% 24 (42.9%) 
One 1546235 32.8% 25 (44.6%) 
> One 
200946 
4.3% 7 (12.5%) 
If SES was not assessed 
(N=24), did study assess 
ethnicity? 
Yes 
1761764 
37.4% 5 (8.9%) 
No 
1199348 
25.5% 19 (33.9%) 
SES measure 
One SES measure -Non-Income related  
Education 
28395 0.6% 
1 (1.8%) 
One SES measure -Income related  
Prescription drug coverage or 
medication copayment amount 1171195 
24.9% 17 (30.4%) 
Income level 
267379 
5.7% 4 (7.1%) 
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social assistance benefits or 
income security benefits 
 
79266 
1.7% 3 (5.4%) 
More than one SES measure  
Two income related measures 
4525 
0.1% 2 (3.6%) 
Three income related 
measures 24443 
0.5% 1 (1.8%) 
Income related + one non-
income related measure 104200 
2.2% 3 (5.4%) 
Income related + two non-
income related measures 14219 
0.3% 1 (1.8%) 
Method to measure income 
Direct  
Link with taxation records 
150609 3.2% 
3 (5.4%) 
Indirect  
Health plan 
53603 
1.1% 2 (3.6%) 
Neighbourhood 
200370 
4.3% 2 (3.6%) 
Follow-up days category 
Up to 180 1426148 30.3% 13 (23.2) 
181-365 
2753990 58.5% 31 (55.4%) 
>365 
502138 
10.7% 
 
8 (14.3%) 
- 
26107 0.6% 
4 (7.1%) 
Abbreviations: ACEIs: Angiotensin Converting Enzyme Inhibitors; AHT: Antihypertensive; ARBs: Angiotensin 
Receptor Blockers; BBs: Beta Blockers; CCBs: Calcium Channel Blockers; HCTZ: Hydrochlorothiazide; 
Medication Possession Ratio 
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eTable ‎3-1: Studies identified in the systematic review 
Reference 
(Year)/ 
Country 
Medication(s) 
studied 
Adherence 
measure 
No of 
subjects 
(total/low 
SES/ high 
SES) 
Follow
-up 
(days) 
SES covariates studied  OR/HR of non-adherence 
(95%CI) p-value  
SES 
measure 
used 
Number of 
domain(s) in 
SES measure 
(one/Multiple) 
Quality 
score 
Wong164 
(2011)/Hong 
Kong 
HCTZ Discontinuat
ion  
(9398/ 
2536/6862) 
180 
 
Pay status 
Fee waivers 
Fee payers 
OR for discontinuation 
1.00 (reference) 
0.85 (0.74–0.98) 0.027 
Payment 
status 
one 13/25 
(>50%) 
Rasmussen80 
(2007)/ON, 
Canada 
BBs, CCBs PDC BBs cohort: 
(24319/7232
/17087), 
CCBs 
(9168/3212/
5956) 
365 BBs cohort 
Low income (no/yes) 
 
CCBs cohort 
 
Low income (no/yes) 
OR for PDC <40% vs.≥80% 
1.05(0.91-1.11) 
 
OR for PDC<40%  vs. ≥80% 
 
1.07(0.94-1.23) 
Income one 18/25 
(>50%) 
Setoguchi68(20
10) /New 
Jersey, USA 
ABs, BBs PDC  46,278 365   None NA 15/25 
(>50%) 
Monane165 
(1997) / New 
Jersey, USA 
ACEIs, BBs, CBs,  
HCTZ  
Days 
covered 
8643 365   None NA 14/25 
(>50%) 
Bloom59 
(1998)/ USA 
ACEIs, ARBs, 
BBs, CCBs, 
HCTZ 
Discontinuat
ion 
21723 365   None NA 15/25 
(>50%) 
Degli Esposti60 
(2002)/Italy 
ACEIs, BBs, 
CCBs, HCTZ 
Discontinuat
ion  
16783 365   None NA 17/25 
(>50%) 
Yang166 
(2009)/USA 
ACEIs, ARBs PDC 1075285 180   None NA 14/26 
(>50%) 
Shaya167 
(2009)/Maryla
nd, USA 
Combination of 
ACEIs, CCBs, or 
HCTZ 
MPR 568 365 (at 
least) 
  None NA 15/25 
(>50%) 
Elliott61 
(2007)/USA 
amlodipine, 
HCTZ, lisinopril,  
valsartan 
Discontinuat
ion 
60685 365   None NA 15/24 
(>50%) 
Perreault168 
(2005)/Québec
, Canada 
ACEIs, BBs, 
CCBS,  diuretics 
alone or in 
combination 
Discontinuat
ion 
(21011/4412
/16599) 
365  
Social assistance 
(no/yes)   
 
OR for Discontinuation  
 
0.75(0.70-0.79) 
 
Social 
assistance 
status  
one 15/24 
(>50%) 
signorovitch169 
(2012) / USA  
BBs Discontinuat
ion 
173200 365   None NA 14/25 
(>50%) 
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Taira170 (2007) 
/ Hawaii, 
USA170 
ACEIs, ARBs, 
BBs, CCBs, 
HCTZ 
MPR (28395/1949
9/8896) 
365-
1095 
Education 
<High school 
High school 
College 
Post-graduate 
OR for MPR<80% 
1(reference) 
0.91(1.00-0.83) 
0.84(0.91-0.77) 
0.87(1.00-0.77) 
Education one 17/25 
(>50%) 
Van Wijk171 
(2008)/ 
Pennsylvania 
USA, BC 
Canada  
and the 
Netherland 
ACEIs, ARBs, 
BBs, CCBs, 
HCTZ 
  
Discontinuat
ion 
USA: 
(9664/3651/
6013) 
Canada: 
(25377/ 
7180/14647)
, The 
Netherland: 
(24603/1376
3/10840) 
365 (at 
least) 
USA cohort 
Income 
Low 
High 
 
Canada cohort 
Income 
Low 
Medium 
High 
 
The Netherlands 
cohort 
Income 
Low 
High 
HR for Discontinuation 
 
1 (reference)  
1.06 (0.98–1.14) 0.130 
 
HR for Discontinuation 
 
1 (reference) 
0.86(0.79–0.93)<0.001 
0.81(0.77–0.85)<0.001 
 
HR for Discontinuation 
 
 
1 (reference) 
0.95(0.90–0.99)0.016 
Income  one 16/24 
(>50%) 
Wong172 
(2010)/Hong 
Kong 
ACEIs MPR (6408/1622/
4786) 
- Pay status 
Fee waivers 
Fee payers 
OR for MPR<80% 
1.00_(reference) 
0.85(0.72-1.02)0.08 
Payment 
status 
one 19/24 
(>50%) 
Yeaw173 
(2009)/USA  
ARBs Discontinuat
ion and PDC 
7722 360  
Copay of index 
medication 
 
Copay of index 
medication 
OR for Discontinuation 
 
1.00(1.00-1.00)<0.001 
 
OR for PDC<80% 
1.00(1.00-1.00)<0.001 
Copay one 19/25 
(>50%) 
Lamb70 
(2009)/Saskatc
hewan, Canada 
ACEIs, ARBs, 
BBs 
Fill 
frequency  
8805 365   None NA 19/25 
(>50%) 
Gogovor174 
(2007)/Quebec
, Canada 
ACEIs Discontinuat
ion  
Secondary 
prevention: 
(1620/ 
521/1099 ), 
primary 
prevention: 
(4596/933 / 
3663) 
216 
(mean) 
Secondary prevention 
Social assistance 
(no/yes) 
Primary prevention 
Social assistance 
(no/yes) 
 
OR for discontinuation 
 
0.98(0.79–1.20) 
OR for discontinuation 
 
0.79(0.70–0.90) 
 
Social 
assistance 
status  
one  
Vegter175 
(2011)/The 
Netherland 
ACEIs, ARBs Discontinuat
ion 
51181  365   None NA 17/24 
(>50%) 
Siegel176 
(2007)/USA 
ACEIs, ARBs, 
CCBS, HCTZ, and 
alpha blockers 
MPR 40492 180 
(At 
least) 
  None NA 17/25 
(>50%) 
Friedman177 
(2010)/Ontario
, Canada 
ACEIs, ARBs, 
CCBS, HCTZ 
Discontinuat
ion and 
MPR 
(207473/407
78/40258) 
total/lowest 
quintile/high
est quintile 
730  
 
Income (per quintile) 
 
 
 
Income (per quintile) 
 
Income (per quintile) 
OR for discontinuation 
(same medication) 
0.96(0.96-0.97)<.0001 
OR Class discontinuation 
(any AHT medication) 
 
0.97(0.98-0.97)<.0001 
OR for MPR<80% 
0.91(0.89-0.93)<.0001 
Income  one 18/25 
(>50%) 
Wong178 
(2011)/Hong 
Kong 
ACEIs Discontinuat
ion  
(7153/1839/
5314) 
180 Pay status 
Fee waivers 
Fee payers 
OR for discontinuation 
1(reference) 
0.86(0.73-1.00)0.055 
Payment 
status 
one 19/25 
(>50%) 
Corrao179 
(2009)/Italy 
ACEIs, BBs, 
CCBs, diuretics  
Discontinuat
ion 
(71469/1429
3/14293) 
(total/lowest 
quintile/high
est quintile) 
365  
Income >2333 € 
Income 1500–2333 € 
Income 1083–1500 € 
Income 625–1083 € 
Income ≤625 € 
Living together 
Living alone 
HR for discontinuing  
0.98(0.95-1.02) 
1.01(1.00-1.02) 
1.01(1.00-1.02) 
1.02(1.01-1.04) 
1.00(reference) 
1.00(reference) 
1.00(0.98-1.02) 
Income/Hou
sehold 
composition  
one/one 14/25 
(>50%) 
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Eagle180 
(2004)/USA+ 
13 countries 
ACEIs, BBs Discontinuat
ion 
BBs: (7738), 
ACEIs: 
(2379) 
180   None NA 17/25 
(>50%) 
Wong181 
(2010)/Hong 
Kong 
Combination 
therapy including 
triamterine 
/HCTZ, amiloride 
/HCTZ, 
irebesartan 
/HCTZ, and 
losartan/ 
HCTZ 
Discontinuat
ion 
(29253/7299
/21954) 
180 Pay status 
Fee waivers 
Fee payers 
 
OR for discontinuation 
1.00(reference) 
0.90(0.81–1.00)0.059 
 
Payment 
status 
one 17/25 
(>50%) 
Wogen182 
(2003)/USA 
Amlodipine, 
valsartan,  
lisinopril 
Discontinuat
ion 
(142945) 365   None NA 19/25 
(>50%) 
Yang183 
(2010)/USA 
ACEIs, ARBs PDC  (599141) 270 
(mini
mum) 
  None NA 19/25 
(>50%) 
Kramer184 
(2006)/USA* 
BBs 
 
PDC  (17035/3419
/13616) 
360 Health plan type 
Commercial v Medicare 
/ Males age 35-64         
Commercial v Medicare 
/ Females age 35-64   
Commercial v Medicare 
/ Males age 65+      
Commercial v Medicare 
/ Females age 65+ 
OR for PDC<75% 
 
0.33(0.26-0.42) 
 
0.42(0.23-0.77) 
 
0.67(0.57-0.78) 
 
0.57(0.48-0.69) 
Health plan 
type 
one 15/25 
(>50%) 
Degli 
Esposti185 
(2002)/Italy 
ACEIs, ARBs, 
BBs, CCBs, 
diuretics 
Discontinuat
ion 
(7312) 1005   None NA 18/25 
(>50%) 
Shah186 
(2009)/Minnes
ota, USA 
ACEIs, ARBs, 
BBs 
Discontinuat
ion 
BBs: 248, 
ACEI:180 
1530 
(Mean
) 
  None NA 20/25 
(>50%) 
Wong187 
(2010)/Hong 
Kong 
BBs Discontinuat
ion 
(19177/5088
/14089) 
180 Pay status 
Fee waivers 
Fee payers 
OR for discontinuation  
1.00 (reference) 
0.78 (0.71–0.85) <0.001 
Payment 
status 
one 22/25 
(>50%) 
Ude188 
(2008)/German
y 
ACEIs MPR 221881 365-
547 
  None NA 19/25 
(>50%) 
Sung189 
(2009)/Korea 
ACEIs, ARBs, 
BBs, CCBs, 
HCTZ, 
combination 
CMA  (725220/670
678/52265) 
365 
(Mini
mum) 
Health security 
program 
NHIP 
MAP 
OR for CMA<80% 
 
0.99(0.97-1.02) 
1.00(reference) 
Health plan 
type 
one 19/25 
(>50%) 
Evans64 
(2009)/Saskatc
hewan, Canada 
ACEIs, ARBs, 
BBS, CCBs 
Discontinuat
ion 
(52039/1086
5/41174) 
(total/SAP+
Family+Seni
or/none) 
365 Income security benefit 
None 
SAP 
Family-based 
Senior-based 
OR for discontinuation 
0.88(0.76-1.00)0.05 
1(reference) 
0.63(0.51-0.76) <0.0001 
0.95(0.89-1.03) 0.23 
Income 
security 
benefit 
one 21/25 
(>50%) 
Wong190  
(2009)/Hong 
Kong 
CCBs MPR and 
discontinuati
on  
(20156/5280
/14876) 
180 Pay status 
Fee waivers 
Fee payers 
Pay status 
Fee waivers 
Fee payers 
OR for MPR<80% 
1.00(reference) 
0.92(0.83-1.00)0.05 
OR for discontinuation 
1.0 (reference) 
0.87 (0.73–1.04) 0.128 
Payment 
status 
one 20/25 
(>50%) 
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Wong191  
(2010)/Hong 
Kong 
HCTZ MPR  (8551/2279/
6272) 
180 Pay status 
Fee waivers 
Fee payers 
OR for MPR<80% 
1.00(reference) 
0.78(0.68-0.89) <0.001 
Payment 
status 
one 20/25 
(>50%) 
Wong192 
(2009)/Hong 
Kong 
ACEI, BBs, 
CCBs, HCTZ  
 
Discontinuat
ion 
(93286/2481
4/68472) 
180 Pay status 
Fee waivers 
Fee payers 
OR for Discontinuation 
1.00 (ref.) 
0.83 (0.79–0.87) <0.001 
Payment 
status 
one 18/25 
(>50%) 
Wong193  
(2010)/Hong 
Kong 
ACEIs, ARBs, 
BBs, CCBs, 
HCTZ, others 
(including a-
blockers, 
potassium-sparing 
and other 
diuretics, 
vasodilators and 
combos) 
MPR (83884/2186
0/62024) 
189 
(max) 
Pay status 
Fee waivers 
Fee payers 
 
OR for MPR<80% 
1.00(reference) 
0.88(0.84-0.92) <0.001 
 
 
Payment 
status 
one 19/25 
(>50%) 
Wong194 
(2009)/Hong 
Kong 
BBs MPR (15918/4057
/11861) 
Two 
consec
utive 
visits 
Pay status 
Fee waivers 
Fee payers 
OR for MPR<80% 
1.00(reference) 
0.86(0.78-0.94)0.001 
 
Payment 
status 
one 13/25 
(>50%) 
Frech-
Tamas195 
(2010)/USA 
ACEIs, ARBs, 
BBs,   CCBs, 
HCTZ, 
combination 
MPR  (68538) 365  
Average copay 
OR MPR<80% 
 0.977< 0.0001 
Copay one 17/23 
(>50%) 
Pataky196 
(2007)/BC, 
Canada 
ACEIs, BBs PDC  ACEIs: 
(11494/4117
/3220), BBs: 
(12949/4587
/3674) 
(Total 
/Top30% 
/low30%) 
365 ACEIs group: 
Private Payer  
Income Group 
Low 30% 
middle 40%   
top 30%  
Social Assistance 
(no/yes) 
BBs group: 
Private Payer  
Income Group 
Low 30% 
middle 40%   
top 30%  
Social Assistance 
(no/yes)  
OR for PDC<80% 
0.81(0.74-0.89)<0.001 
 
1.00(reference) 
1.10(1.00-1.22)0.062 
0.83(0.74-0.93)0.002 
 
1.15( 0.93-1.40)0.191 
 
 
0.88(0.80-0.96)0.007 
1(reference) 
1.03(0.93-1.14)0.612 
0.88(0.79-0.99)0.034 
 
1.08(0.88-1.31)0.460 
Health plan 
type/Income 
group/Social 
assistance 
one/one/one 17/25 
(>50%) 
Rasmussen197  
(2007)/Denmar
k 
BBs First gap Income 
(29160/9709
/9738), 
Education 
(29160/1507
8/3430) 
180 Age 30-64 year 
Income 
High 
Medium 
Low 
Education 
High 
Medium 
Low 
Age 65-74 
Income 
High 
Medium 
Low 
Education 
High 
Medium 
Low 
OR for first gap>90days 
 
1.02(0.96–1.10) 0.79 
1.01(0.95–1.08) 0.79 
1(reference) 
 
1.08(0.99–1.17) 0.03 
0.97(0.92–1.03) 0.03 
1(reference) 
 
 
1.11(1.01–1.22)0.05 
1.01(0.93–1.11)0.05 
1(reference) 
 
1.05(0.93–1.18)0.68 
1.03(0.95–1.12)0.68 
1(reference) 
Income 
/Education 
one/one 18/25 
(>50%) 
Roe198 
(2000)/USA 
ACEIs Discontinuat
ion 
236 180   None NA 16/25 
(>50%) 
Khan199 
(2010)/Ontario
, Canada** 
ACEIs, ARBs, 
BBs, CCBs,    
HCTZ,  
ACEIs+ HCTZ  
MPR Income:(357
1/1453/2118
), living 
alone(3571/7
04/2867) 
365 No OR reported for SES 
covariates 
 Income/Livi
ng alone 
one/one 17/26 
(>50%) 
Corrao 200 
(2010)/Italy 
ACEIs, ARBs, 
BBs, CCBs, alpha-
blockers  
Discontinuat
ion  
CDL cohort 
(433680), 
CSD 
(12491) 
270   None NA 14/25 
(>50%) 
 128 
 
Van Dijk 2007 
201 /The 
Netherland 
ACEIS, ARBs, 
BBs, and diuretics 
 
Early drop-
out and 
Refill 
adherence 
14219 365 Education 
Precollege  
College/university 
Type of insurance 
Public 
Private 
Employment status 
Not employed/school 
Employed/school 
 
 
Education 
Precollege  
College/university 
Type of insurance 
Public 
Private 
Employment status 
Not employed/school 
Employed/school 
OR for early drop-out 
1(reference) 
1.34(1.06-1.69) 
 
1(reference) 
1.12(0.93-1.35) 
 
1(reference) 
1.08(0.88-1.32) 
 
OR for refill 
adherence<80% 
1(reference) 
1.04(0.85-1.27) 
 
1(reference) 
1.09(0.95-1.25) 
 
1(reference) 
1.07(0.89-1.27) 
Education/ty
pe of health 
insurance/e
mployment 
status 
one/one/one 16/24 
(>50%) 
Van Wijk 
2007202 /The 
Netherland 
ACEIs, ARBs, 
BBs, CCBs and  
HCTZ 
Reinitiating 
after 
discontinuati
on 
(18357/1102
7/ 7330) 
Max 
2190 
Type of insurance 
 
Public 
Private 
OR for NOT reinitiating 
 
1(reference) 
0.99(0.95–1.04) 
Type of 
insurance 
one 16/24 
(>50%) 
Van Wijk 
2005203 /The 
Netherland 
ACEIs, alpha-
blockers, BBs, 
CCBs and HCTZ 
Discontinuat
ion 
(2325/840/ 
1485) 
- Type of insurance 
Public 
Private 
OR for discontinuation 
1(reference) 
1.16(0.93-1.47) 
Type of 
insurance 
one 16/24 
(>50%) 
Lai204 /(2011) / 
Canada** 
ACEIs, 
BBs, CCBs, and 
diuretics 
PDC (9926/2377/
1649) 
365 Income OR for PDC<80% Income one 19/25 
(>50%) 
Charles 205 
(2003)/ USA 
ACEIs, BBs and 
CCBs 
Adherence 
ratio 
ACEI cohort 
(2377), BBs 
cohort 
(1659), CCB 
( 2148) 
540   None NA 11/24 
(<50%) 
Baily 206 
(1996)/USA 
ACEIS, adrenergic 
agents, alpha-
blockers, 
BBs, CCBs, direct 
vasodilators, and 
thiazide diuretics 
Refill failure 1366 -   None NA 11/25 
(<50%) 
Glader 207 
(2010) 
/Sweden 
ACEIs/ARBs, 
BBs,   CCBs, 
diuretics  
Persistence 12152 720   None  
(Living 
alone vs 
institutionali
zed and  the 
support of 
next of kin 
were not 
considered 
as SES) 
NA 11/25 
(<50%) 
Zeng 208 
(2010) /USA 
ARBs and CCBs PDC 4525 365 Type of insurance 
Medicaid 
Commercial HMOs 
Copay category 
0-5$ 
6-15$ 
16-25$ 
26-50$ 
>50$ 
OR for PDC<80% 
1(reference) 
0.60(0.44-0.81)0.01 
 
1(reference) 
1.08(0.94-1.25) 
0.95(0.82-1.11) 
1.09(0.94-1.23) 
1.49(1.28-1.75) 
Type of 
insurance/co
payment 
category 
1/1 11/24 
(<50%) 
Brixner 209 
(2008) / USA 
Valsartan and 
HCTZ 
combination` 
MPR 8711 365   None NA 12/25 
(<50%) 
Patel 210 (2008) 
/ USA 
HCTZ alone or 
with combined 
with either ACEI, 
ARBs or BBs  
MPR and 
discontinuati
on 
48212 365 Type of insurance 
Medicaid 
Commercial HMOs 
HR for discontinuation 
1(reference) 
0.75 <0.0001 
 
Type of 
insurance/av
erage copay 
1/1 12/25 
(<50%) 
Roe 211 (1999) 
/ USA 
ACEIs MPR 869 210   None NA 12/24 
(<50%) 
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Liberman  (39) 
/ (2011) / USA 
ACEIs, ARBs MPR ACEIs: 7400  
ARBs:3274 
365 ACEIs: 
Income ( by zip code) 
Highest quintile 
Lowest quintile 
Copayment 
Highest quintile 
Lowest quintile 
ARBs: 
Income ( by zip code) 
Highest quintile 
Lowest quintile 
Copayment 
Highest quintile 
Lowest quintile 
OR for MPR<80% 
 
0.84(0.73-0.98) 
1(reference) 
 
1.09(0.55-2.17) 
1(reference) 
 
 
0.65(0.52-0.81) 
1(reference) 
 
1.53(1.09-2.13) 
1(reference) 
Income / 
Copayment 
($ per day of 
supply) 
1/1 8/24 
(<50%) 
Abbreviations: ACEIs: Angiotensin Converting Enzyme Inhibitors; AHT: Antihypertensive; ARBs: Angiotensin Receptor Blockers; BBs: Beta Blockers; CCBs: Calcium Channel Blockers; CI: Confidence 
Interval; HCTZ: Hydrochlorothiazide; HMO:  Health Maintenance Organization; HR  Hazards Ratio; M+C:  Medicare + Choice; MAP:   Medical Aid Program; MPR:  Medication Possession Ratio; NA: Not 
Applicable; NHIP:  National Health Insurance Program; OR Odds Ratio; PDC:  Proportion of Days Covered; POS:  Point Of Service, PPO:  Preferred Provider Organization; SAP Saskatchewan Assistance 
Plan 
* Risk estimates were obtained through contact with author(s). 
** Risk estimates could not be obtained through contact with author(s). 
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CHAPTER -4- MULTIPLE VERSUS SINGLE-DOMAIN MEASUREMENTS 
OF SOCIO-ECONOMIC STATUS (SES) FOR PREDICTING NON-
ADHERENCE TO STATIN MEDICATIONS: AN OBSERVATIONAL 
POPULATION-BASED COHORT STUDY 
4.1 Abstract 
Background: Socioeconomic status (SES) is strongly linked to several theoretical determinants 
of medication non-adherence and may therefore be an important predictor at the population level. 
However, it is a complex characteristic that cannot be easily represented in population-based 
models.  We compared the performance of multiple versus single domain measures of SES as 
predictors of statin adherence. Methods: This study was a retrospective cohort using population-
based administrative data mapped to area-level census information from Saskatchewan, Canada 
between 1994 and 2008.  Eligible individuals received a statin medication following discharge 
from a hospitalization for coronary heart disease and were followed for one year.  Logistic 
regression models were constructed to assess the predictors of optimal adherence using different 
types of SES measures.  The relative impact of each SES measure was assessed by its adjusted 
odds ratio and improvement over the predictive accuracy of the base model.  Results: More than 
two thirds (i.e., 68.8%; 6,517/9,478) of eligible individuals exhibited optimal adherence (i.e. ≥ 
80%) at one year. The estimated impact of SES on optimal adherence differed depending on the 
SES measure tested. The highest performing single-domain measure, household income (OR 
0.75; 95% CI 0.72 to 0.92; model c-statistic improvement 0.4%, p=0.04) generated a similar 
result to the multiple-domain measure (adjusted OR 0.74; 95% CI 0.62 to 0.88; model c-statistic 
improvement 0.7%, p=0.01).  Conclusion: Multi-domain measurements of SES using 
 131 
 
administrative databases mapped to census data are not associated with better performance in 
predicting medication adherence compared to single-domain measures such as household 
income.     
4.2 Background 
Non-adherence to statin medications (i.e., HMG CoA reductase inhibitors) is a well-known and 
highly prevalent barrier to the prevention of cardiovascular events in patients who have coronary 
heart disease (CHD).
54,57,71,80,84,212
 However, even with extensive research into its potential 
causes, robust predictors of non-adherence have never been found.
58
  Strong theoretical 
reasoning points to socioeconomic status (SES) as an important predictor of non-adherence.
16
  
However, a recent systematic review found high SES to be associated with an 11% decrease in 
the odds of non-adherence to antihypertensive medications.
213
  In relative terms, this impact was 
quite small and was obtained from studies demonstrating an excessive degree of heterogeneity.   
Substantial variation exists with respect to the approaches used to account for SES.  Out of 56 
eligible antihypertensive adherence studies identified in the systematic review above, 24 studies 
(43%) had no measure of SES.  When SES was identified, it was typically represented by a 
single measure relating to income or medication co-payment.  Although economic factors are 
likely important,
104
 SES may influence medication non-adherence through several other means 
such as health care access, availability of support, and/or health literacy.
86
   
Multiple-domain measures such as poverty or deprivation indices
177,214-219
 account for the 
various elements of SES, effectively predict health outcomes, and can be estimated from census 
data in population-based studies.
157
 For example, the deprivation index (DI) developed by 
Pampalon et al
157
 provides an overall SES ranking based on three material (i.e., income, 
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education and employment) and three social determinants (i.e., living arrangements, family 
structure, and living condition).  This measure was developed in Canada, and has been strongly 
associated with mortality in previous studies.
220-222
  Despite the apparent relevance to medication 
adherence research, multiple-domain SES measures have rarely been used.218,219  We 
hypothesized that the use of this multiple domain measure of SES would be a stronger predictor 
of non-adherence to statin medications compared to single domain measures among a cohort of 
patients with established CHD in Saskatchewan, Canada.       
4.3 Methods 
4.3.1 Data source 
A retrospective, observational study was conducted using administrative data maintained by the 
Saskatchewan Ministry of Health (MOH) and area-level census information. The government of 
Saskatchewan maintains several databases including the population registry, prescription drug 
file (pharmacy dispensations), physician services and hospital services databases. Nearly 99% of 
all residents in Saskatchewan are covered by the Saskatchewan Ministry of Health for physician 
and hospital services. Inmates of federal prisons, the armed forces and the Royal Canadian 
Mounted Police (RCMP) are not included because they receive health benefits from the 
Canadian federal government.  The prescription drug data captures dispensations for 
approximately 90% of Saskatchewan’s residents. This database does not capture dispensations 
for patients who are eligible for federal prescription coverage (such as First Nations population) 
and does not capture medications excluded from the provincial formulary or over-the-counter 
(OTC) medications. Each dispensation record captures several fields including: patient study ID, 
dispensing date, medication name, drug identification number (DIN) and quantity dispensed.  
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The only SES variables captured with the MOH are receipt of income security benefits and the 
level of cost sharing by the Drug Plan. Other SES indicators were obtained by mapping subjects’ 
residential postal codes to national census statistics summarized for specific geographic areas 
(i.e., dissemination areas DA) in Saskatchewan defined and collected by Statistics Canada.
223
  A 
DA is the smallest standard geographic area with a population of 400 to 700 persons, and all 
census data are disseminated at this level.
223
 Saskatchewan databases have previously been used 
to perform high quality studies of drug utilization and outcomes.
57,70,130-132
 
 
This approval for this study was obtained from the Biomedical Research Ethics Board (Bio-REB 
#10-162) at the University of Saskatchewan. 
4.3.2 Cohort 
Eligible study individuals were at least 30 years of age and received at least one dispensation for 
a statin medication within 90 days
80,133
 of discharge from a hospitalization for CHD between 
January 1
st
, 1994 and December 31
st
, 2008.  Similar to previous studies,
57
 existence of CHD was 
verified by a hospital discharge with a primary/most responsible diagnosis of an acute coronary 
syndrome (ACS) and/or a hospital or physician-claim procedure code for coronary 
revascularization.  ACS was identified using the International Classification of Diseases (ICD) 
diagnostic codes for myocardial infarction (MI) or unstable angina (UA) captured through the 
hospital discharge file [Appendix 4-1]. Coronary revascularization procedures (i.e., coronary 
artery bypass surgery (CABG) or percutaneous coronary interventions (PCI)) were captured 
through the physician services database (i.e., fee-for-service claims) and/or the hospital discharge 
file [Appendix 4-1]. The positive predictive value, sensitivity, and specificity of ACS 
identification using administrative databases have been estimated between 85-98%.
134-139
  For 
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individuals with multiple eligible hospitalizations, the earliest hospital discharge for CHD within 
the study period was considered the index date.  
Individuals were excluded if they were enrolled as a provincial beneficiary for less than five 
years preceding the CHD hospitalization, experienced a ACS/revascularization within the 
previous five years, received a statin medication within the previous one year, or if they died or  
their coverage was terminated < 365 days following their first statin dispensation.
57,65
   
4.3.3 Measures 
4.3.3.1 Adherence 
We measured one-year adherence using the “tablets-per-day” method that assumes all statin 
medications are prescribed for use once per day.
224
 “Tablets-per-day” was calculated by dividing 
the sum of all tablets dispensed by the total number of days in the observation period (i.e., 365 
days). Consistent with previous studies, optimal adherence was defined using a threshold of 80% 
or higher.
143,144
  Switching between statin medications was allowed and number of days spent in 
the hospital during follow-up period was subtracted from the denominator because hospitalized 
patients in Saskatchewan receive medications from institutional supplies that are not captured 
through the prescription drug database.
145
  Previous studies have shown the tablets per day 
measure to be highly correlated with other measures of adherence using Saskatchewan data.
57,70
  
4.3.3.2 Socio-Economic Status (SES) 
For each eligible individual, both single-domain and multi-domain measurements of SES were 
estimated.  Single domain SES indicators included provincial medication benefit (any level of 
cost sharing by the Drug Plan for the first statin prescription), cost of prescription not paid by the 
government (<29$, 29$ to 59$, 60$ to 79$, and ≥80$ in Canadian dollars), receipt of income  
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security benefits, and area of residence (rural/urban).  Also, the Statistics Canada 2001 
community profile was used to estimate household income quintile.
225
  For this ecological 
variable, individuals were assigned the mean income level corresponding to the ‘dissemination 
area’ identified by their residential postal code [Appendix 4-2].  
The multi-domain measure of SES was the deprivation index (DI) outlined by Pampalon et al.
157
  
This variable is also an ecological measure derived from aggregate-level SES variables reported 
in the 2006 census at the level of ‘dissemination-areas’.  The DI was expressed as a quintile 
relative to all Saskatchewan residents [Appendix 4-2].  In addition to testing the overall DI score, 
the individual material and social domain scores were tested separately to ensure their influence 
on adherence was consistent.   
4.3.4 Analysis Procedure 
Crude and adjusted odds ratios (ORs) for the effect of each SES indicator were obtained from 
logistic regression models using optimal adherence (Tablets-per-day ≥ 80%) as the dependent 
variable.  To obtain the adjusted ORs, a multiple logistic regression model was initially built 
using non-SES factors only. Subsequently, each SES indicator was added to this “base” model 
separately to obtain its adjusted OR.   The resulting models containing each SES indicator were 
assessed for the size of the OR corresponding to SES. In addition, the overall predictive accuracy 
of each model containing an SES indicator was compared to the base-model using the c-
statistic,
226
 and Brier score.
226
 The change in c-statistic was tested using the DeLong test.
227
 
Several categories of non-SES factors were considered for the adjusted “base” model including 
demographic, condition-related, therapy-related, patient-related, and health-system-related 
factors [Appendix 4-3]. Variable selection was carried-out using the process described by 
Hosmer and Lemeshow.
228
 Briefly, a multivariable model was created with all variables that 
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were significantly associated with the outcome on univariate analysis. Then, variables were 
retained in the final model were either significantly associated with the outcome or improved 
model fit.
228
 Variables that were deemed clinically important and included in the adjusted model 
regardless of their statistical significance include age, sex, and index year.  Multicollinearity was 
examined by calculating the variance inflation factor (VIF) where values more than 10 were 
interpreted as important multicollinearity.
147
  The primary analysis was executed using cases 
where all SES information were available, and then verified using the entire population after 
imputing missing SES information using a multiple imputation approach.
229-231
  In the multiple 
imputations method we first formed a predictive model for the missing quintiles based on all 
other available subjects’ variables including age, sex, year of index, and comorbidity score. A 
multiple imputation approach was then employed to designate income quintile, using a 
Monotone logistic regression method.  This method is favored to achieve the best prediction as it 
accounts for both the natural variability of data as well as the uncertainty of the imputation 
process.
229-231
 We used SAS 9.3 software (SAS Institute Inc., Cary, NC, USA) to perform the 
analysis. 
4.4 Results 
A total of 43,118 individuals were discharged from hospital in Saskatchewan between January 
1
st
, 1994 and December 31
st
, 2008 with a primary/most responsible diagnosis of an acute 
coronary syndrome (ACS) and/or a procedure for coronary revascularization. From them, 9,478 
individuals (22.0%) received a dispensation for a statin mediation within 90 days of the index 
date and met all other inclusion criteria [Figure 4-1].  The mean age of individuals on their index 
date was 64.6 years (SD=11.9; median=66.0; IQR=55.0 to 74.0) and 70.6% (n=6,688) were male. 
Almost one half of all individuals (49.8%; n=4,719) received a revascularization procedure 
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during the course of their ACS hospitalization. The remaining individuals either had an ACS 
hospitalization only (36.0%; n=3,414), or revascularization procedure only (14.2%; n=1,345). 
More than one half of individuals received atorvastatin as their first statin prescription post-index 
(55.5%; n=5,260). The average number of days between hospital discharge and the first statin 
dispensation was 8.5 (SD=19.6) [Table 4-1].  A DI quintile was not available for 3.5% of the 
cohort, while income quintile was missing for 33.4%.  Thus, all SES information were available 
for 6110 (64.5%) of our cohort.  
More than two thirds (68.8%; n=6,517) of all statin users in our cohort achieved optimal 
adherence (i.e. ≥ 80%) at one year. The percentage of adherent individuals increased 
substantially over the study period from 54.1% in 1994 to 75.8% in 2007 [Figure 4-2].  A similar 
trend was noticed among individuals classified with low SES using all six single-domain and 
three multiple-domains SES measures (data not shown).   
The estimated association of SES with statin adherence varied depending on the SES measure 
tested (Table 4-2).  The OR associated with the multiple-domain DI indicated a 26% decrease in 
the odds of achieving optimal adherence for individuals classified in the lowest SES quintile 
compared to the highest (adjusted OR 0.74; 95% CI 0.62 to 0.88).  Similarly, two single-domain 
measures, rural versus urban residence (adjusted OR 0.77; 95% CI 0.68 to 0.87), and lowest 
versus highest household income quintile (adjusted OR 0.75; 95% CI 0.63 to 0.90) produced 
similar estimates (Figure 4-3).  In contrast, no significant association between SES and 
adherence was observed using the four remaining single-domain measures: provincial 
medication benefit, prescription cost not covered by the government, and receipt of income 
security benefits.  
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Minimal improvements in predictive accuracy (<1%) was observed over the baseline model 
when any of the SES measures were included and none of the models were highly predictive 
when estimated using the c-statistic (Table 4-2).  Further, Brier scores were similar in models 
containing single-domain or multiple-domains measures and were not improved over the base 
model.  Similar results were obtained when the individual components of the DI were tested 
individually and when the three most significant SES measures were added simultaneously to the 
model.  Also, results were similar when we imputed missing values using multiple imputations 
(data not shown).  The independent effects of all non-SES variables in addition to DI quintiles on 
the odds of being adherent to statin medications are reported in [Table 4-3]. 
The consistent performance between the multiple domain DI and single-domain household 
income appeared to be a result of a correlation between the two measures (Spearman’s 
correlation coefficient 0.65; 95%CI 0.63 to 0.66).  restricting the cohort to individuals classified 
in the highest and lowest quintiles based on the DI or household income, the correlation between 
measures was highly significant (Spearman’s correlation coefficient 0.94; 95%CI 0.94 to 
0.95).In contrast, rural/urban status was not strongly correlated with either the DI or household 
income (data not shown).  
4.5 Discussion 
We compared the association between various SES measures defined from health-administrative 
databases and aggregated census data as predictors of statin adherence among individuals with 
CHD between 1994 and 2008.  Overall, first-year adherence to statin medications improved 
dramatically over the period of study, from 54.1% in 1994 to 75.8% in 2007.  Prediction 
accuracy of multivariable models were only slightly improved with the addition of SES 
measures, regardless of the type.  Further, the multiple-domain DI did not perform remarkably 
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better than all single-domain measures despite its theoretical advantages of representing factors 
including low income, low education/literacy, and poor access to care.  Low SES estimated by 
the multiple-domain DI was associated with a 26% reduction in the odds of being adherent 
(OR=0.74, 95%CI 0.62 to 0.88, p=<0.01).  On the other hand, low SES estimated by household 
income resulted in very similar findings (OR 0.75; 95% CI 0.63 to 0.90) with similar prediction 
accuracy.  
Theoretically, SES assessment should reflect its multifaceted nature by considering several 
factors from material and social domains.
104
 Previous studies on the determinants of medication 
adherence have largely focused on economic measures of SES, possibly missing the influence of 
other SES domains through health behavior,
232
 health literacy,
233
 and communication.
234
  
However, the theoretical advantages of using a multiple-domain measure of SES to predict 
medication adherence were not realized in this retrospective cohort study.  One possible 
explanation is that medication non-adherence is a ubiquitous problem among all patient groups 
regardless of demographic or socio-economic factors.  The evidence for the latter hypothesis is 
mounting as predictive accuracy of adherence models derived in this study and others has been 
far from optimal when studied at the population level.
235
  In addition, the multiple-domain 
measure of SES used in this study was highly concordant with the single-domain measure of 
household income suggesting the multiple-domain measure may have been limited in its ability 
to discriminate individuals beyond income.     
The trend towards increasing levels of adherence observed in this study is positive and consistent 
with previous research.
67-69
 However, a sizeable number of individuals (n=8,971) were excluded 
for not receiving any statin prescriptions after hospital discharge. This number of individuals 
represents 48.6% of all individuals who would be otherwise eligible for inclusion in our cohort.  
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It is assumed these individuals either did not receive a prescription from a physician, or failed to 
get it filled at the pharmacy (i.e., primary non-adherence).
20-25
  SES may have influenced both of 
these situations but the databases used in this study provided no information to allow 
discrimination between them.   Adding this number to the number of non-adherent individuals in 
our cohort would raise the estimate of the proportion of patients who are potentially divested 
from the benefits of statin medications from 31.2% to 64.7%. 
Our study has several strengths: different measures of SES derived from administrative databases 
and census data were examined; the cohort was relatively homogeneous because subjects have a 
single condition (CHD) and are prescribed a medication for which there is no alternative class; 
and the covered population was virtually universal with no restrictions on age or socioeconomic 
status.  However, there are also several limitations. First, SES variables were estimated from 
national census data reported by geographic DAs and not reported at the individual level. Also, 
due to restrictions in the availability of data, the census information used for income assessment 
was from the 2001 census, whereas the multiple domains DI was derived from the 2006 census. 
However, the geographic distribution of the Saskatchewan population remained relatively stable 
during this period.  Second, our data do not have clinical information on patients such as disease 
severity or laboratory values which may influence adherence. Third, our model was not cross-
validated in an external sample. Thus, its generalizability to other patient cohorts is not known. 
Even more, our study was performed on statin medications, which may limit the generalizability 
to other chronic disease medications.  Fifth, no information was available from private insurers; 
thus, prescription costs not paid by the government may not have resulted in out-of-pocket 
payments for all individuals.  Lastly, we excluded patients who died or whose coverage 
terminated during the first year post index date.  Although patients who survive for one year post 
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index date may be systematically different from those who die, the consequences of statin non-
adherence are most likely evident among early survivors.  Finally, we were unable to identify a 
gold-standard SES measure, so the aim was to determine which measure accounted for the 
largest proportion of adherence.  However, we cannot be sure that measures with the strongest 
association with SES were necessarily the best performing measures. 
To our knowledge, this is the first study that systematically examined the association between 
different measures of SES derived from administrative databases and census data and medication 
adherence.  Considering that the vast majority of previous studies on medication adherence have 
used single-domain SES indicators, our study indicated that available multi-domain measures are 
not better in accounting the overall burden of non-adherence. More research is needed to find the 
best methodology to account for this confounding.    
4.6 Disclaimer 
This Study is based in part on de-identified data provided by the Saskatchewan Ministry of Health. The 
interpretation and conclusions contained herein do not necessarily represent those of the Government of 
Saskatchewan or the Saskatchewan Ministry of Health. 
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Table ‎4-1: Characteristic of individuals included in cohort 
Characteristic 
Non-Adherent 
(n=2,961; 31.2%) 
n(%) 
Adherent (n=6,517; 
68.8%) n(%) 
Total (n=9,478) 
n(%) 
Chi-
square or 
T-test p-
value 
Age 
mean (SD) 64.3(12.2) 64.7(11.8) 64.6(11.9) 0.01 
<55 717(24.2%) 1465(22.5%) 2201(23.0%) 
0.30 
55-65 777(26.2%) 1772(27.2%) 2579(26.9%) 
66-73 653(22.1%) 1447(22.2%) 2132(22.2%) 
≥74 814(27.5%) 1833(28.1%) 2685(27.9%) 
Male gender 2087(70.5%) 4601(70.6%) 6688(70.6%) 0.91 
Index year 
1994-1997 269(9.1%) 406(6.2%) 675(7.0%) 
<0.01 
1998-2001 829(28.0%) 1637(25.1%) 2466 
2002-2005 1298(43.8%) 2904(44.6%) 4202 
2006-2007 565(19.1%) 1570(24.1%) 2135 
Type of index diagnosis 
ACS+PROC 1219(41.2%) 3500(53.7%) 4719(49.8%) 
<0.01 ACS only 1316(44.4%) 2098(32.2%) 3414(36.0%) 
PROC only 426(14.4%) 919(14.1%) 1345(14.2%) 
Duration (in days) of index 
hospitalization 
mean (SD) 9.2(8.5) 8.2(9.9) 8.9 (9.0) <0.01 
≥10 days 669(22.6%) 1820(27.9%) 2489(26.3%) <0.01 
Time from index to statin 
prescription 
mean (SD) 10.3(21.4) 7.7(18.7) 8.5(19.6) <0.01 
more than 1 
day 
842(28.4%) 1421(21.8%) 2263(23.9%) <0.01 
At least one prescription in 
post-index year 
 
BB 2411(81.4%) 5538(85.0%) 7949(83.9%) <0.01 
ACEI/ARB 2213(74.7%) 5403(82.9%) 7616(80.4%) <0.01 
CCB 672(22.7%) 1476(22.7%) 2148(22.7%) 0.96 
diuretic 977(33.0%) 2426(37.2%) 3403(35.9%) <0.01 
anticoagulants 426(14.4%) 1099(16.9%) 1525(16.1%) <0.01 
antiplatelet 1461(49.3%) 3928(60.3%) 5389(56.9%) <0.01 
nitrates 1942(65.6%) 4281(65.7%) 6223(65.7%) 0.92 
other lipid 
drugs 
192(6.5%) 229(3.5%) 421(4.4%) <0.01 
At least one statin prescription with 28 days’ 
supply in post-index year 
102(3.4%) 505(7.8%) 607(6.4%) <0.01 
High statin dose on first prescription post index€ 1497(50.6%) 3563(54.7%) 5060(53.4%) <0.01 
Atorvastatin on first prescription post index 1674(56.5%) 3586(55.0%) 5260(55.5%) 0.17 
>4 distinct (non-statin) medications received in 
post-index year 
1649(55.7%) 4083(62.7%) 5732(60.5%) <0.01 
Chronic disease score ≥4 1389(46.9%) 2968 (45.5%) 4357 (46.0%) 0.22 
Diagnosis in hospital or 
physician records in pre-index 
year 
DM 400 (13.5%) 905(13.9%) 1305 (13.8%) 0.62 
HTN 1045(35.3%) 2474(38.0%) 3519(37.1%) 0.01 
Specialty of prescribing 
physician of the first statin 
prescription 
GP 439 (14.8%) 697(10.7%) 1136(12.0%) 
<0.01 
cardiologist 1341(45.3%) 3364(51.6%) 4705(49.6%) 
internist 643(21.7%) 1236(19.0%) 1879(19.8%) 
cardiac surgeon 323(10.9%) 787(12.1%) 1110(11.7%) 
other 215(7.3%) 433(6.6%) 648(6.8%) 
≥5 physician’s visits in the first 3 months following 
the first statin dispensation 
2150(72.6%) 5027(77.1%) 7177(75.7%) <0.01 
Any hospitalization in pre-index year 861(29.1%) 2100(32.2%) 2569(27.1%) <0.01 
Rural residence yes 1663(56.2%) 2608(48.5%) 4825(50.9%) <0.01 
Household income quintile  
missing 1077(36.4%) 2091(32.1%) 3168(33.4%) - 
1 (lowest) 395(13.3%) 777(11.9%) 1172(12.4%) 
<0.01 
2 370(12.5%) 892(13.7%) 1262(13.3%) 
3 362(12.2%) 931(14.3%) 1293(13.6%) 
4 393(13.3%) 857(13.2%) 1250(13.2%) 
5 (highest) 364(12.3%) 969(14.9%) 1333(14.1%) 
Provincial prescription benefitΩ 987(33.3%) 2483(38.1%) 3470(36.6%) <0.01 
level of Rx cost not covered by 
the Drug Plan 
<29$ 667(22.5%) 1668(25.6%) 2335(24.6%) 
<0.01 
29$ to 59$ 753(25.4%) 1650(25.3%) 2403(25.4%) 
50$ to 79$ 821(27.7%) 1570(24.1%) 2391(25.2%) 
≥80$ 720(24.3%) 1629(25%) 2349(24.8%) 
Receipt of income security benefits 679(22.9%) 1431(22.0%) 2110(22.3%) 0.29 
Deprivation index quintile missing 117(4.0%) 220(3.4%) 337(3.6%) - 
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1 (most 
deprived) 
603(20.4%) 1220(18.7%) 1823(19.2%) 
0.01 
2 510(17.2%) 1012(15.5%) 1522(16.1%) 
3 609(20.6%) 1467(22.5%) 2076(21.9%) 
4 590(19.9%) 1322(20.3%) 1912(20.1%) 
5 (least 
deprived) 
532(18.0%) 1276(19.6%) 1808(19.1%) 
Material component of 
deprivation index (quintile) 
missing 117(4.0%) 220(3.4%) 337(3.6%) - 
1 (most 
deprived) 
588(19.9%) 1161(17.8%) 1749(18.5%) 
0.01 
2 598(20.2%) 1329(20.4%) 1927(20.3%) 
3 687(23.2%) 1429(21.9%) 2116(22.3%) 
4 568(19.2%) 1369(21.0%) 1937(20.4%) 
5 (least 
deprived) 
403(13.6%) 1009(15.5%) 1412(14.9%) 
Social component of 
deprivation index (quintile) 
missing 117(4.0%) 220(3.4%) 337(3.6%) - 
1 (most 
deprived) 
588(19.9%) 1221(18.7%) 1809(19.1%) 
0.15 
2 483(16.3%) 1141(17.5%) 1624(17.1%) 
3 502(17.0%) 1172(18.0%) 1674(17.7%) 
4 580(19.6%) 1190(18.3%) 1770(18.7%) 
5 (least 
deprived) 
691(23.3%) 1573(24.1%) 2264(23.9%) 
Abbreviations:  ACS: Acute Coronary Syndrome; ACEI/ARB: Angiotensin Converting Enzyme-Inhibitor /Angiotensin Receptor-Blockers; 
BB: Beta-blockers; CCBs: Calcium Channel Blockers; DM: Diabetes Mellitus; GP: General Practitioner; HTN: Hypertension; PROC: 
Procedure of revascularization. 
€: High dose statin was defined150,151 as having rosuvastatin >5mg, atorvastatin ≥20mg, or simvastatin ≥40mg 
Ω: Provincial prescription benefit was defined as any cost-sharing  by government health insurance on first statin dispensation after index date 
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Table ‎4-2: The adjusted independent effects of each SES variables on the probability of 
being adherent to statin medication 
Variable 
Odds 
Ratio 
Estimate 
95% Wald 
Confidence 
Limits 
p-value 
from 
Wald 
Chi-
Square 
test 
Brier 
Score 
C-statics 
(95% 
Confidence 
Limits) 
Change in C-
statistics from base 
model (0.651) 
p-value 
from 
DeLong 
test for 
C-
statistics 
change 
absolute % 
Residence Rural 0.814 0.72 0.92 <0.01* 0.196 
0.653 
(0.638 to 
0.668) 
0.0037 0.57% 0.04* 
Household 
income 
quintile 
1 (lowest) 0.75 0.63 0.90 <0.01* 
0.196 
0.653 
(0.638 to 
0.668) 
0.0031 0.48% 0.04* 
2 0.92 0.77 1.11 0.77 
3 1.01 0.84 1.21 0.08 
4 0.88 0.74 1.05 0.60 
5 (highest) reference   - 
Provincial prescription 
benefit 
1.13 0.99 1.29 0.08 0.208 
0.650 
(0.635 to 
0.665) 
0.0005 0.08% 0.54 
level of 
prescription 
cost not 
covered by 
the Drug Plan 
($) 
<29 1.03 0.86 1.24 0.49 
0.208 
0.650 
(0.635 to 
0.665) 
0.0002 0.03% 0.75 
29$ to 59 0.92 0.78 1.10 0.19 
50$ to 79 1.02 0.85 1.21 0.67 
≥80 reference   - 
Receipt of income security 
benefits 
0.86 0.74 1.00 0.05 0.196 
0.650 
(0.635 to 
0.665) 
0.0009 0.14% 0.27 
Deprivation 
index quintile 
1 (most 
deprived) 
0.76 0.64 0.91 <0.01* 
0.196 
0.654 
(0.639 to 
0.669) 
0.0046 0.71% 0.01* 
2 0.91 0.76 1.10 0.21 
3 0.92 0.76 1.11 0.49 
4 0.82 0.68 1.01 0.29 
5 (least 
deprived) 
reference   - 
Quintile of 
material 
component of 
deprivation 
index 
1 (most 
deprived) 
0.78 0.64 0.94 <0.01* 
0.196 
0.653 
(0.638 to 
0.668) 
0.0031 0.48% 0.03* 
2 0.97 0.80 1.17 0.56 
3 0.92 0.77 1.10 0.74 
4 1.04 0.88 1.24 0.05 
5 (least 
deprived) 
reference   - 
Quintile of 
social 
component of 
deprivation 
index 
1 (most 
deprived) 
0.76 0.64 0.91 0.01* 
0.196 
0.651 
(0.636 to 
0.666) 
0.0016 0.25% 0.28 
2 0.91 0.76 1.10 0.54 
3 0.92 0.76 1.11 0.49 
4 0.82 0.68 1.00 0.29 
5 (least 
deprived) 
reference   - 
  
 155 
 
Table ‎4-3: The independent effects of all non-SES variables and DI on the odds of being 
adherent to statin medication from multivariate logistic regression model 
Characteristic 
Odds Ratio 
Estimate 
95% Wald Confidence 
Limits 
p-value from 
Wald Chi-
Square test 
Deprivation index quintile 1 (most deprived) 0.74 0.62 0.88 <0.01 
2 0.83 0.69 1.00 0.21 
3 1.02 0.85 1.22 0.03 
4 0.93 0.78 1.12 0.51 
5 (least deprived) reference   - 
Age 
<55 reference    
55-65 1.11 0.95 1.31 0.06 
66-73 0.98 0.83 1.17 0.55 
≥74 0.97 0.81 1.15 0.37 
Male gender 0.98 0.86 1.11 0.72 
Index year 
1994 reference    
1995 0.93 0.41 2.11 0.04 
1996 1.43 0.68 3.03 0.69 
1997 1.51 0.74 3.07 0.87 
1998 1.64 0.81 3.31 0.66 
1999 1.75 0.88 3.48 0.29 
2000 1.46 0.73 2.90 0.60 
2001 1.69 0.85 3.35 0.40 
2002 1.34 0.68 2.66 0.14 
2003 1.58 0.80 3.14 0.80 
2004 1.57 0.79 3.13 0.87 
2005 1.95 0.98 3.91 0.02 
2006 1.89 0.95 3.80 0.05 
2007 2.54 1.26 5.13 <0.01 
Type of index diagnosis 
ACS+PROC reference    
ACS only 0.68 0.58 0.79 <0.01 
PROC only 0.94 0.77 1.14 0.16 
Duration  of index hospitalization ≥10 days 1.24 1.08 1.44 <0.01 
Time from index to statin prescription more than 1 day 0.84 0.73 0.97 0.02 
At least one prescription in post-index 
year 
BB 1.21 1.04 1.41 0.01 
ACEI/ARB 1.44 1.24 1.68 <0.01 
anticoagulants 1.12 0.95 1.33 0.19 
antiplatelet 1.45 1.29 1.64 <0.01 
other lipid drugs 0.43 0.33 0.56 <0.01 
At least one statin prescription with 28 days’ supply in post-
index year 
2.09 1.57 2.78 <0.01 
High statin dose on first prescription post index 0.92 0.79 1.06 0.25 
Atorvastatin on first prescription post index 0.75 0.66 0.86 <0.01 
Choric disease score ≥4 1.08 0.95 1.23 0.26 
Specialty of prescribing physician of the 
first statin prescription 
GP reference   - 
cardiologist 1.20 0.97 1.49 0.48 
internist 1.12 0.90 1.40 0.63 
cardiac surgeon 1.24 0.93 1.65 0.44 
other 1.24 0.94 1.64 0.44 
≥5 physician visits in the first 3 months following the first statin 
dispensation 
1.21 1.06 1.39 0.01 
Any hospitalization in pre-index year 0.86 0.75 0.98 0.02 
Abbreviations:  ACS: Acute Coronary Syndrome; ACEI/ARB: Angiotensin Converting Enzyme-Inhibitor /Angiotensin Receptor-
Blockers; BB: Beta-blockers; CCBs: Calcium Channel Blockers; DM: Diabetes Mellitus; GP: General Practitioner; HTN: Hypertension; 
PROC: Procedure of revascularization. 
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43,118 individuals experienced 
coronary heart disease (CHD) 
between January 1
st
, 1994 and 
December 31
st
, 2008   
Excluded 7,983 individuals WITH at least one prescription of statin 
within 365 days pre-index date 
35,135 individuals 
Excluded 7,924 individuals who filled their first statin prescription 
beyond 90 days post-index date 
 
27,211 individuals 
20,215 individuals 
Excluded 6,996 individuals who emigrated OR died within one year 
of first statin dispensation 
 
19,368 individuals 
Excluded 847 individuals WITHOUT continuous beneficiary status 
over 5 years pre-index  
Excluded 120 individuals whose age< 30 on index date 
19,248 individuals 
Excluded 799 individuals with at least one ACS hospitalization or 
revascularization procedure within 5 years pre-index date 
18,449 individuals 
Excluded 8,971 individuals who did not have any statin prescription 
post-index 
9,478 individuals 
Figure ‎4-1: Flow chart of individuals in study 
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Figure ‎4-2: Percentage of individuals exhibiting adherence ≥80% to statin medications 
during the first year post ACS hospitalization, stratified by index year 
 
 
*Adherence was defined by a “tablets per day” of 80% or higher 
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Figure ‎4-3: The crude and adjusted independent effects of each SES variables on the 
probability of being adherent to statin medication 
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Appendix ‎4-1: Subjects’ selection of eligible individuals depending on the existence of CHD  
Subject Selection Diagnoses from primary/most responsible diagnosis Hospital Services 
Database 
ICD-9* ICD-10-CA Description 
410 I21 - I22.xxx myocardial infarction (MI) 
411 I20.0xx and I24.xxx unstable angina (UA) 
*ICD-9 was used until March 31, 2001, when ICD-10-CA reporting started 
ICD-9: Manual of the international statistical classification of diseases, injuries, and causes 
of death, 9th revision. Geneva: The Organization; 1977.  
ICD-10-CA: International statistical classification of diseases and related health problems, 
tenth revision, Canada. Canadian Institute for Health Information; 2003. 
  
Subject Selection Revascularization Procedures from Physician’s Services Database 
and Hospital Services Database 
Physician database Hospital services database Description 
FSC CCP* CCI  
328A  1.IJ.50.GQ-BD-x PTCA/PCI^ 
329A  1.IJ.50.GQ-BF-x  
331A 48.02 1.IJ.50.GQ-OA-x  
335A 48.03 1.IJ.57.GQ-xx-x  
548A 48.09 1.IJ.57.GS-xx-x  
138L 48.1x 1.IJ.76.xx-xx-x CABG† 
153L     
154L       
155L       
161L       
654L       
655L       
* CCP was used for procedures until April 1st 2001, when CCI reporting started  
^ The term PCI (percutaneous coronary intervention) now replaces PTCA (percutaneous transluminal angioplasty) because it includes the 
use of balloons, stents and atherectomy devices while PTCA is a nonsurgical procedure to relieve narrowing and obstruction of vessels. 
†CABG: Coronary Artery Bypass Surgery 
FSC: Physician fee-for-service codes (FSCs) are listed in the Payment schedule for insured services provided by a physician in 
Saskatchewan 
http://www.health.gov.sk.ca/adx/aspx/adxGetMedia.aspx?DocID=2453,94,88,Documents&MediaID=1658&Filename=physician-payment-
schedule-april-2008.pdf 
CCP: Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures, Statistics Canada 1986.  
CCI: Canadian Classification of Health Interventions , Canadian Institute for Health Information 2003 
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Appendix ‎4-2: Socio-Economic Status (SES) measures 
SES measure Database source  Domain 
Income security benefit 
(yes/no) 
Individual was a recipient of provincial or federal 
income security benefits on index date. 
Single 
Provincial prescription 
benefit (yes/no) 
 Provincial Drug Plan shared cost of first statin 
dispensation after index date. 
Single 
Prescription copayment 
cost in CDN dollars not 
covered by the drug plan 
(<29$, 29$ to 59$, 60$ to 
79$, and ≥80$) 
Level of prescription cost not covered by the 
provincial drug plan on first statin dispensation after 
index date. 
Single 
Household income quintile  The mean household income in the dissemination 
area (DA) of individual’s postal code on index date 
(categorized in quintiles relative to provincial 
population), based on Statistics Canada 2001 
community profile.   
Single 
Rural residence (yes/no) Individual’s area of residence’s postal code on index 
date was mapped to rural agglomeration area as 
defined by Statistics Canada.   
Single 
Deprivation Index (DI) Individual’s postal code on index date mapped to 
dissemination area (DA):  three material and three 
social SES domains (categorized as quintiles relative 
to all residents of Saskatchewan), based on 2006 
census data. 
Multiple  
Quintile of material 
component of deprivation 
index  
Individual’s postal code on index date mapped to 
dissemination area (DA): three material SES domains 
(categorized as quintiles relative to all residents of 
Saskatchewan), based on 2006 census data. 
Multiple  
Quintile of social 
component of deprivation 
index  
Individual’s postal code on index date mapped to 
dissemination area (DA):  three social SES domains 
(categorized as quintiles relative to all residents of 
Saskatchewan), based on 2006 census data. 
Multiple  
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Appendix ‎4-3: Non-SES variables considered for the adjusted “base” model 
Variable category Included variables 
Demographic variables  age at index date 
 gender 
 year of discharge 
Condition-related 
variables 
 type of index diagnosis (ACS only, ACS plus 
revascularization, or revascularization only) 
 duration of index hospitalization 
 number of days between index date and first dispensation 
of statin 
Therapy-related factors  filling at least one prescription for specific cardiovascular 
medication(s) during the first year post-index including 
(beta-blockers; angiotensin converting enzyme-inhibitor 
(ACEI) or angiotensin receptor-blockers (ARB); calcium 
channel blockers (CCBs); diuretics; anticoagulants; 
antiplatelets; nitrates; or other lipid drugs - yes/no for 
each) [Appendix4-4],  
 filling at least one prescription with a quantity of 28 
tablets
153
 as an evidence of unit-of-use packaging.
154,155
  
 receiving a high (versus low) statin dose on first 
prescription post index,
149-152
  
 the individual statin used on first prescription post index 
(atorvastatin versus others)
156
  
 burden of medications defined as the total number of 
distinct medications’ therapeutic groups dispensed to 
subject 
Patient-related factors  Chronic Disease Score (CDS),236 
 specific comorbid conditions of diabetes,163 and 
hypertension
58
 reported in any physician or hospitalization 
visit in the year prior to the index date [Appendix 4-5] 
Health system-related 
factors 
 specialty of prescribing physician for the first statin 
dispensation (general practitioner (GP), cardiologist, 
general internist, cardiac surgeon, other) 
 number of physicians follow-up visits in the first 3 months 
following the first statin dispensation 
 any prior hospitalization in the pre-index year. 
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Appendix ‎4-4: Medications assessed in the multi-variate model 
Medication category Medications included 
Statin mediation (i.e., HMG-CoA 
reductase inhibitors) 
Atorvastatin, atorvastatin / amlodipine combination, 
cerivastatin, fluvastatin, lovastatin, pravastatin, 
rosuvastatin, and simvastatin 
Angiotensin Converting Enzyme-
Inhibitors (ACE-Inhibitors) 
Benazepril, captopril, cilazapril, cilazapril / HCTZ 
combination, enalapril, enalapril/HCTZ combination, 
fosinopril, lisinopril lisinopril/HCTZ combination, 
perindopril ,perindopril/indapamide  combination, 
quinapril quinapril/HCTZ combination, ramipril, and 
trandolapril 
Angiotensin Receptor-Blockers 
(ARBs) 
Candesartan, candesartan/HCTZ combination, 
eprosartan, eprosartan / HCTZ combination, 
irbesartan,  irbesartan/HCTZ combination, losartan,  
losartan/HCTZ combination, olmesartan, 
Olemsartan/HCTZ combination, telmisartan,  
telmisartan/HCTZ combination, valsartan, and  
valsartan/HCTZ combination 
Beta Blockers Acebutolol, atenolol, atenolol / chlorthalidone 
combination, labetolol, metoprolol, metoprolol / 
HCTZ combination, nadolol, oxprenolol, pindolol, 
pindolol/HCTZ combination, propranolol, 
propranolol / HCTZ combination, timolol, and 
timolol / HCTZ combination 
Calcium Channel Blockers 
(CCBs) 
Amlodipine, felodipine, nicardipine, nifedipine long 
acting, diltiazem, and verapamil 
Diuretics Amiloride, amiloride/HCTZ, bumetanide, 
chlorthalidone, ethacrynic acid, furosemide, 
hydrochlorothiazide (HCTZ), indapamide, 
metolazone, spironolactone, spironolactone/HCTZ, 
triamterene, triamterene/HCTZ 
Anticoagulants Acenocoumarol,  dalteparin,  enoxaparin,  heparin,  
nadroparin,  tinzaparin,  warfarin 
Antiplatelet ASA,  clopidogrel,  dipyridamole /ASA,  
pentoxifylline,  sulfinpyrazone,  ticlopidine 
Nitrates Erythrityl tetranitrate,  isosorbide dinitrate,  
isosorbide-5-mononitrate,  nitroglycerin 
Other lipid drugs Bezafibrate, cholestyramine, clofibrate, colestipol, 
ezetimibe, fenofibrate, gemfibrozil, niacin, probucol 
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Appendix ‎4-5 Comorbid conditions 
Comorbid conditions used in multivariable model from Hospital Services and physician 
services Database 
ICD-9 ICD-10-CA Description 
250.x E10 - E14.xxx Diabetes & diabetes with complications 
401 - 404.x 
I10 to I15.xxx 
except when I11 is 
reported with I50 
where’s case was 
considered heart 
failure 
hypertension 
 
*ICD-9 was used until March 31, 2001, when ICD-10-CA reporting started 
ICD-9: Manual of the international statistical classification of diseases, injuries, and causes 
of death, 9th revision. Geneva: The Organization; 1977.  
ICD-10-CA: International statistical classification of diseases and related health problems, 
tenth revision, Canada. Canadian Institute for Health Information; 2003. 
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CHAPTER -5- PHARMACIST INTERVENTION IN CARDIAC 
REHABILITATION: A RANDOMIZED CONTROLLED TRIAL 
5.1 Abstract 
Purpose: We aimed to determine the extent to which a telephone-based pharmacist intervention 
would: a) be utilized by individuals not attending a traditional Cardiac Rehabilitation (CR) 
program; b) facilitate adherence to cardiovascular medications. Methods: We conducted a 
randomized, controlled open-label trial among patients eligible for CR in Saskatoon, Canada. 
Patients were invited to participate in a telephone-based CR regardless of participation in the 
formal program.  Subjects in the intervention group were assessed by the CR pharmacist and 
received education and counseling on medication adherence. The primary endpoint was 
adherence to cardiovascular medication assessed by electronic filling records over a minimum of 
six months.  Mean adherence was expected to reach 70% during the follow up period. Results: 
Patient recruitment was halted early due to low enrolment.  Of the 95 patients randomized, 90% 
had also registered in the traditional CR program. During the follow-up period, 129 telephone 
interactions were performed (median 2 calls) with every subject receiving at least one 
interaction. Over the study period, the mean adherence to all recently initiated cardiovascular 
medications combined was 88.8% in the intervention group and 89.9% in the usual care group 
(p=0.73). Conclusions: Participation in traditional CR programs does not appear to be influenced 
by the availability of telephone-based education and support.  Further, the high rate of adherence 
among the control group may suggest that CR programs are attracting ‘healthy adherers’ who 
                                                 

 This work is published in the Journal of Cardiopulmonary Rehabilitation and Prevention (2012;32(6):394-399). No 
permission letter is needed to reuse in thesis/dissertation from Wolters Kluwer Health, Lippincott Williams & 
Wilkins. 
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volunteer for such programs while missing those with the greatest need for health system 
resources.  
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5.2 Introduction 
Enrollment in cardiac rehabilitation (CR) programs is known to be poor, ranging from 15-50% of 
the targeted population.
1
 Ironically, patients who do not participate in CR programs have more 
cardiovascular risk factors such as smoking, sedentary lifestyle, poor diet and higher LDL-
Cholesterol, while having less knowledge about how to manage these factors.
2
 Several barriers to 
CR participation have been identified, but convenience (i.e., proximity) appears to be an 
important factor.
3
   
For patients who do participate in CR programs, individual and long-term follow-up to support 
optimal medication use is not typically provided despite a high prevalence of medication non-
adherence in the post-Acute Coronary Syndrome  (post-ACS) setting.
4
 For example, it has been 
reported that approximately 60% of patients surviving their first cardiovascular event remained 
adherent to statins, Beta-blockers or Angiotensin Converting Enzyme-Inhibitors (ACE-
Inhibitors)/ Angiotensin Receptor-Blockers (ARBs) one year post-ACS.
5
 As non-adherence is an 
important predictor of mortality in high risk cardiovascular patients, interventions to improve 
adherence are likely to improve patient outcomes.
6
  Consequently, the Canadian Guidelines for 
Cardiac Rehabilitation emphasize medication adherence strategies as a core component of CR.
7
 
Telephone interventions have been shown to be effective in improving medication adherence;
8
 at 
the same time, providing a CR service over the telephone may improve the 
accessibility/convenience among patients who cannot attend a traditional program. We 
conducted a prospective, randomized, controlled open-label trial to determine the effectiveness 
of adding a telephone-based CR intervention aimed at improving adherence to cardiovascular 
medications.  We hypothesized that the intervention would improve medication adherence and 
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its convenience would result in significant increase in the utilization of CR services by CR 
invitees not attending the traditional program.  
5.3 Methods 
5.3.1 Subjects 
Between Oct 1
st
 2009 and June 30
th
 2010, all patients who received a mailed invitation to 
participate in the CR program in Saskatoon, Saskatchewan, Canada were invited to participate in 
our trial, irrespective of whether they chose to participate in the formal CR program.  Patients 
expressing interest were enrolled if they were over 30 years of age and met the following 
inclusion criteria: 1. experienced an Acute Coronary Syndrome (ACS) hospitalization [ST 
elevation Myocardial Infarction (STEMI), Non-STEMI, Percutaneous Transluminal Coronary 
Intervention (PTCA), or Coronary Artery Bypass Graft (CABG) surgery] or revascularization 
procedure within the previous 3 months; and 2. Were newly initiated on at least one 
cardiovascular medication (statin, ACE-Inhibitor/ARB or Beta-blocker) defined as no prior use 
within the previous one year.  The rationale for this criterion is that non-adherence has shown to 
be higher among patients initiating new medications.
9
 Each ACS event was confirmed by a 
documented diagnosis within the hospital chart.  Patients were excluded if they had inaccessible 
laboratory results or prescription data to confirm eligibility.   
5.3.2 Randomization 
The principal investigator (W.A.) obtained informed consent from subjects and randomized them 
in permuted blocks of six to receive either a pharmacist-intervention or usual care.  Group 
allocation codes were prepared before trial initiation using a random number table and were kept 
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in sealed envelopes and opened sequentially by the principal investigator (W.A.) for every new 
subject.  Neither subjects nor the researcher were blinded to the intervention.  
5.3.3 Intervention 
Initially, the pharmacist telephoned all subjects in the intervention group and followed a specific 
set of probes to identify barriers to optimal utilization or adherence with post-ACS medications. 
These probes consisted of four questions the principle investigator (W.A.) asked subjects during 
the initial interview. The four questions are: 1) is there any medication you are not sure why it 
was prescribed to you? 2) Do you have any issues or problems with the medications you are 
taking? 3) Have you heard or read any negative information or “facts” about your drugs?  4) Do 
you have any question about your doctor’s recommendations?  Based on this assessment, the 
pharmacist established the date of the next call within one to two weeks according to the need to 
support medication adherence including education on side effects or intolerance, cost concerns 
and drug interactions.  The pharmacist contacted family physicians if warranted to address 
important issues.   
5.3.4 Endpoints 
The primary endpoint was the mean adherence to newly initiated cardiovascular medications 
(ACE-Inhibitors/ARBs, Beta-blockers and/or statins) beginning from the date of enrolment in the 
trial until the end of follow-up.  Adherence for post-ACS medications was determined using the 
Medication Possession Ratio (MPR) for each therapeutic category using electronic dispensation 
records.  Switching between members of the same medication category was allowed.   Optimal 
adherence was defined as an MPR greater than or equal to 80%, which is consistent with other 
studies.
5
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5.3.5 Sample size calculation 
We anticipated that the control group would exhibit a mean adherence level to newly initiated 
cardiovascular medications of 70% over six months of follow-up.
10,11
  Therefore, 72 patients per 
arm were required to detect a 15% improvement in the mean adherence level within the 
intervention group at an alpha of 0.05 and beta of 0.80.   
5.3.6 Data Analysis 
We used χ2 test to compare the differences between frequency values and Student’s t-test to 
compare mean values for statistical significance. PASW statistics 18 software (IBM Corporation 
2010) was used to perform statistical tests.  
The trial was approved by the Biomedical Research Ethics Board (Bio-REB #09-152) at the 
University of Saskatchewan. 
5.4 Results 
Over the 9 month recruitment period, 235 individuals were invited to participate in the trial 
following a cardiac hospitalization together with the letter of invitation for the CR program.  
Additionally, 82 patients were referred to CR by a health care professional and were invited 
during the CR. Thus, a total of 317 eligible patients were invited to participate in the trial.  
Among those 317 patients, 152 (48%) attended the traditional CR program, and 165 (52%) did 
not. Out of the 152 patients who enrolled in the traditional CR program, 67% (103 /152) also 
agreed to participate in the pharmacist-intervention trial.  Conversely, of 165 invitees who did 
not enroll in the CR program, only 11% (19/165) agreed to participate in the trial despite two 
mailed invitations and one phone call attempt. Subject recruitment was halted on June 30th, 2010 
due to slow enrolment. Altogether, of the 122 patients who agreed to participate, 27 were 
excluded due to ineligibility.  Ultimately, of the 95 patients who were enrolled, 90% (86 / 95) 
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had also participated in the CR program. One patient died shortly after randomization, and his 
data was not included in the analysis.  
There were no statistically significant differences between the pharmacist-intervention and usual 
care groups in any baseline characteristic after randomization.  Mean age of trial participants 
overall was 62.8 yrs, 78.7% were male, and the mean household income based on each subjects’ 
residence area was $68723.60 per annum which is close to the mean household income in the 
city of Saskatoon of $66507.00 reported in 2006 census. However, only 2% of trial participants 
lived in low income areas, in spite of the fact that 29% of Saskatoon’s population reside in these 
areas with higher cardiovascular morbidity. The mean time from hospital discharge to 
randomization was 55.1 days and the mean follow-up time was 320 days. Most patients (71.2%) 
initiated at least three new cardiovascular medications (including Clopidogrel). The utilization of 
cardiovascular medications was optimal with 100% for statins, 98% for ACE-Inhibitors and 96% 
for Beta-blockers [Table 1]. 
Among subjects in the pharmacist-intervention group, 129 telephone interactions were 
performed (median 2; range 1-8) with every subject receiving at least one interaction. In contrast, 
four interactions were made with the usual care group in order to address a clinical question that 
could not be ethically ignored by the pharmacist.     
The mean MPR of all newly initiated cardiovascular medications over the trial period was 88.8% 
[95% Confidence Interval (CI) 84.2%–93.9%] among subjects in the pharmacist-intervention 
group compared to 89.9% [95%CI 86.0%–94.2%] in the usual care group despite no ongoing 
support during the trial period (p=0.73). Adherence was also similar between groups when 
calculated for each cardiovascular medication category, as well as for all cardiovascular 
medications (previously and newly initiated combined) [Table 2].  Overall, the proportion of 
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individuals exhibiting optimal adherence (MPR  80%) to each newly initiated cardiovascular 
medication was 82.6% and 79.2% in pharmacist-intervention and usual care groups respectively 
(p=0.44).  Subgroup analyses revealed consistent findings among men, women, type of event, 
and duration of follow up.  
5.5 Discussion 
We conducted a randomized controlled open-label trial that examined a pharmacist intervention 
to improve cardiovascular medication adherence among patients being discharged from hospital 
after an ACS. In contrast to the high rate of participation among patients who had concurrently 
enrolled in the traditional CR program, interest among non-CR participants was minimal despite 
the apparent convenience of our telephone-based trial. As a result, over 90% of our subjects had 
also volunteered for CR.  Although power was lower than anticipated due to slow recruitment, 
none of the outcomes differed between groups.  However, the problem of low power seems 
irrelevant considering the control group exhibited a mean adherence rate of almost 90% when we 
were expecting a rate of 70% based on published studies.
12
    
The high level of adherence observed in our trial might have been due to the beneficial influence 
of the CR program itself. CR patients receive education and counseling that covers risk reduction 
and healthy behavior recommendations, which may have influenced the optimal outcomes 
among our study sample.
13
  Alternatively, selection bias may have resulted from the fact that 
patients participating in clinical trials are perhaps unique from those who do not.
14
  Along similar 
lines, it is highly probable that patients attending CR programs are unique.  Specifically, the 
voluntary nature of CR programs may result in the selection of low-risk subgroups or “healthy 
adherers” overall.15  That is to say, the high rates of adherence, risk factor management, and 
medication use observed in our study may have been a result of healthy behavior that is over-
 172 
 
represented among patients volunteering for CR programs. Low recruitment is a well-recognized 
problem in CR; and the voluntary nature of these programs likely results in highly selected 
participants who would be at very low risk for major cardiac outcomes.  The results of our study 
would appear to support this hypothesis.    
Our trial had some limitations. First, randomization, intervention, data collection, and analyses 
were all performed by the principal investigator (W.A) due to budget constraints. Second, our 
trial was not blinded and therefore patients knew that adherence would be assessed at the end of 
the trial.  As a result, study results may have been influenced by the Hawthorne effect. Third, our 
trial had a low power due to slow recruitment. However, we believe it is unlikely that the null 
findings were the result of a type II error.  Subjects in the control group exhibited extremely high 
adherence (90%) and the p-value calculated for the primary endpoint showed no indication of a 
trend (p= 0.73).  Regardless, evidence for an improvement in adherence among patients with 
optimal adherence would be a moot point and would not likely result in improved health 
outcomes.      
Our data suggest that patients who participate in voluntary CR programs may not require long-
term individual support for medication use.  Furthermore, our results indicate that many CR 
programs are catering to ‘healthy adherer’ individuals while missing those at the greatest need of 
these health system resources. Further studies would be required to confirm these findings.  
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Table ‎5-1: Patient characteristics in the 2 groups 
Characteristic Pharmacist 
intervention 
N=46 
Usual  
care 
N=48 
P-value 
Age in years: mean (SD) 62.4(10.5) 63.5(11.9) 0.72 
Gender:  n (%) female 9 (20%) 11 (23%) 0.65 
Attended CR:  n (%) 42 (91%) 43 (86%) 0.75 
SES  by neighborhood average family income: mean (SD)  66844.4 (18055.5) 70524.5 (19046.6) 0.39 
SES by income groups:  n (%)     0.60 
             <$30000 2 (4.3%) 0 - 
$30000-59999 16 (34%) 13 (27.1%) - 
$60000-80000 13 (27.7%) 10 (20.8%) - 
>$80000 12 (25.5%) 12 (25%) - 
Suppressed* 4 (8.5%) 13 (27.1%) - 
Diagnosis: n (%)   0.15 
STEMI 3 (6.5%) 0 - 
NSTEMI 4 (8.7%) 0 - 
Stent 7 (15.2%) 12 (25%) - 
CABG 10 (21.7%) 10 (20.8%) - 
STEMI +Stent 13 (28.2%) 17 (35.4%) - 
NSTEMI +Stent 6 (13%) 4 (8.3%) - 
STEMI+CABG 1 (2.1%) 2 (4.2%) - 
NSTEMI+CABG 2 (4.3%) 3 (6.3%) - 
Time from hospital discharge to randomization in days: 
mean (SD) 
51.8 (30.6) 58.3 (35) 0.35 
Observation time in days: mean (SD)  
and range in days 
322.9 (78.8) 
185-433 
318 (80) 
195-451 
0.73 
Medication use n (%)   0.88 
Statin 46 (100%) 48 (100%) - 
ACE-Inhibitor/ARB 46 (100%) 46 (95.8%) - 
Beta-blocker 44 (95.7%) 46 (95.8%) - 
Clopidogrel 34 (73.9%) 36 (75%) - 
ASA 43 (93.5%) 43 (89.6%) - 
Warfarin 4 (8.7%) 9 (18.8%) - 
Clopidogrel+ASA 32 (69.6%) 34 (70.8%) - 
Clopidogrel+ASA+Warfarin 2 (4.3%) 5 (10.4%) - 
Number of new medications of Statin, ACE-Inhibitor/ARB, 
BB, and Clopidogrel n (%) 
  0.93 
1 5 (10.9%) 5 (10.4%) - 
2 8 (17.4%) 9 (17.8%) - 
3 11 (23.9%) 14 (29.2%) - 
4 22 (47.8%) 20 (41.7%) - 
Specific new medication (n) %   0.90 
Statin 35 (76%) 39 (81.5%) - 
ACE-Inhibitor/ARB 33 (71.7%) 32 (66.7%) - 
BB 40 (87%) 41 (85.4) - 
Clopidogrel 34 (73.9%) 33 (68.8%) - 
Number of concurrent medications (number of therapeutic 
classes) in the observation period (SD)  
8 (3.3%) 7.2 (2.7) 0.20 
Baseline LDL-C mean (SD) 3.1 (1.11) 3.2 (1.13) 0.27 
*Residents of neighborhoods from small communities outside the city of Saskatoon were excluded because they are 
suppressed in census data 
Abbreviations: SES: Socio-Economic Status; STEMI: ST elevation Myocardial Infarction; NSTEMI: Non- ST elevation 
Myocardial Infarction; CABG: Coronary Artery Bypass Graft; ACE-Inhibitors: Angiotensin Converting Enzyme-Inhibitor, 
ARB: Angiotensin Receptor Blocker (ARB), ASA: Acetyl-salicylic Acid (or Aspirin), LDL-C: Low-Density Lipoprotein 
Cholesterol 
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Table ‎5-2: Summary of adherence outcomes 
 
  
Outcome 
Pharmacist 
intervention 
N=46 
Usual care 
N=48 
P-value 
Mean MPR
+
 for all newly initiated 
cardiovascular medications (SD) 88.8% (16.4%) 89.9% (14.2%) 0.73 
Mean MPR
+
 for newly initiated statins (SD) 
87.2% (23.4%) 89.8% (16.4%) 0.58 
Mean MPR
+
 for newly initiated ACE-
Inhibitors/ARBs (SD) 87.6% (19.3%) 92.1% (14.6%) 0.30 
Mean MPR
+
 for newly initiated Beta-
Blockers (SD) 89.1% (16.6%) 89.5% (19.9%) 0.92 
Mean MPR
+
 for newly initiated Clopidogrel 
(Plavix) (SD) 95.7% (11.1%) 85.8% (30.9%) 0.83 
Mean MPR
+
 for all cardiovascular 
medications (previously and newly initiated 
combined) (SD) 
88.2% (16.7%) 90.6% (11.2%) 0.43 
The proportion of subjects exhibiting 
optimal adherence of MPR more than or 
equal to 80% to newly initiated Statins, 
ACE-Inhibitors/ARBs, and Beta-Blockers 
82.6% (38/46) 79.2% (38/48) 0.44 
Mean persistence* to newly initiated statins 
(SD) 381.2 days (115.9) 403.0 days (126.0) 0.39 
Mean persistence* to newly initiated ACE-
Inhibitors/ARBs (SD) 349.3 days (104.7) 374.4 days (105.5) 0.34 
Mean persistence* to newly initiated Beta-
blockers (SD) 355.7 days (107.2) 381.0days (116.2) 0.31 
+MPR was calculated by dividing the sum of all daily medication supplies of the same therapeutic category 
during the follow-up period by the total days in this interval *Persistence is defined as the time between the 
first and last fills of medication during the follow-up period. 
Abbreviations: MPR: Medication Possession Ratio, ACE-Inhibitors: Angiotensin Converting Enzyme-
Inhibitors, ARBs: Angiotensin Receptor Blockers, SD: standard deviation.  
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CHAPTER -6- SUMMARY 
6.1 Summary of research 
Four separate, but related, research questions related to cardiovascular medication adherence 
were addressed in this program of research.  The first study (chapter 2) demonstrated that 
estimated mortality benefits associated with statin adherence are substantially influenced by the 
measurement approach and no one approach can be regarded as gold standard.  Findings of the 
second study (chapter 3) challenged conventional wisdom by refuting a strong relationship 
between low SES and poor adherence to anti-hypertensive medications using a systematic review 
and meta-analysis of the literature.  Correspondingly, the third study (chapter 4) showed that 
using multi-domain measurements of SES from ecological measures does not improve the 
performance of a predictive model for adherence. The fourth study (chapter 5) indicated that the 
availability of a pharmacist intervention, consisting of mainly telephone-based education and 
support, does not affect medication adherence among individuals participating in traditional CR 
programs. 
Numerous studies have reported benefits of optimal adherence on mortality rates and other 
important clinical outcomes.
1-5
 However, methods to estimate the association between 
medication adherence and major health outcomes have been highly variable.  Chapter 2 reports 
the impact of modifying the approach to measuring adherence to statin medications for 
estimating the association between adherence and mortality.  Among 9,051 individuals who 
received a statin medication in Saskatchewan, the estimated benefits of high (versus low) 
adherence were substantially impacted by the measurement strategy used.  When statin 
adherence was examined as a repeated measure, a strong association with mortality was observed 
suggesting robust benefits of optimal adherence.  In contrast, optimal adherence defined by a 
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single summary measure indicated no relationship with mortality at all.  Although it has been 
suggested that the repeated measures approach for classifying optimal adherence is less 
vulnerable to survival bias,
6,7
 the study reported in Chapter 2 provides strong evidence against 
this claim.   In fact, the repeated measures approach consistently produced more favourable risk 
estimates for optimal adherence to statins as well as other medications with no known effects on 
clinical outcomes.
1
 This is the first study to challenge the notion that optimal statin adherence 
(versus low statin adherence) is an independent predictor of death among community dwelling 
populations.  Future research is needed to determine the extent to which each measurement 
approach is vulnerable to bias.  Uncovering the true relationship between statin adherence and 
major health outcomes is critical to better understand the public health burden of medication 
non-adherence in today’s health care system.    
One of the most widely recognized predictors of mortality and/or major health outcomes in 
Canadian health care is socioeconomic status (SES).  Strong theoretical evidence suggests SES is 
an important cause of poor medication adherence because of its association with an individual’s 
economic, social, and education-related factors. However, the quantitative relationship between 
SES and medication adherence had not been clearly described.8 Chapter 3 describes a systematic 
review of adherence to antihypertensive medications using population-based electronic 
prescription data.  Several important discoveries were generated from this study.  First, the 
comprehensive review of the literature clearly demonstrated that SES has not been carefully 
measured in medication adherence prediction models.  Almost half of studies reviewed lacked 
any variable relating to SES and the remaining studies relied heavily on income/economic 
assessments as a surrogate marker of SES.  As a result, the validity of the observed association 
between SES and medication adherence is still in question.  To evaluate the validity of these 
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assessments, a comparison study was warranted. Indeed, meta-analysis of all eligible studies in 
Chapter 3 revealed a weak association between SES and adherence.    
Based on the results in Chapter 3, another study was conducted in Chapter 4 to evaluate if a 
comprehensive measure of SES might be a more robust predictor of poor medication adherence 
compared to conventional methods identified in the systematic review.  However, despite the 
theoretical advantages, use of a multiple-domain SES measure did not substantially improve the 
predictive accuracy of a population-based model.  In fact, the addition of any SES measure had a 
very mild impact on predicting adherence overall. Although SES does appear to be a significant 
predictor of SES, its influence on the overall burden of poor adherence at the population level is 
very small.     
Finally, Chapter 5 reports on the findings of a randomized trial focused on improving medication 
adherence among patients surviving an ischemic heart event.
9
 Historically, few patients receive 
interdisciplinary support after hospital discharge through support programs such as cardiac 
rehabilitation (CR).
10
  It was hypothesized that a streamlined intervention carried out by a 
pharmacist might improve uptake in cardiac rehabilitation-type services and also improve 
medication adherence through a low-cost efficient intervention.  Using a randomized, controlled 
design, no difference in the percentage of individuals achieving optimal adherence was observed 
among patients receiving the pharmacist intervention.  However, both study groups (intervention 
and control) exhibited extremely high adherence levels throughout the study period.  Clearly, the 
research subjects recruited for the study were not at-risk for poor adherence.  This finding 
highlights the importance of volunteer bias, not just in research studies, but in health care 
programs such as cardiac rehabilitation.  It is possible that these programs provide service to 
low-risk or healthy adherer type individuals who may not be at risk for poor outcomes.  In a 
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health care system such as Canada, where resources are stretched, health care services must be 
aligned to support individuals at the highest risk for poor outcomes.  Programs to support 
medication adherence will be more effective if a deeper understanding of at-risk populations can 
be achieved through robust research programs. 
During the course of this research program, medication adherence was examined from different 
perspectives. The four independent research studies reported in this dissertation helped clarify 
the nature of this widespread problem.  In brief, it can be concluded that low SES is not 
responsible for a disproportionate level of poor adherence despite the strong theoretical linkages.  
In addition, in contrast to previously published studies, the association between poor adherence 
to statin medications and premature death cannot be verified due to a previously unrecognized 
effect of measurement approach on the results of such studies.  Finally, traditional health services 
interventions must have better access to risk indicators for poor adherence.  Although the 
problem is widespread, certain populations exhibit high levels of adherence without the need for 
additional support.       
Despite years of research, our understanding about medication adherence continues to evolve.  
This dissertation has contributed important information to the area of medication adherence by 
generating quantitative evidence that challenges traditional theoretical paradigms and 
conventional wisdom.  It is essential that research continues in this area to increase the 
availability of quantitative data to accompany the wealth of theoretical frameworks and 
behavioural theories.  Eventually, high quality research will uncover the true nature of this 
important public health problem.          
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